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ABSTRACT 
 
Primary immunodeficiencies (PIDs) are inherited diseases of the immune system. A 
variety of molecular defects can cause PIDs, including mutations in genes PRKDC and 
ATM (ataxia telangiectasia-mutated), both of which in addition lead to DNA repair 
defects. Due to a variety of factors including gene size and sensitivity to DNA damage, 
these genetic defects are not easily amenable to gene addition strategies, and alternative 
gene therapy strategies are actively being sought. One such strategy is genome editing, 
the topic of the current work. 
PRKDC severe combined immunodeficiency (PRKDC-SCID) is a rare inherited disease 
caused by mutations affecting DNA-PKcs (DNA-dependent protein kinase catalytic 
subunit). DNA-PKcs is a key component of non-homologous end joining (NHEJ), a major 
defence mechanism against double-strand break DNA damage. NHEJ is also involved 
in V(D)J recombination, a process necessary to generate functional immunoglobulins 
and T cells receptors, and hence for the development of B and T lymphocytes. 
Consequently, defects in DNA-PKcs lead to enhanced sensitivity to DNA-damaging 
agents, such as ionising radiation, and severe immune defects. 
DNA-PKcs deficiency causes SCID in both animals (mice, dogs, horses) and humans; 
however, the condition is ultra-rare in humans with only two patients identified so far. 
Like with many other PIDs, transplantation of matched bone marrow remains the only 
choice of effective treatment, but it is complicated by sensitivity to conditioning agents 
that cause DNA damage. Gene transfer to haematopoietic stem/progenitor 
(HSC/HSPCs) cells first shown to have major therapeutic effects in SCID-X1, continues 
to show promise. Advances in genome editing have further opened possible approaches 
to treatment by correction of genetic defects.  
Previous work in the laboratory using engineered zinc-finger nucleases (ZFNs) and 
Prkdc repair matrixes demonstrated homology-directed gene correction in SCID mouse 
fibroblasts and HSC/HSPCs, leading to ex vivo rescue of the SCID phenotype with the 
latter. The current project broadly focuses on two major goals: (i) characterisation and 
phenotypic analyses of ZFN-targeted SCID mouse fibroblasts, including molecular 
analyses of genomic correction and rescue of DNA-PK activity, and (ii) in vitro gene 
editing of Prkdc mutation using CRISPR-Cas9 system. 
In this study, we used Streptococcus pyogenes derived Cas9 system to repair the Prkdc 
mutation. Co-delivery of guide RNAs (gRNA) on a Cas9 plasmid along with a corrective 
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donor template demonstrated efficient Prkdc modification in mouse fibroblasts; however, 
this did not restore DNA-PK activity owing to apparently error-prone DNA repair. 
Nonetheless, this study indicated the potential of CRISPR-Cas9 system for targeted 
modification of genes involved in DNA repair disorders.  
Based on this observation, we explored targeting of ATM, which like Prkdc, is involved 
in DNA repair. ATM codes for the protein ATM kinase, deficiency of which leads to Ataxia 
Telangiectasia (AT), a progressive neurodegenerative disease with associated 
immunodeficiency, radiation sensitivity and susceptibility to malignancies. Correction of 
mutations on ATM could rescue residual ATM kinase activity – a therapeutic approach 
for treating AT-related immunodeficiency. We selected and designed gRNAs for disease-
causing mutations – 5762ins137, 103C>T, 2T>C and 7638del9 – and demonstrated 
proof-of-concept editing of ATM locus in human cells. Given the multitude of mutations 
on ATM, we further designed global approaches for partial ATM cDNA knock-in at 
endogenous N/C-terminals or full ATM cDNA knock-in at hAAVS1 locus for application 
in the human haematopoietic stem cells.  
These studies on Prkdc and ATM have shown the feasibility of CRISPR/Cas genome 
editing on both genes. They have also highlighted the possible enhanced risk of 
homology-dependent DNA repair events being associated with novel mutations at the 
repair site, which prevented the recovery of fully repaired fibroblast clones in the case of 
ZFN-treated Prkdc. This work, therefore, points to the need for extra caution in 
therapeutic strategies involving genome editing of DNA repair gene defects. 
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1 Literature Review 
 
 
1.1 Gene Therapy 
Gene therapy is a paradigm of medicine with enormous potential that relates to treatment 
of diseases by the modification and regulation of genes (Wolff and Lederberg 1994). 
Ideally, effective gene therapy should correct the faulty gene to restore its normal 
function and not cause undesirable effects in the rest of the genome (Yanez and Porter 
1998). Gene therapy can be broadly administered using two approaches namely, gene 
addition and gene editing. Gene addition strategies aim at supplementing the genome 
with a functional copy of the faulty gene. This is particularly useful for recessive disorders 
that arise due to lack of or defects in associated genes and their products. Genome 
editing on the contrary allows permanent modification of the existing genome and can 
be used for introduction, disruption or repair of genetic loci of interest. Modifications can 
be carried out in vivo through localized or systemic injections directly into cells or tissues 
of interest, or through ex vivo procedures, where the cellular modification is carried out 
in vitro outside the body followed by re-transplantation of these modified cells back into 
the body (Wolff and Lederberg 1994). The applicability of either gene therapy strategy 
depends on the genetic defect, the kind of cells affected by the diseases and hence to 
be treated, and the appropriate use of gene delivery vectors (Verma and Weitzman 
2005). 
Several gene therapy trials addressing numerous conditions have been performed in the 
past two decades (Fig. 1-1). As of August 2016, 2,409 gene therapy clinical trials have 
been completed, are ongoing or have been approved across 37 countries worldwide, 
with representatives from all five continents 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/). The clear majority of the gene 
therapy trials (82.3%) have addressed cancers, monogenic disorders and chronic 
infection, but only a few have reported clear clinical benefits and in some, individuals 
experienced severe adverse events related to the gene therapy vectors.  
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Figure 1-1 Conditions Addressed by Gene Therapy Trials (August 2016) 
Source: Journal of Gene Medicine www.wiley.com/legacy/wileychi/genmed/ 
 
From the outset, gene therapy aimed to treat inherited disorders, assuming that 
monogenic diseases would be the easiest to target. The ultimate aim in treating 
monogenic diseases by gene therapy is the correction of the disorder by the stable 
transfer of the functioning gene into dividing stem cells to ensure the permanence of the 
correction, and there has been an array of monogenic disease targeted. After cancers, 
monogenic diseases are the second most common group of disorders to be targeted by 
gene therapy (Fig 1.1). Moreover, it also represents the disease group in which the 
greatest success of gene therapy has been achieved to date (Naldini 2015). Amongst 
the gene therapy clinical trials for inherited monogenic disorders, cystic fibrosis, the most 
common inherited genetic disease in Europe and the USA, has been a prime target for 
gene therapy (Alton, Boyd et al. 2015, Griesenbach, Pytel et al. 2015). The second most 
common group of inherited diseases targeted are the primary immunodeficiency 
disorders (PIDs)  (Ginn, Alexander et al. 2013, Cicalese and Aiuti 2015, Naldini 2015).  
In the first clinical trials of gene therapy for PIDs, retroviral vectors were used in which 
expression of the normal transgene was driven by the retroviral vector expression. With 
this approach, successful and durable T cell reconstitution was achieved in patients with 
X-linked severe combined immunodeficiency (SCID-X1) (Cavazzana-Calvo, Hacein-Bey 
et al. 2000, Hacein-Bey-Abina, Hauer et al. 2010, Gaspar, Cooray et al. 2011), 
adenosine deaminase (ADA) deficiency (ADA-SCID) (Blaese, Culver et al. 1995, Kohn, 
Hershfield et al. 1998, Aiuti, Slavin et al. 2002, Gaspar, Cooray et al. 2011, Cicalese, 
Ferrua et al. 2016) and Wiskott–Aldrich syndrome (WAS) (Boztug, Schmidt et al. 2010, 
Moratto, Giliani et al. 2011). Unfortunately, several patients developed leukaemia. These 
serious adverse events were caused by integration of retroviral vectors in proximity of 
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transcription initiation sites of genes (including oncogenes) leading to deregulated 
expression of the targeted oncogenes (Hacein-Bey-Abina, Von Kalle et al. 2003). To 
counter these adverse effects several improvements have been made in developing 
safer vectors and are being used in clinical settings.  
Overall, concern and scepticism rose over the further deployment of these strategies. 
But these attitudes are radically changing. Many phase I/II gene therapy clinical trials 
using improved retro and lentiviral vectors have reported remarkable evidence of efficacy 
and safety for the treatment of PIDs like WAS (Aiuti, Biasco et al. 2013, Hacein-Bey 
Abina, Gaspar et al. 2015, Pala, Morbach et al. 2015) and SCID-X1 (Hacein-Bey-Abina, 
Pai et al. 2014, Sauer, Di Lorenzo et al. 2014). Moreover, these approaches are being 
translated to blood-borne disorders, such as thalassemia (Cavazzana-Calvo, Payen et 
al. 2010), sickle cell disease (Hoban, Orkin et al. 2016, Ribeil, Hacein-Bey-Abina et al. 
2017), haemophilia (Lheriteau, Davidoff et al. 2015); and metabolic disorders like X-
linked adrenoleukodystrophy (Cartier, Hacein-Bey-Abina et al. 2010). 
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1.2 Gene Therapy Vectors 
Gene therapy clinical trials and studies exploit improved vector technologies, ranging 
from simple naked DNA to live viruses, to deliver therapeutic genes. The unifying 
objective however of all these clinical projects is to mediate safe and efficient delivery of 
therapeutic agents into target cells along with stable transgene expression. A variety of 
vectors and delivery platforms have been investigated in gene therapy studies. Although 
non-viral approaches are becoming increasingly common, viral vectors remain by far the 
most popular, having been used in two-thirds of clinical trials performed with adenoviral, 
retroviral (RV), lentiviral (LV) and adeno-associated viral (AAV) vectors being the most 
commonly used gene delivery systems in the clinical settings till date (Fig. 1-2). 
 
Figur e 1-1 
Figure 1-2 Vectors Used in Gene Therapy Clinical Trials (August 2016)         
Source: Journal of Gene Medicine www.wiley.com/legacy/wileychi/genmed/ 
 
The basis of using viruses as vectors lies in harnessing their inherent capability of 
delivering genetic information into cells and re-populating them to produce large amounts 
of progeny. The harmful effects of a viral infection mostly occur from the hazardous 
products of certain viral genes. Therefore, by separating the disease-causing elements, 
viruses can be used as vectors carrying desired genetic information (Verma and 
Weitzman 2005).  
1.2.1 Retroviral Vectors 
Retroviral vectors were the first to be developed for transfer of genetic material in gene 
therapy. Retroviruses belong to the Reteroviridae family of single-stranded RNA 
spherical viruses (80 to 120 nm diameter) (Vogt and Simon 1999). In the nucleus, the 
retroviral particle consists of two copies of single stranded RNA genome along with the 
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enzymes reverse transcriptase, integrase and protease. The viral genome encodes for 
three proteins for gag, pol and env, which are required for viral replication and packaging. 
These components are complexed inside a nucleocapsid protein, which is further 
enclosed inside a second protein shell formed by the capsid protein (Jones and 
Morikawa 1998). Matrix proteins form a layer outside the core and interact with a cell-
derived lipid envelope, which incorporates viral envelope glycoproteins (env), 
responsible for the interaction with specific cell receptors. Two units form these 
glycoproteins, a transmembrane that anchors the protein into the lipid bilayer and a 
surface protein, which binds to the cellular receptor (Fig. 1-3). 
 
Figure 1-3 Schematic Representation of Retroviral Particle 
 
At the onset of infection, the surface glycoprotein envelope interacts with receptors on 
the surface of the target cell to gain entry. When inside the cell, the single stranded viral 
genome is converted into linear double stranded proviral DNA by virus encoded reverse 
transcriptase. The double stranded DNA is transported to the nucleus of the host cells. 
For many types of retroviruses, mitosis, is required for the breakdown of the nuclear 
envelope for the proviral DNA to reach the nucleus. Exceptions to the requirement of cell 
division for infection are lentiviruses that can actively transport the DNA to the nucleus 
of non-dividing cells. Once the provirus reaches the host nucleus, it is integrated into the 
host genome by integrase. The provirus then undergoes transcription and translation 
along with rest of the genome, resulting in assembly of new viral particles that bud off 
the surface of the target cell to infect other cells (Robbins and Ghivizzani 1998, Weiss 
1998, Kurian, Watson et al. 2000). 
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Based on the organization of their genomes, the retroviridae are divided into simple and 
complex retroviruses. Simple retroviruses include oncoretroviruses such as murine 
leukaemia virus while complex retroviruses comprise of lentiviruses like the human 
immunodeficiency virus 1 (HIV-1) (Robbins and Ghivizzani 1998). Vectors derived from 
oncoretroviruses have been attractive for gene therapy as they have a relatively large 
coding capacity (8-10 kb) and allow stable integration of genetic material into the host 
genome, leading to persistent long-term expression. Furthermore, they do not transfer 
viral genes. This avoids the destruction of vector transduced cells by cytotoxic T cells 
that are specific to viral proteins. In this sense, oncoretroviral vectors are less 
immunogenic and do not elicit anti-vector immune responses (Robbins and Ghivizzani 
1998).  
Although numerous clinical studies benefit from the use of oncoretrovirus-based vectors 
owing to their high efficiency in transducing dividing cells (Robbins and Ghivizzani 1998, 
Kurian, Watson et al. 2000). There are some important limitations: (i) instability of the 
viral particle, (ii) low viral titres, (iii) inability to transduce non-dividing cells and (iv) 
insertional mutagenesis (Robbins and Ghivizzani 1998). These limitations were clear in 
the first gene therapy trials where retroviral vectors were used for the treatment of X-
linked severe combined immunodeficiency (SCID-X1), chronic granulomatous disease 
(CGD), adenosine deaminase (ADA)-deficient severe combined immunodeficiency 
(ADA-SCID) and Wiskott-Aldrich syndrome (WAS) (Aiuti, Slavin et al. 2002, Ott, Schmidt 
et al. 2006, Boztug, Schmidt et al. 2010, Cavazzana-Calvo, Payen et al. 2010). While 
the treatment was effective for immune restoration, severe complications arose in some 
of the patients in whom the integrated retroviral vectors led to leukocyte proliferative 
disorders (Hacein-Bey-Abina, Von Kalle et al. 2003, Ott, Schmidt et al. 2006, Braun, 
Boztug et al. 2014).  
1.2.2 Lentiviral Vectors  
Lentivectors resemble retroviral vectors in their ability to integrate into target cell genome 
resulting in persistent transgene expression. They can transduce both dividing and non-
dividing cells, have a larger transgene toleration capacity (~7.5 kb), and a more 
favourable insertional profile than retroviral vectors (Matrai, Chuah et al. 2010). 
Moreover, it is possible to minimise the risk of non-specific insertion by modifying the 
vector design or by employing integration-deficient lentiviral vectors (Yanez-Munoz, 
Balaggan et al. 2006, Philpott and Thrasher 2007, Wanisch and Yanez-Munoz 2009).  
The design of lentivectors is based on the separation of cis- and trans-acting sequences. 
This increases the safety of lentivector produced. Components necessary for virus 
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production are thus divided across packaging, envelope, and transfer plasmid 
constructs. The lentiviral production systems are divided into three different generations 
depending upon the packaging plasmid used for production (Fig. 1-4) (Vigna and Naldini 
2000). 
 
Figure 1-4 Schematic Representation Lentiviral Packaging Constructs 
In the packaging vectors, viral long-term repeats (LTRs) are replaced by strong promoter (CMV) 
and poly-adenylation (poly-A) signal. 1st-generation packaging construct contains all genes 
encoding for structural and accessory proteins of HIV-1 except for the envelope. In the 2nd-
generation packaging construct, all the accessory genes are deleted. In the 3rd-generation 
packaging construct, the sequences encoding the Tat and Rev protein are also eliminated. Rev 
is expressed on a separate construct under the control of the RSV promoter. The envelope 
construct expresses the VSV-G protein under the control of the CMV promoter. PRO, promoter; 
SD, splice donor; SA, splice acceptor; RSV, rous sarcoma virus; CMV, cytomegalo virus; RRE, 
Rev-responsive element; VSV-G, vesicular stomatitis virus glycoprotein; ψ, packaging signal. 
Taken from (Vigna and Naldini 2000). 
 
The first-generation packaging plasmid provides all gag and pol sequences, the viral 
regulatory genes tat and rev and the accessory genes vif, vpr, vpu and nef. Identification 
of the HIV genes disposable for transfer of the genetic cargo allowed the engineering of 
the multiple-attenuated second-generation packaging systems (Zufferey, Nagy et al. 
1997). In these, the four accessory genes, vif, vpr, vpu and nef, are removed without 
negative effects on vector yield or infection efficiency, and as such improving lentivector 
safety, since any replication-competent lentivirus would be devoid of all virulence factors. 
The third-generation lentiviral system further improves on the safety of the second-
generation. It consists of a split-genome packaging system in which the Rev is expressed 
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from a separate plasmid under the control of a heterologous promoter, such as RSV 
(Fig. 1-4) (Dull, Zufferey et al. 1998, Vigna and Naldini 2000, Cockrell and Kafri 2007). 
The lentiviral transfer plasmid which encodes the transgene is depicted in Fig. 1-5. The 
transgene is flanked by LTR sequences and typically, it is the sequences between and 
including the LTRs that are integrated into the host genome (Dull, Zufferey et al. 1998, 
Vigna and Naldini 2000). For safety reasons, lentiviral vectors are all replication 
incompetent and may contain an additional deletion in the 3'LTR, rendering the virus 
self-inactivating (SIN) after integration (Zufferey, Dull et al. 1998). Key components of 
the third-generation lentiviral vector system are listed in Table 1.1.      
 
Figure 1-5 Schematic of Lentivector Transfer Plasmids 
Transgene is driven by an internal promoter. The wild-type LTR transfer vector maintains the 
unmodified HIV LTRs. The SIN transfer vector carries a large deletion in the U3 region 
(represented by [) of the 3’LTR completely inactivating its activity. The 5’ LTR is modified by 
substituting the U3 region with a strong promoter (RSV). The improved SIN vector contains cPPT 
and WPRE sequences. ψ, packaging signal; prom., internal promoter; SD, splice donor; SA, 
splice acceptor; GA, a portion of gag; cPPT: central polypurine tract; WPRE, woodchuck hepatitis 
post-transcriptional regulatory element; LTR, long-terminal repeat. Taken from  (Vigna and Naldini 
2000).
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Table 1-1 Glossary of Third-Generation Lentiviral Vector Components 
PLASMID  ELEMENT DESCRIPTION 
   
ENVELOPE VSV-G Vesicular stomatitis virus G glycoprotein; broad tropism envelope protein used to pseudo type most lentiviral vectors. 
   
PACKAGING Gag Precursor structural protein of the lentiviral particle containing Matrix, Capsid and Nucleocapsid components. 
 Pol Precursor protein containing Reverse Transcriptase and Integrase components. 
 Rev Binds to the Rev Response Element (RRE) within un-spliced and partially spliced transcripts to facilitate nuclear export. 
   
TRANSFER cPPT/cTS 
Central polypurine tract; recognition site for proviral DNA synthesis. Increases transduction efficiency and transgene 
expression. 
 Ψ (Psi) RNA target site for packaging by Nucleocapsid. 
 RRE Rev Response Element; sequence to which the Rev protein binds. 
 WPRE 
Woodchuck hepatitis virus post‐transcriptional regulatory element; sequence that stimulates the expression of 
transgenes via increased nuclear export. 
 LTR Long terminal repeats; U3-R-U5 regions found on either side of a retroviral provirus.  
 U3 
Unique 3'; region at the 3' end of viral genomic RNA. Contains sequences for activation of viral genomic RNA 
transcription. 
 R Repeat region found within both the 5' and 3' LTRs of retro/lentiviral vectors.  
 U5 Unique 5'; region at the 5' end of the viral genomic RNA. 
 5' LTR 
Acts as an RNA pol II promoter. The transcript begins at the beginning of R, is capped, and proceeds through U5 and 
the rest of the provirus.  
 3' LTR Terminates transcription started by 5' LTR by the addition of a poly A tract just after the R sequence. 
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1.2.3 Adeno-Associated Viral Vectors 
To minimize the risk of insertional mutagenesis, vectors capable of site-specific 
integration or devoid of integration are deemed suitable. Adeno-associated viruses 
(AAV) are explored as one such possibility for maintaining prolonged transgene 
expression in non-replicating cells, where they persist in a non-integrating and non-
replicating episomal form (Berns and Giraud 1995, Gao, Alvira et al. 2002, Grimm and 
Kay 2003, Verma and Weitzman 2005, Perabo, Endell et al. 2006, Daya and Berns 
2008). Twelve human serotypes of AAV (AAV-1 to AAV-12) have thus far been identified, 
with the best characterized and most commonly used being AAV2 (Gao, Alvira et al. 
2002, Daya and Berns 2008). These serotypes differ in their tropism, or the types of cells 
they infect, making AAV a very useful system for preferentially transducing specific cell 
types. The lack of pathogenicity of the virus, the persistence of the virus, and the many 
available serotypes have increased AAV's potential as a delivery vehicle for gene 
therapy applications. AAV vectors are currently among the most frequently used viral 
vectors for gene therapy (Carter 2005, Perabo, Endell et al. 2006, Daya and Berns 2008).  
AAV is a small (25 nm), non-enveloped virus that packages a linear single-stranded DNA 
genome. It belongs to the family Parvoviridae and is placed in the genus Dependovirus, 
because productive infection by AAV occurs only in the presence of a helper virus, 
usually either adenovirus or herpesvirus (Gao, Alvira et al. 2002). In the absence of 
helper virus, AAV (serotype 2) can set up latency by integrating into chromosome 
19q13.4 (Shi, Arnold et al. 2001, Grimm and Kay 2003). 
The small 4.8 kb single-stranded DNA AAV genome consists of two open reading frames 
encoding for viral genes replication (Rep) and capsid (Cap), flanked by two 145 bp 
inverted terminal repeats (ITRs) (Daya and Berns 2008, Kwon and Schaffer 2008, 
Kotterman and Schaffer 2014). These ITRs base pair to allow for synthesis of the 
complementary DNA strand. Rep and Cap are translated to produce multiple distinct 
proteins. These include Rep78, Rep68, Rep52, Rep40, which are required for the AAV 
life cycle; and VP1, VP2, VP3, proteins associated with the formation of capsid 
(Kotterman and Schaffer 2014). When constructing an AAV transfer plasmid, the 
transgene is placed between the two ITRs, and Rep and Cap are supplied in trans (Fig. 
1-6) (Kotterman and Schaffer 2014). In addition to Rep and Cap, AAV requires a helper 
plasmid containing genes from adenovirus. These genes (E4, E2a and VA) mediate AAV 
replication (Perabo, Endell et al. 2006, Daya and Berns 2008). The transfer plasmid, 
Rep/Cap, and the helper plasmid are transfected into HEK293 cells, which contain the 
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adenovirus gene E1+, to produce infectious AAV particles (Kotterman and Schaffer 
2014) (Fig. 1-6). 
The separation of Rep and Cap facilitates the viral pseudo-typing, which is the process 
of mixing capsids and genomes from different viral serotypes (Wu, Asokan et al. 2006). 
Use of these pseudo-typed viral vectors improves the transduction efficiency and alters 
the tropism. One common example is AAV2/5, where AAV2 is the genome and AAV5 is 
the capsid. The vector targets neurons that are not efficiently transduced by AAV2/2. 
Furthermore, this serotype shows wide spread expression throughout the brain thus 
indicating improved transduction profile (Georgiadis, Duran et al. 2016). 
 
Figure 1-6 Schematic of AAV Plasmid System 
To produce an adeno-associated viral (AAV) vector, the AAV genome is split into independent 
plasmids. A Rep/Cap plasmid encoding viral proteins necessary for replication and formation of 
AAV particle. The transgene flanked between AAV inverted terminal repeats (ITRs) is supplied 
on a separate plasmid construct. WPRE, woodchuck hepatitis B posttranscriptional regulatory 
element; Rep, replication; Cap, capsid, Poly-A, polyadenylation signal. 
 
As part of its lysogenic cycle, wild-type AAV integrates into the host genome at a specific 
site, AAVS1 on human chromosome 19. This site is favoured due to the presence of a 
Rep binding element; however, random integrations may occur at a much lower 
frequency. As a replication-incompetent virus, AAV cannot enter the lytic cycle without 
help. Another virus, such as adenovirus or herpes simplex virus, or a genotoxic agent 
such as UV radiation or hydroxyurea, is necessary for lytic cycle activation (Grimm and 
Kay 2003, Daya and Berns 2008). 
When recombinant-AAV (rAAV) is used, the Rep protein is supplied in trans, eliminating 
the ability of rAAV to integrate into its preferred site of genomic integration on human 
chromosome 19, termed AAVS1  (Burger, Gorbatyuk et al. 2004, Dismuke, Tenenbaum 
et al. 2013). Instead, the rAAV genome is typically processed into a double stranded, 
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circular episome through double stranded synthesis. These episomes can 
concatemerise, producing high molecular weight structures that are maintained 
extrachromosomally. rAAV are more likely than wild-type AAV to integrate at non-
homologous sites in the genome (Burger, Gorbatyuk et al. 2004). Nonetheless, most 
rAAV particles are thought to be maintained in episomes or concatemers. Episomes 
differ profoundly from viral particles produced during a lytic cycle. rAAV episomes can 
develop chromatin-like organization and persist in non-dividing cells for a period of years 
without damaging the host cell. In contrast, viral particles produced during a lytic cycle 
are quickly released through cell lysis. Episomal stability enables long-term transgene 
expression in non-dividing cells and is a key advantage of rAAV (Dismuke, Tenenbaum 
et al. 2013). 
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1.3 DNA Repair 
1.3.1 Overview 
Repair of DNA double strand breaks (DSBs) plays a critical role in the maintenance of 
the genome. DSB arise frequently because of replication fork stalling and due to the 
attack of exogenous agents. DSBs can be generated by environmental factors such as 
ionizing radiation, by cellular metabolic products and as recombination intermediates. In 
cycling cells, DSBs occur mainly during replication. Repair of broken DNA is essential 
for cellular survival. Left unrepaired or incorrectly repaired, they can lead to genomic 
changes that may result in cell death or cancer. DSBs are the most critical type of DNA 
damage to the cells, as it is believed that a single unrepaired DSB is sufficient for 
inducing apoptosis (Sonoda, Hochegger et al. 2006, Helleday, Lo et al. 2007, Davis and 
Chen 2013, Shibata and Jeggo 2014). 
Two major pathways, homologous recombination (HR) and non-homologous end-joining 
(NHEJ) have evolved to deal with these lesions, and are conserved from yeast to 
vertebrates. Despite the conservation of these pathways, their relative contribution to 
DSB repair varies greatly between these two species. HR plays a dominant role in any 
DSB repair in yeast, whereas NHEJ significantly contributes to DSB repair in vertebrates. 
This active NHEJ requires a regulatory mechanism to choose HR or NHEJ in vertebrate 
cells (Sonoda, Hochegger et al. 2006, Lieber 2010, Davis and Chen 2013). 
1.3.2 Homologous Recombination  
Whereas NHEJ is a conceptually simpler cascade of events, homologous recombination 
is a complex process that exploits undamaged homologous templates of DNA to restore 
and repair damaged DNA sequences. Homologous recombination is initiated by 
CtIP/MRE11-dependent resection of double stranded DNA ends (Li and Heyer 2008). 
The extension of resection is highly regulated and involves the repositioning of 53BP1 
via a BRCA1-dependent process (Liu and West 2004, Li and Heyer 2008). The single-
stranded tails generated by resection are rapidly bound by Replication protein A (RPA). 
Nucleoprotein filaments subsequently form after replacement of RPA by RAD51 via a 
process that involves BRCA2. The nucleoprotein filaments promote invasion of the 
undamaged homologue, strand displacement and D-loop formation. The displaced 
strand pairs with the broken and abandoned strand, generating a heteroduplex molecule 
and a Holliday junction. Subsequently, synthesis using the undamaged strand as a 
template and ligation repairs the DSB. Finally, resolution of the heteroduplex molecule 
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generates crossover or non-crossover products depending on the direction of resolution 
(Fig. 1.7) (Paigen and Petkov 2010).  
1.3.3 Non-Homologous End-Joining  
In mammalian cells, NHEJ DNA repair pathway requires 6 core proteins – Ku70/80 
heterodimer, DNA-PKcs, XRCC4 (X-ray complementing Chinese hamster gene) 4), DNA 
ligase IV, Artemis and XLF or Cernunnos (Fig. 1-7) (Lees-Miller and Meek 2003, Meek, 
Gupta et al. 2004, Mahaney, Meek et al. 2009, Hammel, Yu et al. 2010, Lieber 2010, 
Davis and Chen 2013). Deletion or inactivation of any of these core NHEJ factors induces 
marked sensitivity to ionising radiation and other DSB-inducing agents, as well as defects 
in the V(D)J recombination. In general terms, NHEJ is thought to proceed through the 
following stages: i) detection of the DSB and tethering or protection of the DNA ends; (ii) 
DNA-end processing to remove damaged or non-ligatable groups; and (iii) DNA ligation 
(Lees-Miller and Meek 2003).  
DNA ends are first recognised by the NHEJ factor DNA-PK, which is composed of the 
DNA PKcs and Ku70/80 heterodimer (Blunt, Finnie et al. 1995, Jackson and Jeggo 1995, 
Secretan, Scuric et al. 2004). After initial loading of the Ku70/80 heterodimer onto DNA 
ends, DNA PKcs is recruited to form a DNA end synapsis, ensuring protection from 
exonuclease activities and juxtaposition of DNA ends. The presence of Ku70/80 and 
DNA-PKcs at DNA ends is not rigid but constitutes a dynamic equilibrium of DNA-bound 
and DNA-free protein. Trans autophosphorylation of the ABCDE cluster of DNA PKcs (7 
phosphorylation sites between residues 2,609 and 2,647) causes conformational 
changes that facilitate Artermis nuclease activity (Douglas, Sapkota et al. 2002, 
Secretan, Scuric et al. 2004, Uematsu, Weterings et al. 2007), which is required for the 
opening of hairpin sealed coding joints. During processing of coding ends, nucleotides 
can be lost due to exonuclease activity, and non-template nucleotides can be added by 
terminal deoxynucleotidyl transferase. This contributes tremendously to the diversity of 
antigen receptor repertoire. Trans autophosphorylation of PQR cluster of DNA-PKcs (6 
phosphorylation sites between residues 2,203 and 2,056) functions to limit further end 
processing and to specifically promote end-joining (Ding, Reddy et al. 2003, Block, Yu 
et al. 2004, Lieber 2010, Davis and Chen 2013). Finally, the DNA ends are ligated by 
XRCC4-ligase IV complex, prompted by XLF. 
Cells use two mechanistically distinct end-joining pathways to repair DNA DSBs. 
Classical or c-NHEJ leads to minimal sequence alterations at the repair junctions, 
whereas alt-NHEJ (also known as microhomology-mediated end joining or MMEJ) 
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causes extensive deletions (as well as insertions) that scar the break sites following 
repair (Betermier, Bertrand et al. 2014, Shibata and Jeggo 2014).  
Alt-NHEJ or MMEJ is a mutagenic DSB repair mechanisms that use alignment of 
microhomologous sequences (1-16 nucleotides) flanking the initiating DSB to align the 
ends of repair (Wang, Perrault et al. 2003). Because of which, the process is associated 
with deletions and insertions that mark the original break site, as well as chromosome 
translocations. Whether MMEJ has a physiological role or is simply a back-up repair 
mechanism is a matter of debate (Wang, Perrault et al. 2003, Wang and Xu 2017) 
Classical or c-NHEJ is active throughout the cell cycle and is initiated when the Ku70–
Ku80 heterodimer binds to DNA ends with high affinity. Ku then recruits the Ser/Thr 
kinase DNA-PKcs to phosphorylate several downstream targets, including the terminal 
end-processing enzyme Artemis that cleaves single-stranded overhangs, and DNA 
ligase 4 (LIG4) and the scaffold protein XRCC4, which catalyse the ligation of DNA ends. 
Alt-NHEJ, which is most active in the S and G2 phases of the cell cycle, is dependent on 
signalling by poly(ADP-ribose) polymerase 1 (PARP1) and relies on 5′–3′ resection of 
DNA by MRN (MRE11–RAD50–NBS1) and CtBP-interacting protein (CtIp) (Fig. 1.7) 
(Shibata and Jeggo 2014). Base pairing at the resected ends drives their annealing to 
promote synapsis of opposite ends of a DSB. Annealed ends are subject to fill-in 
synthesis by the low-fidelity DNA polymerase θ (Pol θ), which stabilizes the annealed 
intermediates and promotes end joining, primarily by DNA ligase 3 (LIG 3). Alt-NHEJ 
introduces deletions and insertions that scar the break sites following repair. The 
deletions are caused by extended nucleolytic processing, whereas the insertions result 
from the activity of Pol θ (Hammel, Yu et al. 2010, Black, Kashkina et al. 2016). 
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Figure 1-7 Schematic of DNA Repair Pathways 
Non-homologous end-joining (NHEJ) is the first choice of double stranded break (DSB) repair pathway in mammalian cells. However, if NHEJ does not 
ensure in late s or G2 phases of cell cycle, cells exploit the use of homologous recombination (HR). Separately, in absence of key NHEJ proteins such 
as Ku, DNA ligase IV (LIG4) and DNA protein kinase catalytic sub-unit (DNA-PKcs), the mutagenic alternative NHEJ (alt-NHEJ) predominantly takes 
place. Indels: Insertions or deletions; DNA-PK: DNA protein kinase; RPA: replication protein A; XRCC1/4: X-ray complementing Chinese hamster gene; 
XLF: XRCC4-like factor; LIG 3: DNA ligase 3. Adapted from (Shibata and Jeggo 2014).
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1.4 Genome Editing 
1.4.1 Overview 
Gene editing is a gene therapy approach that relies on designer nucleases to recognise 
and cut specific DNA sequences, and subsequently exploit innate cellular DNA repair 
pathways, namely non-homologous end joining and homology directed repair, to 
introduce targeted modifications in the genome (Fig. 1-8).  
 
Figure 1-8 Resolution of a Double Stranded Break  
A nuclease is targeted towards a defined genomic locus, introducing a DSB. This may undergo 
one of two major repair pathways known as non-homologous end joining (NHEJ) or homology 
directed repair (HDR), depending upon cell cycle stage and availability of a DNA donor template. 
NHEJ is an error prone mechanism, which causes small insertions or deletions (Indels) upon 
ligating the ends of the DNA break. HDR is a precise mechanism which repairs the break by using 
a homologous donor template, normally the sister chromatid.  
 
NHEJ repairs the lesion by directly re-joining the DSBs ends together in a process that 
does not require a repair template. Although NHEJ-repair can be accurate, repeated 
repair of the same DSB eventually results in insertion and deletion mutations (indels) 
joining the break site. Indels created can cause frameshift mutations leading to mRNA 
degradation by nonsense-mediated decay or result in formation of truncated non-
functional proteins (Lees-Miller and Meek 2003). In contrast, HDR allows for repair of the 
targeted genomic region. Since for HR to take place, it is not necessary for the two 
homologs to be chromosomal, the process can be exploited by supplying a donor or 
‘template’ DNA to the cells and transferring that information into its genome (Thomas 
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and Capecchi 1986, Capecchi 1989). Upon introduction of a DSB, HDR machinery 
utilises exogenous single- or double stranded DNA templates that has sequence 
similarity to the break site, to repair the lesion, incorporating any changes encoded in the 
template DNA. Homology-directed gene repair offers potential advantages. First, it 
avoids the potential risks of harmful mutations associated with random non-specific 
integration of therapeutic DNA. Second, it preserves the original expression and 
regulation patterns of the gene. Third, it can correct both recessive and dominant 
disorders, unlike gene addition which are restricted to treating recessive disorders 
(Yanez and Porter 1998).  
In the context of a disease-causing locus, NHEJ can be exploited to excise or disrupt 
deleterious sequences, or even restore the reading frame of a gene (Fig. 1-9). In 
contrast, HDR which requires a donor DNA containing sequences homologous to those 
adjacent to the DSB, can be used to repair a mutation, or to knock-in a block of exons 
(“superexon”) or a full cDNA at either the endogenous locus (reconstituting the wild-type 
sequence) or at a genomic ‘safe harbour’ (a region of DNA where transgenes can 
integrate and express in a predictable manner without insertional mutagenesis or 
perturbation of gene function) (Sadelain, Papapetrou et al. 2011) (Fig. 1-9).  
Gene editing thus opens the possibility of permanently modifying a genomic sequence 
of interest by enabling targeted disruption, insertion, excision, and correction in both ex 
vivo and in vivo settings (Fig. 1-10). 
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Figure 1-9 Gene Editing Strategies Using DNA Repair Pathways 
1) Non-homologous end joining (NHEJ) can be used to disrupt genomic sequences because of insertions or deletions (Indels). This can cause frameshift mutations 
leading to an early stop codon (or restoration of the reading frame ssby splice site disruption). 2) NHEJ can mediate targeted deletions. This requires generation 
of double strand breaks (DSBs) on both sides of the target genomic sequence, which then deletes the intervening sequence while NHEJ re-joins the DNA ends. 3) 
Homology-directed repair (HDR) can be used to correct a specific mutation by introducing a nuclease-mediated DSB (in proximity to the target site) in the presence 
of a homologous donor DNA containing corrective sequence. Upon recombination, the repair template corrects the mutated locus. 4) Likewise, by supplying 
exogenous DNA on the donor template flanked between regions of homology, HDR can be used to mediate targeted gene insertion or knock-in.
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Figure 1-10 Ex Vivo and In Vivo Gene Editing Approaches 
In vivo approaches involve direct transfer (denoted by the syringe) of genome editing reagents 
such as programmable nucleases and donor templates to the human body. In this instance, two 
prominent gene transfer agents, viral vectors and liposomes are shown. Ex-vivo is centred on 
correction of the genetic defect outside of the body. This is a staged-approach whereby: 1) Patient 
cells are obtained. 2) Gene editing is performed in vitro. This involves delivery of nucleases on 
their own or concomitantly with repair template. Optionally, the patient cells can be programmed 
into induced pluripotent stem cells (iPSCs) before or after gene editing. Once corrected, iPSCs 
may be differentiated into cell types of interest. 3) The genetically corrected cells are 
characterized and expanded. 4) The corrected cells are then re-grafted back into the patient 
through autologous transplantation. 
 
To date, four major classes of programmable nucleases have been developed to enable 
targeted genome editing. These include mega-nucleases and their derivatives, zinc 
finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
CRISPR-associated Cas9 nuclease. Based on their mode of DNA recognition these 
nucleases can be classified into two broad categories. First, mega-nucleases, TALENs 
and ZFNs that recognise and specifically bind DNA via protein-DNA interactions and 
second, CRISPR-based Cas9 nuclease, which is guided to specific DNA sequence by 
small RNA molecules forming a RNA-DNA hybrid.  
Meganucleases are natural endonucleases with large (>14 bp) recognition sites. Their 
DNA binding domains are also responsible for cleavage of target sequences (Silva, 
Poirot et al. 2011). ZFNs and TALENs on the other hand are chimeric enzymes 
consisting of a DNA binding domain fused to sequence specific FokI nuclease domain 
(Porteus and Carroll 2005, Urnov, Miller et al. 2005). Targeting using these requires 
extensive protein engineering and complex molecular cloning. In contrast, Cas9 can be 
easily targeted to DNA sequences by changing the base pair sequence of the guide RNA 
that binds directly the target DNA. Cas9 can also be used to create DSBs at multiple 
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sites, known as multiplexing, within the same cell by expression of distinct guide RNA 
molecules. All four nucleases have been shown to achieve efficient genome editing in a 
wide range of organisms and mammalian systems and therapeutic benefit in monogenic 
disease models (Prakash, Moore et al. 2016). 
1.4.2 Zinc Finger Nucleases  
Zinc finger nucleases (ZFNs) are powerful tools used for making directed genomic 
modifications in experimental organisms for functional studies or for creating models of 
human genetic diseases (Porteus and Carroll 2005, Carroll 2011). A ZFN is a fusion 
protein and has a modular structure that is composed of two domains: a DNA-binding 
zinc-finger protein (ZFP) domain and the nuclease domain derived from the FokI 
restriction enzyme (Porteus and Carroll 2005) (Fig. 1-11).  
 
Figure 1-11 Schematic Representation of ZFNs  
Each ZFN monomer is made of a zinc finger protein (ZFP) at the amino terminus and the FokI 
nuclease domain at the carboxyl terminal. Each ZFP binds with 3 base pairs of the sequence. 
Target sequences of ZFN pairs are typically 18-36 base pairs in length, excluding a 5-7 base pair 
spacer region.  
The structurally separated DNA-binding domain of FokI can be replaced with ZFPs to 
create ZFNs, and the FokI nuclease domain must dimerize to cleave DNA. Thus, two 
ZFN monomers are required to form an active nuclease; each monomer must bind to 
adjacent half-sites that are separated by spacers of 5–7 bp (Fig. 1-11). This requirement 
for dimerization doubles the length of recognition sites, which substantially increases the 
specificity of ZFNs. However, the wild-type FokI domain can still form homodimers to 
cleave DNA when one monomer binds to DNA, which often leads to unwanted off-target 
effects. The FokI dimeric interface was artificially modified to generate obligate 
heterodimeric forms, which substantially reduced off-target effects and ZFN cytoxicity 
(Miller, Holmes et al. 2007, Szczepek, Brondani et al. 2007). 
The sequence specificity of ZFNs is determined by ZFPs, which consist of tandem arrays 
of C2H2 zinc-fingers — the most common DNA-binding motif in higher eukaryotes 
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(Durai, Mani et al. 2005). Each zinc-finger recognizes a 3-bp DNA sequence (Urnov, 
Rebar et al. 2010, Carroll 2011), and 3–6 zinc-fingers are used to generate a single ZFN 
subunit that binds to DNA sequences of 9–18 bp (Fig. 1-11).  
The co-crystal structure of a ZFP bound to DNA showed that zinc-finger–DNA 
interactions are modular in nature; each zinc-finger interacts almost independently with 
a 3-bp DNA sequence (Miller, Holmes et al. 2007). Indeed, new ZFPs with desired 
specificities can be constructed by modular assembly of pre-characterized zinc-fingers 
(Kim, Lee et al. 2009). However, ZFNs created using this fast and convenient method 
often either lack DNA targeting activity or are cytotoxic owing to off-target effects (Cornu 
and Cathomen 2010, Ramirez, Certo et al. 2012). Cell-based selection methods and 
modular assembly methods that account for context dependence between neighbouring 
zinc-fingers have been developed to yield functional ZFNs (Maeder, Thibodeau-Beganny 
et al. 2008, Maeder, Thibodeau-Beganny et al. 2009). Nonetheless, it remains 
challenging to construct ZFNs with high activity and low cytotoxicity using publicly 
available resources. 
1.4.3 CRISPR-Cas9 System 
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR 
associated (Cas) are essential components of nucleic-acid-based adaptive immune 
systems that are widespread in bacteria and Archae. Originally identified in Escherichia 
coli (Ishino, Shinagawa et al. 1987), the CRISPR-mediated immune system relies on 
small guide RNAs for sequence-specific detection and destruction of invading 
pathogens, including viruses and plasmids (Barrangou, Fremaux et al. 2007, 
Wiedenheft, Zhou et al. 2009, Mali, Esvelt et al. 2013).  
The CRISPR/Cas immunity occurs in phases (Fig. 1-12). Firstly, in the infection phase, 
in response to a viral infection, bacteria and archaea acquire and integrate short 
fragments of invading nucleic acid (known as protospacers) into their chromosome 
proximal to CRISPR loci. These repetitive loci serve as genetic ‘memory cards’ by 
maintaining a record of encounters with a pathogen. Once the spacer is acquired, the 
repeats duplicate maintaining the architecture of repeat-spacer-repeat. In the next phase 
of immunity which encompasses expression and interference, CRISPR loci with acquired 
spacers are transcribed into precursor CRISPR RNA (pre-crRNA) which is subsequently 
processed into a library comprising of short CRISPR-derived RNAs (crRNAs) with each 
corresponding to a complementary nucleic-acid sequence from invading pathogen. 
These short crRNAs then bind to large protein surveillance complex - Cas protein 
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complex (Cascade) - and mediate detection of any foreign pathogen by surveying the 
intra-cellular space (Brouns, Jore et al. 2008, Wiedenheft, Zhou et al. 2009). 
The CRISPR loci are approximately 20-50 base pairs in length separated by unique 
spacer regions. Within a CRISPR locus the repeats are conserved, but sequences in 
different CRISPR loci differ both in sequence and length. Even more, the repeat-spacer 
units in a CRISPR locus varies widely within and across different species. Owing to this 
variation, the identification of these loci was initially limited but now with use of 
computational programmes that can carry out widespread comparative analyses, related 
structures have been revealed – an (A+T)-rich leader sequence designated as a 
promoter element, and set of four CRISPR-associated (cas 1-4) genes (Jansen, Embden 
et al. 2002).  
Phylogenetic analyses based on Cas1 sequences led to evidence for classification of 
distinct CRISPR types – Type I, II and III (Kunin, Sorek et al. 2007). Type I and III share 
some comparable features, like, specialized Cas endonucleases processes the pre-
crRNAs, and once mature, each rRNA assembles into a large multi-Cas protein complex 
capable of recognizing and cleaving nucleic acids complementary to the crRNA. In 
contrast, type II systems process pre-crRNAs using a ternary complex composed of a 
trans-activating crRNA (termed tracrRNA), RNA specific ribonuclease RNase III, and a 
type-II CRISPR-associated endonuclease Cas9. The Cas9 nuclease with crRNA and 
tracrRNA binds to and cleaves dsDNA protospacer sequences homologous to crRNA 
spacer and lying adjacent to a short protospacer adjacent motif (PAM) recognised by 
Cas9 (Jinek, Chylinski et al. 2012).  Cas9 is thought to be the sole protein responsible 
for crRNA-guided silencing of foreign DNA. The specificity of the CRISPR-Cas system 
relies on tightly bound crRNA, which efficiently guides Cas9 to its target—the 
complementary DNA fragment (Wiedenheft, Zhou et al. 2009).  
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Figure 1-12 CRISPR-Mediated Adaptive Immune Systems 
A diverse set of CRISPR-associated (cas) genes encode proteins required for new spacer 
sequence recognition, CRISPR RNA biogenesis and target interference. Each CRISPR locus 
consist of a series of direct repeats separated by unique spacer sequences acquired from 
invading genetic elements known as protospacers. These sequences are flanked by a short motif 
called protospacer adjacent motif (PAM) that is located on the 5’ (type I) or 3’ (type III) side of the 
foreign DNA. Taken from (Mali, Esvelt et al. 2013). 
 
Cas9 proteins constitute a family of enzymes that require base-paired structure formed 
between the activating tracrRNA and the targeting crRNA to cleave target dsDNA. At 
sites, complementary to the crRNA-guide sequence, the Cas9 HNH nuclease domain 
cleaves the complementary strand, whereas the Cas9 RuvC-like domain cleaves the 
non-complementary strand. The dual tracrRNA:crRNA can be engineered as a single 
artificial RNA chimera, known as single guide RNA or gRNA, to direct sequence-specific 
Cas9 dsDNA cleavage (Jinek, Chylinski et al. 2012, Mali, Esvelt et al. 2013, Cong and 
Zhang 2015).  
The type II CRISPR system from Streptococcus pyogenes has been adapted for inducing 
sequence-specific DSBs and targeted genome editing (Jinek, Chylinski et al. 2012, 
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Doudna and Charpentier 2014, Barrangou and Doudna 2016). In the simplest and most 
widely used form of this system, two components must be introduced into and/or 
expressed in cells or an organism to perform genome editing: the Cas9 nuclease and 
the gRNA, consisting of a fusion of a crRNA and a fixed tracrRNA (Jinek, Chylinski et al. 
2012, Fu, Reyon et al. 2014) (Fig. 1-13).  
 
Figure 1-13 CRISPR/Cas9 Gene Editing Components 
CRISPR-Cas9 system is a rapid gene editing technology. Cas9 is a CRISPR-associated 
endonuclease that can be programmed to mediate a double-stranded break in the DNA. The 
location at which the Cas9 can cut the DNA is specified by short RNA molecule called guide RNA 
(gRNA).  
 
Twenty nucleotides at the 5′ end of the gRNA (corresponding to the protospacer portion 
of the crRNA) directs Cas9 to a specific target DNA site using standard RNA-DNA 
complementarity base-pairing rules. These target sites must lie immediately 5′ of a PAM 
sequence that matches the canonical form 5′-NGG. N stands for any nucleotide. Thus, 
with this system, Cas9 nuclease activity can be directed to any DNA sequence of the 
form N20-NGG simply by altering the first 20 nucleotides of the gRNA to correspond to 
the target DNA sequence.  
Type II CRISPR systems from other species of bacteria that recognize alternative PAM 
sequences and that utilize different crRNA and tracrRNA sequences have also been 
used for targeted genome editing (Heler, Samai et al. 2015). Following the initial 
demonstrations in 2012 that Cas9 could be programmed to cut various DNA sites in vitro 
(Jinek, Chylinski et al. 2012, Mali, Esvelt et al. 2013, Mali, Yang et al. 2013). CRISPR-
Cas9 platform has rapidly developed into a remarkable genome editing tool. Of the 
designer nuclease systems, currently available for precision genome engineering, the 
CRISPR-Cas system is by far the simplest and user friendly, showcasing high efficiency 
as well as versatility across multiple platforms – plants (Bortesi and Fischer 2015), yeasts 
(DiCarlo, Norville et al. 2013), insects (Bassett, Tibbit et al. 2013, Hammond, Galizi et al. 
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2016), monogenic human diseases (Cox, Platt et al. 2015, Prakash, Moore et al. 2016), 
and human embryos and zygotes (Liang, Xu et al. 2015, Tang, Zeng et al. 2017). 
1.4.4 Limitations and Perspective 
Classical gene therapy approaches have centred on the delivery of DNA to augment 
endogenous gene expression. Predominantly, these approaches rely on the transfer of 
functional genes using viral vectors. Retroviral vectors provided the first clear 
demonstrations of therapeutic benefit in primary immunodeficiencies, and they also 
highlighted the risk of adverse events attributable to insertional mutagenesis due to 
genomic integration of proviruses. Some success stories of gene therapy include 
Glybera, the first clinically approved gene therapy in the European Union, which uses an 
AAV vector drug for lipoprotein lipase deficiency – although this has now been retracted 
from the market; Strimvelis, a retroviral vector based drug for ADA-SCID; Spinraza,, an 
antisense oligonucleotide based drug targeting RNA transcript for treatment of all types 
of Spinal Muscular Atrophy; and in the case of cystic fibrosis, repeated nebulization of 
liposomes encoding the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene. These success stories and ongoing research on gene augmentation has paved 
the way for gene editing technologies that hold tremendous promise. The past few years 
have seen notable demonstrations of genome editing being applied across a multitude 
of disease models. Whilst the application of engineered nucleases holds significant 
therapeutic promise, optimum progress can only be achieved by examining the 
advancement of gene editing holistically. Several ubiquitous challenges need to be 
considered, mostly relating to efficacy of genome editing at the target sequence, safety 
concerns related to nuclease-associated off-target effects and delivery of gene editing 
tools. 
Editing efficiency is dependent upon the DNA repair process being relied upon. In 
instances where the desired effect can be achieved by NHEJ, the correction will most 
likely occur at a relatively high frequency as NHEJ is the major repair pathway in 
mammalian cells, although the usefulness of this approach may be limited by the 
stochastic nature of the Indels being formed. As discussed earlier, NHEJ has been used 
to mediate disruption of coding and regulatory sequences, targeted deletions of exons 
or large intervening sequences and disruption of splice sites. Methods that can predict 
and evaluate micro-homology sites can be used to bias the repair towards frameshift 
mutations in protein coding sequence (Bae, Kweon et al. 2014). This would partially 
address the potential reduction in efficiency caused by micro-homology-mediated end 
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joining, a secondary end-joining pathway with a bias for in-frame deletions (Morton, 
Davis et al. 2006). 
Precise HDR-based locus alterations allow targeted insertion or in situ correction of 
mutated DNA sequence that are suitable for a large subset of disease-causing 
mutations. However, they are reliant upon homologous recombination, which in turn is 
normally limited to S and G2 phases of the cell cycle and therefore requires a DNA 
template and inherently occurs at lower frequencies. HDR-based strategies may also 
require enrichment and expansion of corrected cells, normally restricted to ex vivo 
approaches. While ex vivo manipulation may be possible in diseases like those treated 
by correcting bone marrow HSCs, it would limit applications in diseases with multi-organ 
involvement or those where transplantation is not an option. Further progress in enabling 
HDR with higher efficacy would therefore be beneficial. In this respect, a recent report 
has demonstrated that it may be possible to transiently activate HDR in G1 cells by 
restoring BRCA1-PALB2 interaction (Orthwein, Noordermeer et al. 2015), possibly 
facilitating HDR genome-editing in quiescent cells. 
The specificity of genome editing is one of the major safety concerns for translational 
research. Owing to sequence similarities within the genome, endonucleases can cleave 
and modify off-target regions that are distinct from the site of interest. Off-target effects 
can lead to unwanted genetic modifications causing cellular stress, functional impairment 
or enhancement, and oncogenicity, all of which could have detrimental effects clinically 
(Maggio and Goncalves 2015). Considerable work is being undertaken to increase 
fidelity through better design of nuclease components, which has led to improved 
variants such as megaTALs (Boissel, Jarjour et al. 2014), dead Cas9-Fok1 fusion 
nucleases (Tsai, Wyvekens et al. 2014), Cas9 nickases (Ran, Hsu et al. 2013), and Cas9 
nucleases with truncated guide RNAs (Fu, Reyon et al. 2014). Furthermore, screens of 
bacterial strains have led to discovery of several alternative Cas9-nucleases with varying 
specificities (Sapranauskas, Gasiunas et al. 2011, Esvelt, Mali et al. 2013, Hou, Zhang 
et al. 2013, Ran, Cong et al. 2015). More recently, Cpf1, a prominent CRISPR variant 
that requires a shorter RNA and generates a staggered cut which could improve HDR 
(Zetsche, Gootenberg et al. 2015, Kleinstiver, Tsai et al. 2016), a high-fidelity engineered 
Cas9 (Kleinstiver, Pattanayak et al. 2016) that showed high on target specificity, and the 
smallest Cas9 orthologue derived from Campylobacter jejuni, called CjCas9 (Kim, Koo 
et al. 2017), have also been described. These variants highlight the progress in the field 
but still require extensive examination prior to their application in a translational research 
setting. Specificity of modification can also be helped by careful target site selection and 
use of delivery methods that would allow for efficient but transient expression of 
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nucleases. New methods, such as GUIDE-seq (Tsai, Zheng et al. 2015) and BLESS 
(Crosetto, Mitra et al. 2013), have also been developed for unbiased evaluation of off-
target modifications on a genome-wide scale.  
The final challenge pertains to the delivery of gene editing reagents including nucleases 
and a donor template in case of HDR. A variety of delivery approaches are being 
explored depending on cell types to be targeted. Cells that can be cultured and engrafted 
under ex vivo conditions are amenable to delivery via nucleic acids, proteins and viral 
vector systems; mRNA and protein delivery of the nucleases are now well-established 
procedures. However, for in vivo gene editing applications the most promising delivery 
systems are viral vectors. Both integrating and non-integrating viral vector systems have 
been explored in this context, although the latter are favoured due to their safety profile. 
AAV vectors, with a wide range of serotypes and ability to transduce a variety of tissue 
types are promising candidates.  
Despite the outlined challenges, genome editing is advancing at fast pace, with 
continued focus on pioneering and improving strategies. The safe use of ZFNs targeting 
CCR5, the co-receptor necessary for HIV to infect T-cells, to control AIDS, remains a 
milestone of gene-editing in a therapeutic setting (Tebas, Stein et al. 2014). In this case, 
the infusion of autologous CD4 T cells in which the CCR5 gene was rendered 
permanently dysfunctional by ZFNs was deemed safe. 12 patients who had been taking 
antiretroviral drugs were treated with gene edited T cells. After the treatment, six of the 
12 participants stopped their antiretroviral drug therapy and their HIV levels rebounded 
more slowly than normal, and their T-cell levels remained high for weeks. This first small 
trial implicated that gene editing approach seemed to be safe and is an important 
advance in the direction for this kind of research.  
  
43 
 
1.5 PRKDC Severe Combined Immunodeficiency  
1.5.1 Overview 
Severe combined immunodeficiencies (or SCID) are a group of rare genetic disorders 
that are characterised by lack of T or B immune cells. There are several forms of SCID 
with variable underlying genetic causes. Broadly these can be classified into two 
categories: i) T-cell signalling defects giving rise to the commonly occurring (up to 70% 
of all cases) T-B+ form of SCID, and ii) V(D)J recombination defects that causes T-B- 
phenotype. T-B+ SCID patients show complete lack of T cells while B lymphocytes are 
present and functional. T-B- patients on the other hand show complete absence of 
circulating B as well as T lymphocytes.  
Patients with T-B- SCID can have variable genetic defects affecting genes involved in 
different steps of V(D)J recombination. In approximately 70% of T-B- patients, mutations 
are found in the RAG1 and RAG2 gene; while the remaining cases exhibit mutations in 
genes encoding NHEJ proteins – Artemis, LIG4, XLF/Cerunnos and DNA-PKcs. This 
subset of T-B- SCID is known as radiosensitive SCID (or RS-SCID). People with RS-
SCID thus suffer from immune deficiency and are sensitive to ionizing radiations. 
Radiation sensitivity is seen in both bone marrow cells and primary skin fibroblasts. The 
prognosis for RS-SCID patients is poor, with lethality resulting typically within the first 
year of life. Furthermore, patients in this group present with a broad spectrum of clinical 
conditions ranging from radiosensitive leukaemia due to mutations in LIG4, a classical 
form of SCID, to growth retardation, microcephaly and immunodeficiency caused by 
profound T and B cell lymphocytopenia arising from mutations in XLF/Cernunnos or 
PRKDC (van der Burg, Ijspeert et al. 2009, van der Burg, van Dongen et al. 2009, 
Woodbine, Neal et al. 2013). Mutations in Artermis are often null and confer RS-SCID, 
but no overt growth or microcephaly.  
DNA-PK severe combined immunodeficiency is a type of radiosensitive SCID that is 
caused by a defect in DNA PKcs which causes dual effects – difficultly in DNA damage 
repair, for example in response to ionising radiations and lack of immune cells owing to 
faulty V(D)J recombination (Kurimasa, Kumano et al. 1999).   
Biochemical and genetic data have revealed DNA–PK to be composed of three 
components: a catalytic subunit and two regulatory subunits, DNA-binding proteins, 
Ku80 and Ku70. DNA PKcs, product of the PRKDC gene, is a large polypeptide of over 
4000 amino acids. The N-terminal ∼250 kDa of DNA-PKcs contains a putative DNA-
binding domain, a leucine-rich region and a series of HEAT [huntingtin, elongation factor 
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3, A subunit of protein phosphatase 2A and TOR1 (target of rapamycin 1)] repeats (Fig. 
1-14). The C-terminal region contains a FAT [FRAP (FKBP12-rapamycin-associated 
protein), ATM (ataxia telangiectasia mutated), TRRAP (transactivation/transformation 
domain-associated protein)] domain that is characterized by weak amino acid similarity 
to other members of the PIKK family, followed by a kinase domain and a C-terminal 
FATC domain  (Sibanda, Chirgadze et al. 2010, Davis, Chen et al. 2014, Sibanda, 
Chirgadze et al. 2017) (Fig. 1-14). 
 
Figure 1-14 Major Features of DNA-PKcs  
The N-terminal domain containing HEAT repeats and a leucine-rich region (LRR) extends from 
amino acids 1–2908, the FAT domain is from amino acids 2908–3539, the PIKK domain from 
amino acids 3645–4029 and the FATC domain from amino acids 4906–4128. ABCDE cluster 
represents the in vivo phosphorylation sites between Thr2609 and Thr2647 while the PQR cluster 
represents the in vivo phosphorylation sites between Ser2023 and Ser2056. The 2671 cluster 
contains four sites between Thr2671 and Thr2677. Ku interacts at amino acids 3002–3850. HEAT 
repeats: huntingtin, elongation factor 3, A subunit of protein phosphatase 2A and TOR1 (target of 
rapamycin 1)] repeats; FAT: FRAP (FKBP12-rapamycin-associated protein), ATM (ataxia 
telangiectasia mutated), TRRAP (transactivation/transformation domain-associated protein) 
domain; PIKK: phosphoinositidine 3-kianse-like family of protein kinases; FATC: FRAP, ATM, 
TRRAP C-terminal domain.  
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1.5.2 V(D)J Recombination  
V(D)J recombination is the process by which T cells and B cells randomly assemble 
different gene segments – known as variable (V), diversity (D) and joining (J) genes – to 
generate unique receptors (known as antigen receptors) that can collectively recognize 
many different types of molecule (Jung and Alt 2004, Schatz and Ji 2011, Schatz and 
Swanson 2011). 
V(D)J recombination mediates immunoglobulin and T cell receptor gene assembly from 
variable (V), diversity (D), and joining (J) gene segments; a crucial step in differentiation 
of broad range of antigen-specific B and T cells. It is a tightly regulated mechanism 
involving several factors and takes place both in bone marrow and thymus during early 
T and B cell differentiation. Recombination is initiated by the introduction of DSBs at 
recombination signal sequences (RSS) by lymphoid specific RAG 1 or RAG 2 
endonucleases. The DNA ends, including the sequences encoding the antigen receptors 
(termed as coding ends), have hairpin termini; while the RSSs (or signal ends) are blunt 
ended. Re-joining of these recombination intermediates occurs via non-homologous end 
joining pathway of DNA repair (Jung and Alt 2004, Schatz and Ji 2011, Schatz and 
Swanson 2011). 
1.5.3 Murine DNA-PK Deficiency  
Mice lacking DNA-PKcs are experimentally viable, with no overt phenotype other than 
SCID and are classical models for studying mechanisms of DNA damage and repair 
(Bosma, Custer et al. 1983, Bosma and Carroll 1991). Located on chromosome 16, 
Prkdc is a large gene comprising of 86 exons extending across about 193 kb (Araki, 
Fujimori et al. 1997). In mice, SCID is caused by a single T to A transversion in Prkdc 
exon 85 which switches the Tyrosine reside at codon-4046 into a stop codon (Blunt, 
Finnie et al. 1995, Blunt, Gell et al. 1996, Beamish, Jessberger et al. 2000). This results 
in truncation of 83 amino acids at the C-terminal of the protein, thereby losing the highly 
conserved catalytic domain (Beamish, Jessberger et al. 2000).  
1.5.4 DNA-PK Deficiency in Humans 
DNA-PK SCID (OMIM 600899) is an ultra-rare condition in humans with only two patients 
showing mutations in PRKDC identified so far. Recent work strongly suggests that DNA 
PK complex is essential and that a PRKDC null mutation would be incompatible with life 
in humans (Ruis, Fattah et al. 2008).  
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The first human PRKDC SCID patient, a girl (IMD26; 615966) of Turkish descent born of 
consanguineous parents, manifested infantile SCID with absent B and T cells. (van der 
Burg, van Dongen et al. 2009) identified a homozygous c.9185T>G transversion on 
PRKDC, resulting in the substitution of Leuine at pos.3062 to Arginine (L3062R) 
substitution at a highly conserved residue in the FAT domain. The unaffected parents 
were heterozygous for the mutation. The patient also carried a homozygous deletion of 
Gly2113, but this residue is not well conserved and was demonstrated to be non-
pathogenic. Studies of patient cells showed normal DNA-PK kinase and 
autophosphorylation capacity. Patient bone marrow cells showed increased long 
palindromic (P)-nucleotide stretches in the immunoglobulin coding joints, indicating a 
defect in hairpin opening and insufficient Artemis activation. PRKDC-deficient cells 
showed abnormal junctional pattern during V(D)J recombination, as well as impaired 
non-homologous end-joining that could not be restored to normal by mutant L3062R. 
L3062R mutation, which retains kinase and autophosphorylation activity but fails to 
activate Artermis, differs substantially from the spontaneous Prkdc mutations described 
in SCID horses, mice, and dogs, all of which result in truncated proteins. 
(Woodbine, Neal et al. 2013) identified the second PRKDC SCID patient, a boy (IMD26; 
615966) with profound neurologic abnormalities. He carried two compound 
heterozygous mutations in the PRKDC gene: a c.10721C>T transversion, resulting in a 
substitution of Alanine at pos.3574 to Valine (A3574V) inherited from the unaffected 
mother on 1 allele, and a cDNA that lacked exon 16 on the other allele. Genomic 
sequencing of the patient's DNA showed a 1-bp insertion (IVD16+1510insA) 700-bp 
upstream of the intron 16 splice site on the other allele, but it was unclear if this change 
caused the in-frame skipping of exon 16. Immortalized patient cells showed decreased 
but detectable protein, but no detectable kinase activity. Patient cells showed a defect in 
DNA DSB repair following irradiation, which could be rescued by expression of wild type 
PRKDC. The A3574V substitution occurred at a highly-conserved residue within the FAT 
domain, outside the kinase domain. Cells transfected with the mutation showed impaired 
DNA-PKcs function in response to irradiation and a less severe defect in V(D)J end-
joining, suggesting that the missense mutation retained some functional capacity. 
Functional studies of cells lacking exon 16 suggested that it represented a null allele. 
The overall findings were consistent with a loss of function. In addition to SCID, the 
patient had microcephaly, brain malformations, hearing loss, visual impairment, and little 
developmental progress. The patient died at an age of 31 months with intractable 
seizures (Woodbine, Neal et al. 2013). 
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1.5.5 Treatment Approaches 
Currently, human leukocyte antigen (HLA)-identical bone marrow (BM) transplantation 
is the only choice for effective treatment of SCID. Success of this procedure is highly 
dependent on the availability of a suitable matched donor. Gene transfer to 
haematopoietic stem cells (HSCs) first shown to have major therapeutic effects in SCID 
over 10 years ago however continues to show promise. Initially, gamma retroviral gene 
therapy demonstrated long-term clinical efficacy for SCID-X1 and ADA-SCID by 
complementation of a correct copy of the defective gene. However, SCID-X1 trials also 
highlighted oncogenic risks requiring improved vector design for clinical safety (Hacein-
Bey-Abina, Von Kalle et al. 2003). Despite the serious adverse events associated with 
retroviral integration into chromosomal DNA, gene therapy remains an important 
approach for the treatment of SCIDs. The long-term data in over 90 patients with several 
inherited primary immune deficiencies who have received gene therapy using 
conventional gamma retroviral vectors over the last decade show >90% overall survival, 
with the clear majority experiencing clinical benefits, despite insertional mutagenesis in 
around ten patients (Gennery, Slatter et al. 2010). The observed toxicities in these trials 
shared a common mechanism, namely upregulated expression of oncogenes induced 
by powerful enhancer sequences of viral vectors used. Moreover, several regulatory 
agencies have recommended a move away from the continued use of retroviral vectors 
and the development of safer vector designs. This has led to the development of later 
generation vectors with improved efficiency, specificity and safety. Over the last years, 
vector design has been largely modified, and gamma retroviral vectors have been 
replaced by self-inactivating systems for added safety (Seymour and Thrasher 2012, 
Cicalese, Ferrua et al. 2016). Self-inactivating vectors, based on the HIV-1 lentiviral 
vector, in which the HIV LTR is deleted and transgene expression placed under the 
control of an internal promoter with minimal or no enhancer activity have received 
considerable attention. Separately, ex vivo genome editing and HSC transplantation is 
being investigated as a therapeutic approach (Naldini 2015). Currently, human gene 
therapy clinical trials are under way using lentivectors in a wide range of human 
diseases. The proof-of-principle of the therapeutic efficacy of gene therapy targeting the 
immune system has been established by the “successful” clinical trials for the treatment 
of X-SCID (Cavazzana-Calvo et al., 2000). Gene and cell therapy research recently 
reached a fundamental milestone toward the goal to deliver new medicines for orphan 
diseases. In 2016, the European Commission granted market approval 
to GlaxoSmithKline for ex vivo hematopoietic stem cell gene therapy for the treatment of 
ADA-SCID. The medicine, Strimvelis, is an autologous CD34+ enriched cell fraction that 
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contains CD34+ cells transduced with retroviral vector that encodes for the human 
adenosine deaminase cDNA sequence from human haematopoietic stem/progenitor 
(CD34+) cells (Aiuti et al., 2017). It is the first ex vivo stem cells gene therapy to receive 
regulatory approval anywhere in the world and demonstrates the ever-growing profile of 
gene therapy research.  
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1.6 Ataxia Telangiectasia  
1.6.1 Overview 
Ataxia Telangiectasia (A-T) is a complex multi-system neurodegenerative disorder 
caused by defects in a single gene (OMIM 607585). Inherited as an autosomal recessive 
trait A-T has an estimated prevalence of 1 in 40,000-400,000 people (Lavin 2008). This 
frequency varies greatly from country to country. A-T is categorised as a rare disease 
with no cure at present (http://rarediseases.org/rare-diseases/ataxia-telangiectasia/).  
A-T is characterised by neurological and cerebellar manifestations, with ataxia (difficulty 
controlling movement) being evident from first years of life. This gradually progresses to 
affect speech, eye and involuntary movements. Most affected children generally require 
a wheelchair from their early teenage years. Telangiectatic or ‘spider-like’ vessels in the 
eye and skin is the second most common manifestation of the disorder. A-T also 
presents with variable immunodeficiency leading to recurrent infections usually of 
respiratory system, accompanied with immunoglobulin deficiencies and poor response 
to vaccines. Affected individuals also present with hypersensitivity to ionising radiations, 
chromosomal instabilities and highly increased risks to lymphoid malignancies or breast 
cancer in case of women (Chun and Gatti 2004, Lavin 2008).  
The causative gene, known as ataxia telangiectasia mutated (ATM) localises to 
chromosome 11q22-23 and is constitutively expressed in all eukaryotic cells. It encodes 
for A-T mutated (ATM) protein which is a serine/threonine kinase and is a member of the 
phosphoinositide 3-kinase (PIK3)-related protein kinase (PIKK) family, which also 
includes ATM and Rad3-related protein (ATR) and DNA PKcs. ATM protein is an apical 
kinase with central roles in cellular response to DNA double strand breaks, apoptosis 
and cell-cycle checkpoint control (Taylor, Harnden et al. 1975, Jeggo, Carr et al. 1998, 
Lavin 2008). ATM interacts with multiple substrates – an estimated 700 substrates have 
been identified through proteomic analysis (Matsuoka, Ballif et al. 2007) 
ATM has multiple domains - the kinase domain is located close to the C terminus like in 
other members of PIKK family, a FAT domain, an extreme C-terminal FATC domain, N-
terminal substrate binding domain, a leucine zipper and a proline-rich region (Fig. 1.15). 
Protein post-translational modifications includes activation of ATM protein by various 
kinases and phosphatases (PP2A, PP5 and WIP1); auto-phosphorylation at residues 
Ser367, Ser1893, Ser1981; and acetylation by TIP60 on Lys3016, crucial for ATM 
activation (Fig. 1-15) (Lavin 2008).  
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Figure 1-15 Schematic Representation of ATM Protein 
ATM is a member of phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family and 
like other members contains a FAT FRAP [(FKBP12-rapamycin-associated protein)] domain, a 
protein kinase domain and a FATC [FRAP (FKBP12-rapamycin-associated protein), ATM (ataxia 
telangiectasia mutated), TRRAP (transactivation/transformation domain-associated protein)] 
domain. Three autophosphorylation sites Ser367, Ser1983 and Ser1981, have been identified on 
ATM. Three phosphatases, protein phosphatase-2A (PP2A), protein phosphatase-5 (PP5) and 
WIPI, have been implicated in the control of ATM activation. In addition to the binding in the kinase 
domain, several ATM substrates binds to a region near the N terminus of the protein at the 
substrate binding site (SBS). ATM FATC domain functions as a binding site for the 
acetyltransferase TIP60. Ac: acetylation; Nbs1: Nibrin. 
 
1.6.2 A-T Related Immunodeficiency 
ATM kinase is involved in various cellular responses to DNA damage – especially to 
DSBs. DSBs can arise due to exogenous factors or as part of cellular processes. 
Lymphocytes for instance undergo DSBs in the process of V(D)J recombination and Ig 
class switch recombination for their development and maturation. In the absence of ATM, 
DSBs are difficult to repair. This causes a developmental block in the lymphoid 
compartment leading to immune defects associated with A-T (Jeggo, Carr et al. 1998, 
Chun and Gatti 2004). 
A-T related immunodeficiency is one of the key risks for A-T patients. It is characterised 
by reduced numbers of lymphocytes (especially T cells) and immunoglobulin deficiency. 
Thus, patients succumb to recurrent infections and show poor responses to vaccines. 
The immunodeficiency is particularly common in children, with pulmonary failure 
associated with or without infections, being the major cause of failing health and mortality 
(Chopra, Davies et al. 2014). The immunodeficiency of A-T is rarely progressive, but 
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remains stable in most cases without deterioration in symptoms with time. This can have 
a significant impact on the patient’s quality of life and requires long-term management 
(Nowak-Wegrzyn, Crawford et al. 2004, Staples, McDermott et al. 2008, Chopra, Davies 
et al. 2014). 
In its classical form, A-T is caused by the presence of two truncating mutations, which 
results in either a complete lack of ATM protein or a mutant protein with no kinase activity. 
In contrast, subsets of patients harbour mutations that allow the reduced production of 
the normal protein, or a mutant protein with limited kinase activity. Patients with this type 
of A-T, also known as variant A-T, show a milder phenotype with later disease onset, 
often in adulthood, and slower rate of neurodegeneration. A UK study of 80 A-T patients 
showed that patients suffering from variant A-T exhibited less recurrent sinopulmonary 
infections and had a lesser need for prophylactic treatments (Staples, McDermott et al. 
2008). Another study of 296 A-T patients (from the UK and Netherlands) reported that in 
childhood, total absence of ATM kinase activity was associated, exclusively, with 
development of lymphoid tumours. Their findings also suggested that expression of 
some residual ATM kinase activity has a strong protective effect against tumour 
development in A-T in childhood. The residual ATM kinase activity was shown due to the 
presence of leaky splice mutation (IVS40-1050A>G) expressing a low level (~5%) of 
normal ATM (Reiman, Srinivasan et al. 2011). These suggests that therapeutic benefits, 
including normal development of immunological function, might be achieved in A-T 
patients even if only modest increases (~5%) in functional ATM protein levels could be 
obtained (Taylor and Byrd 2005). Treatment of A-T related immune defects could 
therefore have a significant impact on improving the quality of life, including reduced 
rates of infection and perhaps lower cancer risks.  
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1.6.3 Treatment Approaches 
The classical form of A-T typically presents in early childhood. Systemic complications 
and progressive neurological decline lead to a reduced life expectancy and affected 
individuals often die of respiratory complications or a malignancy (Lavin 2008, Taylor, 
Lam et al. 2015). At present, there is no therapy to cure A-T or slow disease progression. 
Typically, patients are managed by a multidisciplinary team which consists of respiratory 
physicians, immunologists, geneticists and neurologists 
(http://www.atsociety.org.uk/clinical-guidance). Disease management is thus merely 
symptomatic and supportive (Lavin, Gueven et al. 2007). Current A-T related 
immunodeficiency is managed by: (i) early antibiotic treatment and continuous 
prophylactic therapy; (ii) use of vaccines; and (iii) regular immunoglobulin therapy 
administered intravenously every 3-4 weeks (Chopra, Davies et al. 2014). Allogeneic 
bone marrow transplantation with a low conditioning regime has also been reported in 
the treatment and long term survival of one patient with A-T (Ussowicz, Musial et al. 
2013). 
In this context, approaches that could allow permanent modification of the ATM gene 
and thus restore ATM protein kinase production could be beneficial. The wide variety of 
ATM mutations, which occur throughout the whole gene without hot spots, makes the 
development of therapies challenging. However, several mutation-targeted therapies are 
already under investigation. Since most A-T causing mutations lead to protein 
truncations due to presence of stop codons, small molecular read through (SMRT) 
compounds have been primarily tested. SMRT compounds can read through premature 
termination codons allowing translation of full-length protein, and have been used in A-T 
patient cell lines to restore ATM expression (Du, Jung et al. 2013). Such SMRT 
compounds have been previously used in the context of Duchenne muscular dystrophy 
and cystic fibrosis and are being evaluated in pre-clinical stages. However, most SMRT 
molecules do not cross the blood-brain barrier (BBB), a critical factor for treating a 
neurological disorder like A-T. Promising work in this field aims at the development of 
SMRT compounds with optimised efficiency, low toxicity, and ideally the ability to cross 
the BBB (Lavin 2008, Du, Jung et al. 2013, Lee, Martin et al. 2013). 
Another significant set of mutations identified amongst A-T patients are those affecting 
splicing. These constitute approximately 30% of mutations, leading to a variety of 
consequences such as exon skipping, intron retention, and activation or creation of new 
splice sites. In many cases, splicing defects lead to loss of ATM protein (Teraoka, Telatar 
et al. 1999). In this context, antisense morpholino oligonucleotides that conceal aberrant 
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splice sites have been used to demonstrate restoration of ATM mRNA and protein in A-
T patient cell lines (Du, Pollard et al. 2007). Again, while this method provides proof-of-
principle, its effectiveness and safety remains to be validated in animal models 
harbouring appropriate mutations. However, peptide-conjugated antisense 
oligonucleotides capable of crossing the BBB have been reported, and novel chemistries 
are under active investigation, so there is mileage for this type of therapy in A-T. 
Delivery of full-length ATM cDNA via viral vectors has also been explored as an 
alternative. Due to the large size of the cDNA (~9.2 kb, plus regulatory sequences) 
(Zhang, Chen et al. 1997), herpes simplex virus (HSV)-based vectors that have a large 
packaging capacity have been tested. One study reported successful introduction of 
ATM cDNA using a HSV amplicon vector in cultures of A-T fibroblasts and Atm-/- mice 
brain with expression in cerebellum (Qi, Shackelford et al. 2004). Separately, a HSV/AAV 
(adeno-associated virus) hybrid was shown to mediate insertion of full-length ATM cDNA 
into the AAV insertion site (AAVS1) in normal and A-T human cells and in transgenic 
Atm-/- mouse cells in vivo, producing functional expression of ATM. No adverse immune 
responses were noted in treated mice although the frequency of insertion was low 
(Cortes, Oehmig et al. 2008). Research on an ATM mini-gene has been previously 
funded but no published outcomes are available so the feasibility of the approach is 
unclear (http://www.atsociety.org.uk/data/files/Research/Molina_WD.pdf; 
http://actionforat.org/gene-therapy-for-the-treatment-of-ataxia-telangiectasia/).   
1.6.4 Cell and Gene Therapy for A-T 
The studies summarised in the previous section suggest that gene therapy could be 
utilised for the permanent modification of ATM to restore its function. With regards to 
immunodeficiency related to A-T, transplantation of haematopoietic stem and progenitor 
cells with functional ATM can be advantageous; especially since low levels of ATM 
activity have been associated with milder phenotypes. HSCs have great therapeutic 
potential because of their ability to self-renew and differentiate. Given their unique 
properties, a small number of genetically modified HSPCs could accomplish lifelong, 
corrective restoration of entire haematopoietic system. Ex vivo gene therapies - based 
on isolation of HSCs from a patient’s bone marrow, expansion and genetic modification 
in culture, followed by transplantation – are one of the best developed and most 
successful forms of cells therapies. In fact, allogenic bone marrow transplantation from 
a matched donor is the only treatment for several hematologic, immunological and 
metabolic conditions. However, due to the risks involved with allogenic transplant and 
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limited availability of matched donors, autologous transplants using patient’s own cells 
have gained momentum. 
Despite BMT being a routine treatment for many immunodeficiencies, it is currently not 
considered safe for treating A-T (http://primaryimmune.org/treatment-information/stem-
cell-and-gene-therapy/). This is mainly because A-T patients present with a very high 
sensitivity to radiotherapy which can be fatal in case a full cytotoxic conditioning regime 
is used to ablate the bone marrow prior to transplantation. There has been one reported 
case of death because of full conditioning BMT in an A-T patient who was undiagnosed 
at the time of treatment (Ghosh, Schuster et al. 2012). On the contrary, long-term survival 
was demonstrated in another A-T patient who received a lower dose conditioning regime 
(Ussowicz, Musial et al. 2013). Likewise, Atm mice studies where BMT was carried out 
using non-myeloablative host-conditioning regimes yielded promising results. BMT using 
Atm-positive cells significantly increased the longevity of Atm-/- mice and overcame the 
high tumour incidence. Moreover, these studies reported reduction in T-cell 
developmental/maturation block, and a reduction in risks of developing lymphoid 
tumours  (Bagley, Cortes et al. 2004, Pietzner, Baer et al. 2013). Furthermore, BMT also 
led to the regeneration of lung tissue (Bagley, Cortes et al. 2004). 
A promising avenue for improving the safety of conditioning is the use of biological 
agents based drugs, such as antibodies, that are specifically targeted to HSCs and other 
haematopoietic cells in the bone marrow niche and that spare non-haematopoietic cells. 
Recently a study described the combined use antibodies targeting HSC surface markers, 
anti c-Kit and anti-CD47, along with T-cell depleting antibodies to eliminate >99% of host 
HSCs and enable robust autologous as well allogenic HSCT in adult immunocompetent 
mice, with no geno-toxic side-effects (Chhabra, Ring et al. 2016). The anti-CD47 
biological agents used in this targeted conditioning regimen is currently being tested for 
safety and efficacy in two separate Phase I human clinical trials (ClinicalTrials.org 
NCT02216409 and NCT02367196). Although the combinatorial use of these antibodies 
has not been tested in humans, there is mileage in the approach. Separately, another 
study pre-clinical described the use of an immunotoxin targeting the HSC restricted 
CD45 receptor to effectively condition immunocompetent mice (Palchaudhuri, Saez et 
al. 2016).  
Given the impact of HSC gene therapy in other immunodeficiencies and due to promising 
results from BMT in Atm mice studies, targeted gene therapy approach can be beneficial 
for AT. Similar success has been reported for Fanconi anemia (FA) which like A-T arises 
due to chromosomal instability and defects in DNA damage signalling and RS-SCID 
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(Rahman, Kuehle et al. 2015). Targeted gene correction of FA mutations in patient cells 
led to rescue of FA phenotype as well as increased efficacy of reprogramming and 
generation of HSCs (Peffault de Latour, Porcher et al. 2013)   In case of RS-SCID, 
correction of underlying mutation led to efficient reprogramming of HSCs followed by the 
restoration of T-cell development and maturation in in vitro assays (Rahman, Kuehle et 
al. 2015). These reports suggest that there is mileage in the study and genome editing 
for DNA repair disorders.   
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1.7 Aims and Objectives 
Programmable nucleases allow defined alterations in the genome with ease-of-use, 
efficiency and specificity. Their availability has led to accurate and widespread genome 
engineering, with multiple applications in basic research, biotechnology and therapy. 
With regards to human gene therapy, nuclease-based gene editing has facilitated the 
development of a broad range of therapeutic strategies based on both non-homologous 
end-joining and homology-dependent repair.  
Diseases of monogenic origin can particularly benefit from such gene correction 
therapies. There are 5,000-8,000 monogenic diseases, defined as inherited conditions 
arising from mutations in a single gene (Rodwell C July 2014). These often manifest 
during childhood and lead to morbidity and sometimes premature death. While each 
monogenic disease is rare, it has been estimated that together they will affect about 6% 
of people at some point in their lives (Rodwell C July 2014). Diagnosis and treatment for 
these diseases remain largely insufficient and the care is primarily palliative, focusing on 
disease management without addressing the underlying genetic defects. The realisation 
of the social and economic importance of rare diseases and the acute need for 
diagnostics and treatments has led to initiatives like the International Rare Disease 
Research Consortium (IRDiRC; http://www.irdirc.org), the Undiagnosed Diseases 
Network (UDN; http://www.genome.gov/27562471) and Syndromes Without a Name UK 
(SWAN UK; http://www.geneticalliance.org.uk/projects/swan.htm). This study focuses on 
gene editing in two rare disease models namely, Prkdc severe combined 
immunodeficiency (Prkdc SCID) and Ataxia Telangiectasia (A-T). Both conditions arise 
due to defects in genes encoding core proteins involved in DNA damage response repair 
pathways, thereby presenting with immunodeficiency and sensitivity to ionising radiation 
in patients.  
The first part of this project builds up from previous work in the laboratory using a mouse 
model of the ultra-rare disease PRKDC SCID, selected for the expected selected 
advantage of corrected haematopoietic progenitors in vivo. Engineered zinc finger 
nucleases (ZFNs) and Prkdc repair matrices were generated to demonstrate homology-
directed repair in polyclonal SCID mice fibroblasts and haematopoietic stem cells which 
led to rescue of T-cell compartment upon transplantation in immune-deficient SCID mice 
(Abdul-Razak 2013). However, demonstration of gene editing events at a clonal level 
remained unexplored, which is an important hallmark of the gene editing workflow. The 
main aims of this section are as follows:  
1. Molecular analysis of gene editing events in ZFN treated Prkdc SCID clones. 
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2. Use of in vitro assays demonstrating DNA damage repair to correlate the 
genomic correction of SCID mutation with rescue of the encoded DNA PKcs 
protein. 
With the advancement in the field of genome editing, the second part of this study will 
aim for proof-of-concept targeting of Prkdc mutation using CRISPR-Cas9 technology. 
The main aims of this section are as follows: 
1. In vitro gene editing of Prkdc in SCID mouse fibroblasts using Streptococcus 
pyogenes Cas9 (spCas9) nuclease. 
2. Homology-mediated repair of Prkdc mutation using Cas9 and plasmid repair 
templates in SCID mouse fibroblasts. 
3. Characterisation of the effects of gene editing through molecular analyses in 
clonal populations. This will allow me to overcome some of the limitations 
observed with the earlier efforts employing ZFNs. 
After demonstrating proof-of-principle efficacy in Prkdc SCID model, this study will 
progress towards gene editing of ATM gene as a therapeutic strategy for Ataxia 
Telangiectasia, a clinically relevant DNA repair disease model. The specific aims for this 
investigation are as follows: 
1. Investigation of ATM gene structure to generate a map of known disease-causing 
mutations. 
2. Development of therapeutic gene editing strategies targeting both A-T specific 
mutations and universal cDNA knock-ins.  
3. Identification of A-T mutations to envision generation of an A-T mouse model.  
4. Production of ATM spCas9 gene editing reagents for ATM gene editing in human 
embryonic kidney (HEK-293T) cells.  
This early pre-clinical work will pave the way for future therapeutic strategies of 
application to human haematopoietic stem cells and the central nervous system (CNS), 
which are the two major tissue targets in A-T. Prime candidates for genome editing in 
the bone marrow compartment will be CD34+ progenitor cells or Purkinje cells for proof-
of-principle genome editing in the context of the CNS. 
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2 Materials and Methods 
 
 
2.1 Bioinformatics 
2.1.1 Web Tools 
▪ Benchling https://benchling.com  
▪ Cas-Designer http://www.rgenome.net/cas-designer/  
▪ CHOPCHOP https://chopchop.rc.fas.harvard.edu  
▪ CHOPCHOPv2 http://chopchop.cbu.uib.no  
▪ EMBOSS Matcher http://www.ebi.ac.uk/Tools/psa/emboss_matcher/  
▪ Ensembl Genome Browser http://www.ensembl.org/index.html  
▪ Human Gene Mutation Database (HGMD®) 
http://www.hgmd.cf.ac.uk/ac/index.php  
▪ MIT CRISPR Designer http://crispr.mit.edu  
▪ Primer-BLAST https://www.ncbi.nlm.nih.gov/tools/primer-blast/  
▪ TIDE https://tide.nki.nl  
2.1.2 Software 
▪ Chromas lite (version 2.6.2) http://technelysium.com.au/wp/  
▪ GraphPad Prism 
▪ Rotor-Gene 6000 (Qiagen) 
▪ SnapGene Viewer http://www.snapgene.com/products/snapgene_viewer/  
▪ Vector NTI ® Express (Thermo Fisher Scientific) 
▪ ZEN lite (Zeiss) 
2.1.3 Selecting Guide RNA Targets 
Identification of guide RNAs (gRNAs) is the first step of a CRISPR-Cas9 gene editing 
experiment. 20 nucleotide gRNAs for SpCas9 nuclease were designed using four 
different wed-based tools – MIT CRISPR Designer, CHOPCHOP, Benchling and Cas-
Designer. To design guides, DNA sequence, genomic location or name of gene of 
interest, and species were input in the design tool. Algorithms specific to each tool 
generated an output with a list of candidate guide sequences with corresponding 
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predicted off-target sites for each input. Programs would find any candidate sequences 
based on the N20NGG sequence pattern principle, where NGG represents the PAM 
region. Guide sequences with minimal likelihood of off-target effects and greater on-
target specificity were chosen for experiments described. Since a 5’ guanine is required 
for transcription from U6 promoters, target sites that lack this feature were extended in 
the 5’ direction by a single guanine. 5’ extensions do not affect gRNA function (Ran, Hsu 
et al. 2013). 
2.1.4 TIDE  
TIDE or Tracking Indels by DEcomposition is a bioinformatic web-tool that is designed 
to detect genome editing by CRISPR-Cas system. TIDE requires as input a control 
sequence data file (obtained from cells transfected without Cas9-gRNA), a sample 
sequence data file (DNA from a pool of cell treated with Cas9-gRNA) and a character 
string representing the sgRNA sequence (20 nt). The sequencing data files were 
imported (.abif format) into TIDE software. Additional parameters were adjusted, if 
necessary. Version 3.1.1 of TIDE code was used for analysis described. TIDE code was 
written in R (Brinkman, Chen et al. 2014).  
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2.2 Molecular Biology 
2.2.1 Media and Buffer Recipes 
2.2.1.1 Luria-Bertani (LB) Broth  
▪ 2% (w/v) LB broth powder (Sigma Aldrich #28713) in deionized water 
▪ Supplemented with 100 µg/ml Ampicillin (Sigma Aldrich #A9393) 
2.2.1.2 LB-Agar Media 
▪ 2% (w/v) LB powder in deionized water 
▪ 1.5% Agar (Sigma Aldrich #A1296) 
▪ Supplemented with 100 µg/ml Ampicillin  
2.2.1.3 NZY+ Broth 
▪ NZ amine broth (Sigma Aldrich #N3518) in deionized water 
▪ 5 g of NaCl (Sigma Aldrich #S7653) 
▪ 1 M MgCl2 (Sigma Aldrich #M8266) 
▪ 1 M MgSO4 (Sigma Aldrich #M2643) 
▪ 2 M glucose (Sigma Aldrich #G8270) 
2.2.1.4 50x TAE Buffer 
▪ 40mM Trizma® base (Sigma Aldrich #T1503) 
▪ 20mM Glacial acetic acid (Sigma Aldrich #1005706) 
▪ 1mM Ethylenedinitrilotetraacetic acid (EDTA; Sigma Aldrich #EDS) 
2.2.2 Cell lines 
▪ Top-10: Chemically competent genetically modified E.coli strain for high-efficacy 
cloning and plasmid propagation (Thermo Fisher Scientific #C404010) 
▪ XL10-Gold: Ultracompetent cells for transformation of large DNA molecules with 
high efficiency (Stratagene #200315)
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2.2.3 Plasmids 
pRY refers to plasmid record in Dr Rafael Yáñez’s laboratory, RHUL.  
2.2.3.1 Lentiviral Vector Construction Plasmids 
▪ pRY397 pMDLg/pRREintD64V: Lentiviral packaging plasmid encoding group 
specific antigen (GAG), polymerase (POL) and integrase (IN) gene with D64V 
mutation. Generated by Dr Rafael Yáñez (Yanez-Munoz, Balaggan et al. 2006). 
▪ pRY398 pMDLg/pRRE: Lentiviral packaging plasmid. Contains Gag and Pol and 
wild-type IN. Kind gift from Prof Luigi Naldini. 
▪ pRY399 pMD2.VSV-G: Envelope plasmid encoding the glycoprotein from the 
vesicular stomatitis virus (VSV-G); viruses pseudo-typed with this envelope have 
extensive host range transduce. Kind gift from Prof Luigi Naldini. 
▪ pRY400 pRSV-REV: Plasmid encoding the Rev protein that is essential in 
transfer of lentiviral RNAs from the nucleus to cytosol. Kind gift from Prof Luigi 
Naldini. 
2.2.3.2 CRISPR-Cas9 Plasmids 
▪ pRY557 pSpCas9(BB)-2A-GFP; PX458: Plasmid encoding Cas9 from S. 
pyogenes with 2A-EGFP, and cloning backbone for sgRNA. Kind gift from Feng 
Zhang lab (Addgene plasmid #48138)  
▪ pRY566: PX458 plasmid with Prkdc gRNA-1 
▪ pRY567: PX458 plasmid with Prkdc gRNA-2 
▪ pRY582: PX458 plasmid with Prkdc gRNA-3 
▪ pRY503: Prkdc-neo donor template (previously generated by H. Abdul-Razak in 
Yáñez lab). 
▪ pRY583: Prkdc-neo template PAM mutated for Prkdc gRNA-1  
▪ pRY584: Prkdc-neo template PAM mutated for Prkdc gRNA-3  
▪ pRY568 lentiCRISPRv2: Lentiviral transfer plasmid vector encoding Cas9 from 
S. pyogenes with 2A-Puro, and a cloning backbone for chimeric gRNA. Kind gift 
from Feng Zhang lab (Addgene plasmid #52961) 
▪ pRY562: lentiCRISPRv2 with Prkdc gRNA-1 
2.2.3.3 Other Plasmids 
▪ pMC-Cre: Plasmid encoding Cre recombinase for mammalian expression (Gu, 
Zou et al. 1993).  
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▪ pRY572 pCAG-GFP:Cre: Plasmid encoding Cre recombinase fused to GFP for 
mammalian expression. Kind gift from Connie Cepko (Addgene plasmid # 
13776). 
▪ pRY396 pCCL.CMV.eGFP.WPRE: Plasmid encoding enhanced green 
fluorescent protein reporter gene (eGFP). Kind gift from Prof Luigi Naldini. 
2.2.4 Bacterial Transformation 
To propagate plasmids, plasmid DNA was transformed and grown in chemically 
competent Top-10 or ultracompetent XL-10 Gold (Stratagene #200315) E. coli bacterial 
strains. Competent cells were stored at -80°C. 50 µl of bacterial cells were used for each 
transformation reaction. Cells were pipetted in a microcentrifuge tube and thawed on ice 
before adding 2 µl (10 pg to 100 ng) of DNA to be transformed. The reaction was gently 
mixed by flicking the bottom of the tube before being incubated on ice for 15 minutes. 
The bacteria were then heat shocked by placing the bottom half or two-thirds of the tube 
in a 42°C heat block for 30 seconds and placed back on ice for another 10 minutes. 900 
µl of warm antibiotic-free LB broth (NZY+ broth for XL-10 Gold) was added to the 
microcentrifuge tube. The mixture was then transferred to a sterile 14 ml vent cap tube 
(Greiner Bio One #187261) which was then placed on a shaker (225 rpm) at 37°C for 30 
minutes for the outgrowth of bacteria. Transformation mixture was then mixed and plated 
on warm LB-agar plates with 100 µg/ml of ampicillin. Plates were incubated at 37°C 
overnight. 
2.2.5 Mini-prep of Plasmid DNA 
Low quantities of plasmid DNA were prepared using the QIAprep spin Miniprep kit 
(Qiagen #27104). Single bacterial colonies from the agar plates were picked and grown 
up in a starter culture of 5 ml of 2% LB Broth with 100 µg/ml of ampicillin at 37°C in a 
shaking incubator (225 rpm) overnight. For long term storage, a glycerol stock was made 
by mixing 500 µl of mini-culture with sterile glycerol (Sigma Aldrich #G5516) at a final 
concentration of 15% and stored at -80 °C in a cryovial. 4 ml of each starter culture was 
then centrifuged at 8,000 rpm for 3 minutes at room temperature. The supernatant was 
removed and the cells resuspended in 250 µl Buffer P1 before being transferred to a 
microcentrifuge tube. 250 µl of Buffer P2 was added and the tube mixed thoroughly 
through multiple inversions. 350 µl of Buffer N3 was then added and mixed immediately 
through inversions followed by centrifugation for 10 minutes at 13,000 rpm. 800 µl of the 
supernatant was then added to a QIAprep spin column and centrifuged at 13,000 rpm 
for 30 seconds. The flow-through was discarded and the spin column washed by the 
addition of 500 µl of Buffer PB and centrifuged at 13,000 rpm for 30 seconds. 750 µl of 
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Buffer PE was then added to the column and centrifuged at 13,000 rpm for 30 seconds. 
The flow-through was discarded and the column centrifuged at 13,000 rpm for 1 minute 
to remove residual wash buffer. The QIAprep column was then placed in a sterile 
microcentrifuge tube and the DNA eluted in 50 µl of Buffer EB by incubation at room 
temperature for 1 minute followed by centrifugation at 13,000 rpm for 1 minute. The 
plasmid DNA was quantified using NanoDrop ND-1000.  
2.2.6 Maxi-prep of Plasmid DNA 
Once the plasmid was confirmed through restriction digests, the Endo-Free Plasmid Maxi 
Kit (Qiagen #12362) was used for large scale plasmid DNA preparation. From a starter 
culture, 250 µl was placed in 250 ml (1:1000 dilution) of fresh, sterile LB broth and left to 
grow on a shaker (225 rpm) at 37°C overnight. Bacterial cells were harvested by 
centrifugation at 3,500 rpm at 4°C for 30 minutes. The supernatant was discarded and 
the pellet thoroughly re-suspended in 10 ml Buffer P1. 10 ml of Buffer P2 was mixed by 
multiple inversions and incubated at room temperature for 5 minutes. 10 ml of chilled 
Buffer P3 was added and mixed by inverting. The lysed cell mixture was then applied to 
the barrel of QIAfilter Cartridge and incubated for 10 minutes. The lysate was filtered by 
inserting a plunger into the barrel. 2.5 ml of Buffer ER was added to the filtered lysate 
collected from the QIAfilter Cartridge and mixed before incubating on ice for 30 minutes. 
The QIAGEN-tip 500 was equilibrated by applying 10 ml of Buffer QBT and allowing the 
column to empty via gravity flow. The filtered lysate was added to the QIAGEN-tip 500, 
which was then washed with 30 ml of Buffer QC twice. DNA was eluted into 15 ml of 
Buffer QN and precipitated using 10.5 ml (0.7 volumes) of isopropanol followed by 
centrifugation at 6,000 rpm for 60 minutes at 4°C. The supernatant was carefully 
decanted and the pellet washed with 5 ml of endo-toxin free room temperature 70% 
ethanol, before another centrifugation at 6,000 rpm for 30 minutes at 4°C. The 
supernatant was removed and the pellet allowed to air dry in a laminar flow hood before 
being dissolved in endotoxin-free Buffer TE. An aliquot of plasmid DNA was then 
quantified using ND-1000. The stock plasmid DNA was kept endotoxin-free and only 
used under a laminar flow hood.  
2.2.7 Mammalian DNA Extraction   
Genomic DNA was extracted using DNasy® Extraction Kit (Qiagen #69504). First, cells 
were harvested from the tissue culture vessel using 0.25% Trypsin-EDTA (Thermo 
Fisher Scientific #25200056) and pelleted by centrifugation at 300 ×𝑔 for 5 minutes. The 
pellets were then washed with PBS to remove excess growth media and suspended in 
200 µl PBS. From here, DNA was extracted as per manufacturer’s protocol. Genomic 
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DNA was eluted in TE buffer or sterile water and stored at -20°C. DNA concentration 
was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific) with a 0.2 mm path length.  
2.2.8 Gel Electrophoresis 
Gel electrophoresis was carried out in 1x TAE Buffer. 0.7-3.5% w/v agarose (Bioline 
#41026) gels were prepared using 1x TAE buffer by heating in a microwave in 30 
seconds short-bursts until agarose was fully dissolved. The mixture was cooled before 
adding 0.5 μg/ml ethidium bromide (Sigma Aldrich #E1510). The gel was poured into 
electrophoresis tanks and cooled. Gel electrophoresis was carried out in 1x TAE buffer 
containing 0.5 μg/ml ethidium bromide at 1 Volt per cm for 60 mins. Gel images were 
visualised and captured under UV trans illumination using Bio-Rad Gel Doc 2000 system. 
2.2.9 Restriction Digests 
Restriction digests were carried out in 25 to 50 µl reactions. Each reaction consisted of 
sterile water, restriction enzyme (New England Biolabs), corresponding buffer solution, 
and genomic or plasmid DNA. The reaction was gently mixed and incubated at enzyme 
specific temperature. Incubation time was based upon the quantity of DNA to be digested 
(3 hours for DNA 1 µg DNA or overnight for 10 µg DNA). Digested DNA fragments were 
analysed using gel electrophoresis.  
2.2.10 PCR Purification 
For sequencing, PCR products were first run on a gel to test for correct amplification 
followed by purification using QIAquick PCR Purification Kit (Qiagen #28104) using a 
microcentrifuge. 5 volumes of Buffer PB 1 were added to 1 volume of the PCR sample 
and mixed. The pH was adjusted using 3 M sodium acetate, pH 5.0 (Sigma Aldrich 
#W302406), as required. The DNA was applied to a QIAquick column and placed in a 2 
ml collection tube and centrifuged. Each centrifugation step was carried out at 13,000 
rpm for 1 minute. The flow through was discarded and the spin column was washed by 
addition of 750 µl Buffer PE by centrifugation. The flow through was discarded again and 
the column centrifuged for an additional 1 minute to completely remove residual ethanol.  
Lastly, the QIAquick column was placed in a 1.5 ml microcentrifuge tube and the bound 
DNA was eluted in 30 µl Buffer EB (10 mM Tris-Cl, pH 8.5) by centrifugation.
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2.2.11 Sequencing 
Sequencing was carried using the cycle sequencing technology (dideoxy chain 
termination) on Applied Biosystems 3703XL automated DNA sequencing machines 
(MWG Eurofins, UK). Data were analysed using Chromas Lite software. 
2.3 Cell Culture 
2.3.1 Media and Buffer Recipes 
2.3.1.1 Growth Media 
▪ Dulbecco’s Modified Eagle Medium (DMEM) high glucose (4.5 g/L) with stable 
glutamine and sodium pyruvate (Sigma Aldrich #41966052) 
▪ 10% Heat-inactivated foetal bovine serum (Sigma Aldrich #10270106) 
▪ 100 U/ml Penicillin and 100 µg/ml Streptomycin (Sigma Aldrich #15070063) 
2.3.1.2 Freezing Media  
▪ 40% DMEM   
▪ 50% Heat-inactivated foetal bovine serum  
▪ 10% Dimethylsulfoxide (DMSO; Sigma Aldrich #D8418) 
2.3.1.3 2x HEPES-Buffered Saline (HBS) Buffer, pH 7.12 
▪ 100 mM HEPES (Sigma Aldrich #H3375) 
▪ 281 mM NaCl 
▪ 1.5 mM Sodium phosphate dibasic (Na2HPO4; Sigma Aldrich #S3264) 
2.3.1.4 Detergent Lysis Buffer 
• 0.45% Nonidet P40 (NP40; Sigma Aldrich #NP40) 
• 0.45% Tween-20 (Sigma Aldrich #P1379) 
2.3.2 Cell lines 
Most of the cell lines described in this Thesis were obtained as frozen stocks with low 
passage numbers (p0-p3) from liquid nitrogen storage in Dr Yáñez’s laboratory at Centre 
for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of 
London (RHUL), unless otherwise stated. 
▪ Balb/c 3T3: Primary skin fibroblasts obtained from C57 balb/c mice. Courtesy of 
Prof John Thacker, MRC Harwell. 
▪ Balb/c mTert 3T3: Balb/c 3T3 fibroblasts immortalised using mTert gene 
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▪ SCID mTert 3T3: Primary skin fibroblasts obtained from C57 balb/c SCID mice 
and immortalised using mTert gene. SCID 3T3 fibroblasts (Courtesy of Prof John 
Thacker, MRC Harwell), immortalised by H. Abdul-Razak in Yáñez lab. 
▪ HEK-293T/HEK-293T clone 17: Variant of human embryonic kidney 239 cell line 
containing a temperature-sensitive SV40 large T-antigen (ATCC #CRL-
3216/11268) 
▪ HEK-293T-Cas9: HEK-293T cells stably expressing Cas9 from AAVS1 
(GeneCopoeia Inc. #SL502) 
▪ HeLa: Human cell line derived from cervical cancer (ATCC #CCL2) 
2.3.3 Storage 
For long term storage, cells were washed with 1x phosphate buffered saline (PBS) 
solution, pH 7.4 (Thermo Fisher Scientific #10010023) and detached from tissue culture 
vessel using Trypsin-EDTA. Trypsin was inactivated by the addition of 9 ml of pre-
warmed growth media. Cells were pelleted by centrifugation at 300 x g or 5 minutes and 
re-suspended in cold freezing medium. Suspended cells were aliquoted into cryovials 
(Thermo Fisher Scientific # 10654721) and cooled slowly to -80°C in isopropanol 
containers overnight before long-term storage in liquid nitrogen (gaseous phase). 
2.3.4 Thawing of Frozen Cells  
To thaw cells, frozen cell aliquots were retrieved from liquid nitrogen and rapidly warmed 
in 37 °C water bath. Defrosted cells were mixed with 9 ml pre-warmed growth medium 
and pelleted by centrifugation at 1000 rpm for 5 mins to remove all traces of DMSO. The 
cell pellets were then re-suspended in warmed growth media, transferred to tissue 
culture flasks and maintained at 37°C under 5% CO2 atmospheric conditions.  
2.3.5 Cell Maintenance and Sub-Culture 
All cell culture work was performed under Class II laminar flow hoods using sterile tissue-
culture grade plastic ware. HEK293T, HEK293T-Cas9, HeLa, C57 Balb/c mTert 3T3, 
and C57 Balb/c SCID mTert 3T3 cells were maintained in growth medium at 37°C under 
5% CO2 atmospheric conditions. C57 Balb/c mTert 3T3 and C57 Balb/c SCID mTert 3T3 
cells were grown with 3 µg/ml puromycin (Sigma Aldrich #P8833). 
Cells were sub-cultured every 2-3 days or upon reaching 80-90% confluency. For sub-
culture, the growth media was aspirated and cells were washed with 1X PBS (Thermo 
Fisher Scientific #10010023) to remove traces of media. Cells were detached from 
surface of flask by incubation with Trypsin-EDTA for 1 min at 37°C. Trypsin was 
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inactivated by adding growth media and cells were pelleted by centrifugation at 3,000 
rpm for 5 minutes. The media was removed thereafter and cells were re-suspended in 
fresh pre-warmed growth media. 1:5 to 1:10 of the suspended cells were placed in a 
fresh flask with additional growth and allowed to grow in the incubator. 
2.3.6 Generation of Clonal Populations 
Single-cell colonies were obtained by plating cells at a low seeding density, 
approximately 100-1000 cells, in 10 cm tissue culture plates. Cells were continued to 
grow for 7-10 days until small circular colonies (with a diameter of roughly 1 mm) were 
visible. Colonies were picked up using 3 mm sterile cloning discs (Sigma Aldrich 
#Z374431). To do so, first colonies were marked at the bottom of the dish. Next, the 
culture medium was gently aspirated and the plate was washed with 1x PBS to remove 
traces of growth media. Using sterile forceps, cloning discs were briefly dipped in 
Trypsin-EDTA and gently placed on marked colonies for 30-60 seconds. After 1 minute, 
cells adhered to the discs were transferred to 96-well plates. On reaching confluency, 
cells were again detached using Trypsin-EDTA and transferred to larger culture vessels 
for expansion, leaving the cloning discs behind in 96-well plates. 
2.3.7 Crystal Violet Staining 
Cells to be stained were first washed with 1 ml 1x PBS followed by 5 minute incubation 
in 1 ml diluted (1:10 in water) crystal violet. A stock solution of crystal violet (Sigma 
Aldrich #C0775) is 1% (w/v) in ethanol, kept at room temperature. Once stained, crystal 
violet was discarded and the tissue culture vessel was gently washed with water to 
remove excess crystal violet. Finally, the tissue culture plates were left upside-down to 
air-dry and the colonies were scored by eye. 
2.3.8 Mammalian Cell Transfection 
2.3.8.1 Lipofectamine-2000 
Purified plasmid DNA or RNA were mixed with Lipofectamine®2000 (Thermo Fisher 
Scientific #11668019) in growth media without selection drugs. The mixture was 
incubated at RT for 30 mins to facilitate formation of lipid-DNA complexes. After 
incubation, the transfection mix was dropwise added on to plated cells. The solution was 
evenly distributed by gently rocking the plates before putting the plates in a cell culture 
incubator. Transfected cells were harvested 24 to 48 hours post-transfection. 
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2.3.8.2 Calcium-Phosphate Co-Precipitation 
For 15 cm plates, a DNA mix was prepared by mixing 25 µg of purified plasmid DNA 
made up to 112.5 with µl 1x Buffer TE, 1,012.5 µl of tissue-culture quality grade water 
(Thermo Fisher Scientific #15230188) and 125 µl of 2.5 M CaCl2 (Sigma Aldrich #C5670). 
The mix was then vortexed and incubated for 5 min at RT. This was followed by the 
addition of 1,250 µl of 2x HBS drop wise to the DNA mix while vortexing at high speed. 
The mixture was immediately added on to the plated cells (80-90% confluent) and gently 
mixing with the growth medium. 14 to16 hours post-transfection, the growth medium was 
aspirated and cells were twice washed with 1x PBS, before 25 ml fresh growth media 
being added. Cells were grown for 2-3 days before harvesting. Based on surface area 
ratios of tissue culture vessels, the protocol was scaled up and down as per need.  
2.3.9 Cell Viability Assay 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was used to 
detect the cell viability after exposure to Melphalan. The assay depends on the 
conversion of the water soluble MTT into insoluble MTT-formazan crystals by 
mitochondrial dehydrogenases of living cells. The crystals are then solubilised and the 
concentration of solution is determined by optical density at 570 nm (Price and McMillan 
1990, Hansen and Bross 2010, van Meerloo, Kaspers et al. 2011). A 5 mg/ml MTT 
(Sigma Aldrich #M2003) stock solution was prepared in 1x PBS then filtered and kept at 
4 °C in dark till use. Cells were seeded in 24-well plates. After 24 hours, the culture 
medium was replaced with growth medium with added10 µM Melphalan (Sigma Aldrich 
#M2011). After 1 hour incubation at 37°C, medium containing the drug was replaced with 
fresh growth media. The plates were incubated for 4 days prior to determining cell 
viability by measurement of MTT conversion. MTT solution at a final concentration of 1 
mg/ml was added to each sample, incubated for 4 hours and then the medium removed 
gently without disturbing the formazan crystals. The plates were left for 1 hour to dry then 
DMSO was added to dissolve the crystals, and incubated with agitation for 10 min. Later, 
100 μl from each sample were transferred into 96-well plate to measure the optical 
density at 570 nm using GloMax®-Microplate Multimode Reader (Promega) The optical 
density from control untreated cells was considered as 100 % viability.
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2.3.10 Clonogenic Survival Analysis 
At day 1 of the analysis, one T25 cm flask containing 2 x 105 cells per sample cell line 
and one 10 cm dish containing 6 x 104 feeder cells were set up per sample cell line to be 
tested. Feeder cells were a wild-type cell line irradiated using 35 Gγ before being plated 
into growth medium supplemented with new born calf serum. The following day, cells 
from T25 flasks were trypsinizied and counted. These were then diluted, treated and 
plated on to 10 cm feeder plates. Cell numbers used were: 
▪ 0 Gγ - 200 cells 
▪ 1 Gγ - 400 cells 
▪ 3 Gγ - 2,000 cells 
▪ 5 Gγ - 10,000 cells 
▪ 7 Gγ - 30,000 cells 
Cells were stained and counted between days 12 to 21 by adding 1 ml of Methylene blue 
(Sigma Aldrich #M9140) directly to the growth medium of each dish before incubating 
them for 45 minutes at room temperature. After incubation, the growth medium was 
poured, plates washed with water and left to air dry before scoring.  
2.3.11 Immunofluorescence  
Slides were prepared by placing coverslips into 3cm dishes and 2 x 105 cells were added. 
For G0/G1 analysis, the cells were grown at 37°C until confluent or starved of serum by 
using 0.5% FBS for 3 to 4 days. For G2 analysis, cells were cultured until they reached 
60-80% confluency. To monitor repair kinetics after IR exposure, each dish was 
irradiated with 3 Gγ (9 seconds/Gγ) at 0.25, 2, 6, 24, 48, and 72 hour intervals. All dishes 
were processed together. Cells were fixed for 10 minutes at room temperature using 3% 
paraformaldehyde and 2% sucrose in 1x PBS. Next, the cells were permeabilized using 
0.2% TritonX-100 (Sigma Aldrich #X100) in PBS for 2.5 minutes at room temperature 
and washed with 1x PBS three times.  
Primary and secondary antibodies were diluted in PBS supplemented with 2% bovine 
serum fraction V albumin (Sigma Aldrich #A2153). Primary incubations were performed 
for 30 minutes at 37°C and secondary for 20 minutes at 37°C followed by three washes 
with 1x PBS. Nuclei were counterstained by DAPI (0.000025% in PBS) for 10 minutes at 
room temperature, followed by three PBS washes. Coverslips were mounted onto 
microscope slides in Vectashield and sealed with clear nail varnish before counting 
H2AX foci using fluorescence microscope. A total of 15 views including 10 cells were 
counted per sample.   
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2.3.12 Fluorescence Activated Cell Sorting (FACS) 
Zinc-finger nuclease targeted fibroblast clones treated with a plasmid encoding Cre and 
GFP were subjected to cell sorting. Two days after transient transfection, cells were 
sorted using FACSAria III (BD Biosciences). GFP-positive clones were collected and 
maintained in conditioned growth media in 96-well plates. 
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2.4 Prkdc Zinc Finger Nuclease Gene Editing  
2.4.1 Inside-Out PCR  
The donor-genome 3’ junction was amplified using an inside-out PCR where the forward 
primer lied within the region of homology (that is sequence present in the repair template) 
while the reverse primer was designed to bind in the genomic sequence lying outside 
the region of homology, thus absent from the repair template. This amplicon would only 
be present in targeted cells and absent from non-targeted cells where the donor template 
may integrate at random genomic loci. For PCR, genomic DNA was extracted from 1 x 
106 G418-R cells and the concentration was measured using a Nanodrop ND-1000. 
Following primer sequences (Sigma Aldrich) were used for the inside-out PCR. The 
amplicon length was 1,335 bp.  
GT1-F: 5’- TCGCCTTCTTGACGAGTTCT-3’  
GT1-R: 5’- TTTTCCCCCTCATGTCACTC -3’  
For PCR amplification, 50 μl reactions were prepared containing 10 μl 5 × GoTaq® 
reaction buffer, 1.5 μl of 10 mM dNTPs, 4 μl of 25 mM MgCl2, 1.5 μl of 10 μM of each 
forward and reverse primer, 200 ng DNA template (genomic DNA extracted from gene-
targeted cells), and 0.5 μl of 5 u/μl GoTaq DNA polymerase (Promega #M7650). Thermo-
cycling conditions were: initial denaturation at 95°C for 2 min, then 35 cycles of 95°C for 
45 sec, 59°C for 60 sec, 72°C for 72 sec, followed by final extension at 72°C for 5 min.  
2.4.2 Mutation Analysis  
A single PCR amplifying a short (304 bp) region around ZFN cleavage and SCID 
mutation loci was used to analyse sequence mutations at both sites. The following 
primers (Sigma Aldrich) were used for the reaction.  
mDNA-PK-F: 5’ GCAGACAATGCTGAGAAAAGG 3’  
mDNA-PK-R: 5’ GCACAAAACAGACAAGGGTGT 3’ 
The PCR reaction consisted of: 1 x Go Taq® reaction buffer, 2 mM MgCl2, 0.4 mM 
dNTPs, 0.5 µM of forward and reverse primers, and 0.05 U/µl Taq DNA polymerase 
(Promega #M7650). Thermo-cycling conditions were: initial denaturation at 95°C for 5 
min, then 35 cycles of 95°C for 30 sec, 60°C for 30 sec, 68°C for 40 sec, followed by 
final extension at 68°C for 2 min, holding the reaction at 4°C. 
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10 µl of the PCR product was tested on 1% agarose gel. On determining the correct size, 
the remaining PCR mixture was purified using QIAquick PCR purification kit protocol, 
mixed with 2 µl of 10 µM forward primer and sequenced (MWG Eurofins, UK).  
2.4.3 Cre-LoxP Recombination 
2.4.3.1 Neo Removal PCR tests 
Two PCRs were designed to screen cells for loss of neo cassette. The first reaction was 
designed to amplify a 1,000 bp region within the neo gene using the following primers 
(Sigma Aldrich). 
Neo-Removal-F: 5’ CCGGCATTCTGCACGCTTCA 3’ 
Neo-Removal-R: 5’ AGTGGCACCTTCCAGGGTCA 3’ 
The PCR mix contained: 1 x Go Taq® reaction buffer, 2 mM MgCl2, 0.4 mM dNTPs, 0.3 
µM of forward and reverse primers, and 0.05 U/µl of Taq DNA polymerase (Promega 
#M7650). Thermo-cycling conditions were: initial denaturation at 94°C for 2 min, then 40 
cycles of 94°C for 30 sec, 60.4°C for 30 sec, 72°C for 60 sec, followed by final extension 
at 72°C for 5 min, holding the reaction at 4°C.     
The second PCR was designed to amplify the region around left LoxP site using the 
following primers (Sigma Aldrich).  
Left-loxp-F: 5’ AATCCTTGGGCCATTGTGAGT 3’ 
Left-loxp-R: 5’ AGAGGCCACTTGTGTAGCG 3’ 
The PCR mix contained: 1 × Go Taq® reaction buffer, 1.5 mM MgCl2, 0.3 mM dNTPs, 
0.3 µM of forward and reverse primers, and 0.05 U/µl of Taq DNA polymerase (Promega 
#M7650). Thermo-cycling conditions were: initial denaturation at 95°C for 2 min, then 35 
cycles of 95°C for 45 sec, 65°C for 60 sec, 72°C for 15 sec, followed by final extension 
at 72°C for 5 min, holding the reaction at 4°C.     
2.4.3.2 Neo removal using pMC-Cre 
2 x 106 cells from ZFN targeted clones (c.5, c.11 and c.12) were seeded in 10 cm plates 
containing 10 ml growth medium with G418 (800 µg/ml; Thermo Fisher Scientific 
#10131027) and puromycin (3 µg/ml). Two hours before transfection the media was 
discarded to remove the selection drugs and fresh growth medium was added. 10 µg of 
purified, endo-toxin free pMC-Cre-15 plasmid was used for transfection using a calcium 
phosphate co-precipitation method. 16 hours after transfection the growth medium was 
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discarded again and cells were washed with 1x PBS two times to remove excessive 
calcium precipitate. Fresh growth medium (without G418) was added and cells incubated 
for further 48 hours at 37°C. Subsequently, the cells were harvested and seeded for 
generation of monoclonal populations.  
To screen for the removal of neo, 2 x 105 cells from each of 20 clones per sample were 
isolated in 200 µl PBS. Cells were lysed by adding 25 µL of detergent lysis buffer followed 
by addition of 1 µl of Pronase (Sigma Aldrich #PRON-RO). The reaction was then 
incubated at 50°C for 1 hour to facilitate cell lysis followed by 10 minutes at 94°C to 
inactivate the enzyme and then stored on ice. 25 µl of the cell lysate was directly mixed 
with 25 µl PCR mix to screen for removal of neo (Section 2.5.3.1).  
2.4.3.3 Neo removal using pCAG-Cre:GFP  
5 x 105 cells from ZFN targeted clones (c.3, c.5, c.10 and c.11) were seeded in 6-well 
plates containing 2 ml growth medium with G418 (800 µg/ml) and puromycin (3 µg/ml). 
Two hours before transfection the media was discarded to remove the selection drugs 
and fresh growth media was added. 2 µg of purified endo-toxin free pCAG-GFP:Cre 
plasmid was used for transfection using 12 µl Lipofectamine-2000® (6:1 Lipofectamine: 
DNA ratio) and plates were incubated at 37°C for 48 hours. After 48 hours, cells were 
harvested for FACS. Sorted cell clones (10 per sample) were expanded in culture in 
standard growth medium without G418. Genomic DNA was harvested from 1 x 106 cells 
for downstream PCRs to screen for loss of neo (Section 2.5.3.1). 
2.4.4 Indel Detection Using Amplicon Analysis (IDAA) 
IDAA was carried out at University of Copenhagen as reported previously (Yang, 
Steentoft et al. 2015). The following primer sequences were used for IDAA in ZFN 
targeted fibroblast clones. Primers were obtained from TAG Copenhagen, Denmark 
(http://tagc.com/).  
mDNA-PK-F: 5’ GCAGACAATGCTGAGAAAAGG 3’  
mDNA-PK-R: 5’ GCACAAAACAGACAAGGGTGT 3’ 
Amplicons were fluorophore labelled by tri-primer amplification using a universal 6-FAM 
5′-labelled primer FamF and primers flanking the gene editing target site of which the 
sense primer carried an FamF target sequence extension. PCR was performed in 25 μl 
using AmpliTaq Gold (ABI/Life Technologies), 0.5:0.05:0.5 μM (FamF:F:R) primers and 
a touchdown thermocycling profile using an initial 72°C annealing temperature ramping 
down by 1 degree/cycle to 58°C followed by an additional 25 cycles using 58°C annealing 
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temperature. Denaturation and elongation was performed at 95°C for 45 sec and 72°C 
for 30 sec respectively. 1 µl of the PCR reaction or dilutions hereof was mixed with 0.5 
μl LIZ600 or LIZ500 size standard (ABI/Life Technologies) and applied to fragment 
analysis on ABI3010 sequenator (ABI/Life Technologies) using conditions recommended 
by the manufacturer. Raw data obtained were analysed using Peak Scanner Software 
V1.0 (ABI/Life Technologies).  
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2.5 Prkdc CRISPR-Cas9 Gene Editing  
2.5.1 Insert Oligo Design 
To clone the guide sequence into the sgRNA scaffolds of PX458 and lentiCRISPRv2 
plasmids, two oligos containing appropriate overhangs and 5’ guanine residue was 
designed for each guide, as reported previously (Sanjana, Shalem et al. 2014). Oligo 
sequences for each guide RNA are described in Table 2-1. 
Sequences were obtained as standard de-salted DNA oligos (Sigma Aldrich) and 
suspended as 100 µM stock solutions. Oligos were phosphorylated and hybridised in a 
single reaction. 1 µl each of the forward and reverse oligos were mixed with 1 µl of 10 x 
T4 ligation buffer (New England Biolabs #B0202) and 0.5 µl of T4 polynucleotide kinase 
(New England Biolabs #M0201) made up to a final volume of 10 µl with sterile water. 
The mix was heated to 37°C for 30 minutes then 95°C for 5 minutes with a temperature 
ramp down to 25°C at 5°C per minute (Techne-512). 
Table 2-1 Prkdc gRNA oligos sequences. 
Overhangs are highlighted in grey. 5’ guanine and complementary cytosine residues are indicated 
in bold. 
  
Annealed oligo sequence with overhangs  
 Prkdc gRNA-1 oligos 
 Forward 5’ CACCGTGCTAAGAGAAAGTTAGCAG 3’ 
 Complement 3’     CACGATTCTCTTTCAATCGTCCAAA 5’ 
 Reverse complement 5’ AAACCTGCTAACTTTCTCTTAGCAC     3’ 
 Prkdc gRNA-2 oligos  
 Forward 5’ CACCGGCATAGCGTATTTTATGTTG 3’ 
 Complement 3’     CCGTATCGCATAAAATACAACCAAA 5’ 
 Reverse complement 5’ AAACCAACATAAAATACGCTATGCC     3’ 
 
 
2.5.2 Production of Cas9-gRNA Plasmids 
Cloning of annealed Prkdc gRNAs 1 and 2 into PX458 plasmid backbone was carried 
out using a single-step digestion-ligation protocol as previously reported (Cong, Ran et 
al. 2013). The annealed oligo mix was diluted 1:250 in sterile water. 100 ng of the uncut 
PX458 plasmid was mixed with 2 µl of the diluted annealed oligos, with 1 µl of FastDigest 
BpilI (BbSI; Thermo Fisher Scientific #FD1014), 2 µl of FastDigest buffer, 0.5 µl of T4 
Ligase (New England Biolabs #M0202S), 1 µl of DTT (100 mM stock; Sigma #DTT-RO), 
1 µl of ATP (10 mM stock; New England Biolabs #P0756S) and sterile water made up to 
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a final volume of 20 µl. The mix was placed in a heat cycle of 37°C for 5 mins then 23°C 
for 5 mins for 6 cycles and stored at 4°C. The ligated plasmid was then transformed into 
Top-10 competent cells. Transformed cells were streaked on LB agar plates with 
ampicillin and incubated at 37°C for 24 hours. Single colonies were picked and grown in 
a 5 ml starter culture at 37°C overnight before a mini-prep was performed. 
To check for successful ligation the recombinant plasmid was sequenced (MWG 
Eurofins, UK) using the following primer (Sigma Aldrich) located in the upstream U6 
promoter.  
hU6-F: 5’ TACGATACAAGGCTGTTAGAGAG 3’ 
2.5.3 Indel Detection by TIDE  
To analyse indels introduced by Cas9 the genomic region surrounding PAM regions at 
the targeted sites were amplified using PCR and subjected to sequencing. Sequence 
traces from control and edited cells were analysed using TIDE software to quantify 
indels. 
The following primers were used for the amplification of regions (304 bp) around gRNA-
1 and 2 PAM. 
mDNA-PK-F: 5’ GCAGACAATGCTGAGAAAAGG 3’  
mDNA-PK-R: 5’ GCACAAAACAGACAAGGGTGT 3’  
The PCR reaction consisted of: 1 x Q5 reaction buffer, 0.2 mM dNTPs, 0.5 µM of forward 
and reverse primers, and 0.02 U/µl Q5 Hot Start polymerase (New England Biolabs 
#M0493). Thermo-cycling conditions were: initial denaturation at 98°C for 30 sec, then 
35 cycles of 9°C for 10 sec, 60°C for 30 sec, 72°C for 10 sec, followed by final extension 
at 72°C for 2 min, holding the reaction at 4°C. 
The following primers were used for the amplification of region (805 bp) around gRNA-3 
PAM. 
mDNA-PK-F: 5’ GCAGACAATGCTGAGAAAAGG 3’  
SCID-G3-R: 5’ CTTCTGGGGTCATGCCTAGC 3’ 
The PCR reaction consisted of: 1 x Go Taq® green reaction buffer, 1.5 mM MgCl2, 0.2 
mM dNTPs, 0.5 µM of forward and reverse primers, and 0.05 U/µl Taq DNA polymerase 
(Promega #M7650). Thermo-cycling conditions were: initial denaturation at 95°C for 5 
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min, then 35 cycles of 95°C for 30 sec, 59°C for 30 sec, 72°C for 48 sec, followed by 
final extension at 72°C for 5 min then holding the reaction at 4°C. 
10 µl of the PCR product was tested on 1% agarose gel. On determining the correct size, 
the remaining PCR mixture was purified using QIAquick PCR purification kit protocol, 
mixed with 2 µl of 10 µM forward primer and sequenced (MWG Eurofins, UK).  
2.5.4 Modification of Repair Template  
PAM regions for Prkdc gRNA-1 and 3 present in Prkdc-neo donor DNA template were 
mutated using QuickChange II XL Site-Directed Mutagenesis Kit (Agilent #200521). 
QuikChange Primer Design Program 
http://www.genomics.agilent.com/primerDesignProgram.jsp was used to design the 
following primers, which were obtained as PAGE-purified oligos (Sigma Aldrich). 
G117T-F: 5’ AAGAGAAAGTTAGCAGGTGCCAACCCAGCTGTTAT 3’ 
G117T-R: 5’ ATAACAGCTGGGTTGGCACCTGCTAACTTTCTCTT 3’  
G213A-F: 5’ ACACTTCTGAGCAGTATGACACTTCACTGTGTAGATG 3’ 
G213A-R: 5’ CATCTACACAGTGAAGTGTCATACTGCTCAGAAGTGT 3’  
Each mutant strand synthesis PCR reaction comprised of 1x Reaction buffer, 40 ng of 
dsDNA template, 125 ng of primer # forward, 125 ng of primer # reverse, 1 µl of 
proprietary dNTP mix, 3 µl of QuickSolution reagent and 1 µl of PfuUltra HF DNA 
polymerase (2.5 U/µl) in a total volume of 50 µl. Thermo-cycling conditions used were: 
denaturation at 95°C for 1 min, followed by 18 cycles of 95°C 50 sec, annealing at 95°C 
for 50 sec, 68°C 14 mins (1 min/kb of plasmid length), and final extension at 68°C for 7 
mins. Parental DNA was digested by incubating the PCR mix with 1 µl of Dpn I restriction 
enzyme (10 U/µl) at 37°C for 90 mins. 2 µl of Dpn I-treated was transformed into XL10-
Gold ultracompetent cells.  
The plasmid DNA was verified for mutagenesis by sequencing (MWG Eurofins, UK) 
using the following primer (Sigma Aldrich). 
mDNA-PK-F: 5’ GCAGACAATGCTGAGAAAAGG 3’  
2.5.5 Gene Targeting 
1 x 106 SCID mTert 3T3 cells were seeded in 10 cm plates with 10 ml growth media 
containing 3 ug/ml Puromycin. 4 hours later, plasmid constructs encoding genome 
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editing reagents (10 µg each) were transfected using calcium phosphate co-precipitation 
method, as described in Table 2-2. 
Table 2-2 CRISPR-Cas9 gene targeting plasmid transfections 
Plate # CRISPR-Cas9 Plasmid Donor DNA Plasmid 
Plate 1 Cas9-GFP (pRY557) Prkdc-neo (pRY503) 
Plate 2 Cas9-GFP-gRNA-1 (pRY566) Prkdc-neo 
Plate 3 Cas9-GFP-gRNA-2 (pRY567) Prkdc-neo 
Plate 4 Cas9-GFP-gRNA-3 (pRY582) Prkdc-neo 
Plate 5 Cas9-GFP-gRNA-1 Prkdc-neo-mut-PAM-g1 (pRY583) 
Plate 6 Cas9-GFP-gRNA-3 Prkdc-neo-mut-PAM-g3 (pRY584) 
Plate 7 Cas9-GFP - 
Plate 8 - Prkdc-neo 
Plate 9 - Prkdc-neo-mut-PAM-g1 
Plate 10 - Prkdc-neo-mut-PAM-g3 
 
Since Cas9 plasmid constructs used contained a GFP reporter gene plasmid expression 
was monitored by fluorescence microscopy at 24 and 48 hour time-points after 
transfection. After 48 hours, the cells were washed with 1 x PBS two times and selected 
for gene targeting by addition of 800 µg/ml G418. The next day the cells were trypsinized 
and seeded for the generation of monoclonal populations and crystal violet staining. 
Separately, the polyclonal cell pool was also expanded. 
2.5.6 Production of LentiCRISPRv2 Plasmid 
Cloning of annealed Prkdc gRNA-1 into lentiCRISPRv2 plasmid backbone was carried 
out using a single-step digestion-ligation protocol as previously reported (Cong et al., 
2013). The annealed oligo mix was diluted 1:250 in sterile water. 100 ng of the uncut 
lentiCRISPRv2 plasmid was mixed with 2 µl of the diluted annealed oligos, with 1 µl of 
BsmBI (Thermo Fisher #FD0454), 2 µl of FastDigest buffer, 0.5 µl of T4 Ligase (New 
England Biolabs #M0202S), 1 µl of DTT (100 mM stock; Sigma #DTT-RO), 1 µl of ATP 
(10 mM stock; New England Biolabs #P0756S) and sterile water made up to a final 
volume of 20 µl. The mix was placed in a heat cycle of 37°C for 5 minutes then 23°C for 
5 minutes for 6 cycles and stored at 4°C. The ligated plasmid was then transformed into 
Top-10 competent cells. Transformed cells were streaked on LB agar plates with 
ampicillin and incubated at 37°C for 24 hours. Single colonies were picked and grown in 
a 5 ml starter culture at 37°C overnight before a mini-prep was performed. 
To check for successful ligation, the recombinant plasmid was sequenced (MWG 
Eurofins, UK) using the following primer located in the upstream U6 promoter.  
hU6-F: 5’ TACGATACAAGGCTGTTAGAGAG 3’ 
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2.5.7 LentiCRISPRv2 Vector Production   
HIV-1-based vectors were produced by transient transfection of HEK-293T cells using 
the calcium phosphate co-precipitation method. 72 hours prior to transfection, 3 X 106 
cells were seeded in 15 cm plates containing 25 ml growth media. At about 80% 
confluency, the medium was replaced with 20 ml fresh growth medium, 2 hours before 
transfection. HEK-293T cells were co-transfected with four plasmids in molar ratio of 
1:1:1:2 (packaging: REV: envelope: transfer). 12.5 μg of integration-proficient or 
integration-deficient packaging plasmid (pMDLg/pRRE or pMDLg/pRRE-intD64V 
respectively), 7 μg of VSV-G pseudotyping plasmid (pMD2.VSV-G), 6.25 μg of REV 
plasmid (pRSV-rev) and 32 μg of transfer plasmid of choice were added to a 50 ml tube. 
The DNA was mixed with 125 μl of 2.5 M CaCl2, vortexed and incubated for 5 min at RT. 
To each tube 1,250 μl of 2x HBS Buffer was added drop-wise whilst vortexing at high 
speed. The DNA mixture was then immediately mixed gently with the media on the plated 
cells. At 14-16 hours after transfection, the medium was replaced with 18 ml of growth 
medium. Subsequently, at 48 hours post-transfection, media containing viral particles 
was harvested and plates replaced with 18 ml growth medium for second harvest done 
at 72 hours post-transfection. The harvested viral supernatant was cleared by 
centrifugation at 1000 x g for 10 min at RT and then passed through 0.22 μm-pore-size 
filters to remove suspended cells or debris. The filtered supernatant was then transferred 
to polyallomer centrifuge tubes (Beckman Coulter # 326823) and concentrated by 
ultracentrifugation (50,000 x g for 2 hours at 4°C). After centrifugation, the supernatant 
was discarded and pelleted viral particles resuspended in 50 μl of serum free DMEM. 
Viral suspension was then transferred to 1.5 ml microfuge tubes and spun at 1000 x g 
for 10 min at 4°C. The supernatant was then transferred to a new microfuge tube. The 
viral stock was adjusted to 10 mM MgCl2 (Sigma Aldrich #M8266), DNase I (Promega 
#M6101) was added at 5 U/ml and the mixture was incubated at 37°C for 30 min. This 
step is required to remove any residual DNA. Finally, virus suspensions were aliquoted 
and frozen at -80 °C. 
2.5.8 LentiCRISPRv2 Vector Titration 
To assess the titres of lentiviral vectors, HeLa cells were transduced with dilutions of the 
concentrated vectors and qPCR was performed on total DNA extracted from these cells. 
1 x 105 cells were seeded in 6-well plates one day before transduction. Cells were 
transduced in parallel with 1 in 2,000 and 1 in 20,000 dilutions of the prepared virus (each 
lentiviral vector had two preparations, harvest day 1 and day 2) in 2 ml of growth medium 
containing 8 µg/ml polybrene (Sigma Aldrich #TR-1003). A mock sample incubated with 
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only growth medium was also included. 24 hours post transduction, cells were harvested 
using trypsin and DNA was extracted from these using the QIAGEN DNeasy® tissue kit 
in a final volume of 400 µl through two sequential column elutions. In order to quantify 
the vector genomic DNA in transduced HeLa cells, the late reverse transcript (LRT) 
region, common to all lentiviral vectors cDNAs (Yoder and Fishel 2008) was amplified 
using LRT specific (Butler, Hansen et al. 2001) and quantified by qPCR (Rotor-Gene 
6000). The primer sequences were as follows: 
LRT-F: 5' TGTGTGCCCGTCTGTTGTGT 3' 
LRT-R: 5' GAGTCCTGCGTCGAGAGAGC 3' 
The reaction mixture comprised of: 100 nM of each primer, 1X SensiMixPlus SYBR 
(Bioline # QT650-05), and 6.25 µl of the sample DNA in a final volume of 20 µl. 102-107 
copies of plasmid pHR’SIN-cPPT-SEW DNA per reaction were used as standards. 
Samples were analysed in duplicates and standards were in triplicates (including the 
negative control). The thermocycling conditions were: 50°C for 2 min, 95°C for 10 min 
and 50 cycles of 95°C for 15 sec/ 60°C for 60 sec. A melting curve calculation was 
performed at the end with a continuous reading between 50 and 100°C.  
The LRT copy number titre was normalised to the number of cells transduced, which was 
determined though a parallel qPCR reaction. The number of cells was quantified using 
primers located in the beta actin gene following the same thermocycling conditions as 
the LRT reaction. The primer sequences were as follows: 
Actin-F: 5' TCACCCACACTGTGCCCATCTACGA 3' 
Actin-R: 5' CAGCGGAACCGCTCATTGCCAATGG 3' 
The reaction was performed under the following conditions: 100 nM of each primer, 1 X 
SensiMixPlus SYBR, and 5 µl of the sample DNA in a final volume of 20 µl. DNA 
extracted from 106 HeLa cells using QIAGEN DNeasy® tissue kit was used to prepare 
the standard curve (101-105 cells) for this reaction. The final titre was expressed as qPCR 
transducing units/ml vector stock. 
2.5.9 LentiCRISPRv2 Vector Transduction 
1 x 104 balb/c wild-type and SCID mTert fibroblasts were seeded in 48-well plates one 
day before viral transduction in 1 ml growth media containing puromycin. Cells were 
transduced with lentiCRISPRv2 vector at a MOI 40 in 500 µl of growth medium containing 
8 µg/ml polybrene. The plates were incubated for 48 hours at 37°C before harvesting for 
genomic DNA extraction. 
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2.6 ATM CRISPR-Cas9 Gene Editing 
2.6.1 gRNA Transfection 
ATM gRNAs were obtained as purified synthetic RNA oligos at a final concentration of 3 
µM (Synthego®, USA). 100,000 HEK293T-Cas9 cells were plated in 24-well plates and 
transfected with 30 nM gRNAs using 2.5 µl Lipofectamine-2000®. Plates were incubated 
at 37°C, 5% CO2 for 72 hours before harvesting for DNA extraction to detect gene editing.  
2.6.2 Indel Detection by TIDE 
To analyse indels introduced by Cas9 the genomic region surrounding PAM regions at 
the targeted sites were amplified using PCR, subjected to sequencing and analysed 
using TIDE software to quantify indels. Details of primer sequences, concentrations and 
annealing temperatures (Tm) are mentioned in Table 2.3. All primers were obtained from 
Sigma Aldrich. 
The PCR reaction consisted of: 1 x Go Taq® clear reaction buffer, 1.5 mM MgCl2, 0.4 
mM dNTPs, forward and reverse primers, and 0.05 U/µl Taq DNA polymerase (Promega 
#M7650). Thermo-cycling conditions were: initial denaturation at 95°C for 5 min, then 35 
cycles of 95°C for 30 sec, Tm°C (Table 3) for 30 sec, 72°C for 40-60 sec (calculated as 
1 min/kb), followed by final extension at 72°C for 5 min, then holding the reaction at 4°C. 
10 µl of the PCR product was tested on 1% agarose gel. On determining the correct size, 
the remaining PCR mixture was purified using QIAquick PCR purification kit protocol, 
mixed with 2 µl of 10 µM forward primer, except for ATM intron 32 where reverse primer 
was used for sequencing, and sequenced (MWG Eurofins, UK).  
Table 2-3 List of oligos for ATM CRISPR-Cas9 targets  
Name  Sequence (5’-3’) Conc. Amplicon  Tm °C  
2T>C-F CTACTACTGCAAGCAAGGCAAA 
0.5 µM 289 bp 51 
2T>C-R TGGTTCACAATTTCAGAACACAC 
103C>T-F ACAGTGATGTGTGTTCTGAA 
0.3 µM 225 bp 51 
103C>T-R GTTTCAGGATCTCGAATCAG 
5762ins-F ATTGGGGTAGAATGGTGTTGAC 
0.4 µM 211 bp 62.8 
5762ins-R TTTGTTTTTGCCCAACATACTG 
Int3-F ATCCTTGAGTGCTCATTTCCTT 
0.3 µM 768 bp 58.2 
Int3-R TGTTCTAGTTGACGGCAGCA 
Int32-F TTACAGAGCACTTGGTACTTTTGA 
0.5 µM 223 bp 51 
Int32-R CCCAGCTTTTAGTTTCTGTGTTTT 
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2.6.3 Whole-Genome Sequencing 
After 72 hours of ATM gRNA transfections in HEK293T-Cas9 cells, genomic DNA was 
isolated using a DNeasy Blood & Tissue kit and on-target loci were amplified for targeted 
deep sequencing. Deep sequencing libraries were generated by PCR. TruSeq HT Dual 
Index primers were used to label each sample. Pooled libraries were subjected to paired-
end sequencing (LAS, Inc.).  
2.7 Statistics 
Mean and standard deviation were calculated using Microsoft Excel. GraphPad Prism 
software was used for statistical analyses. Standard data was presented as mean ± 
standard error of the mean (SEM). One- or two-way ANOVA with appropriate post hoc 
tests were used in most cases. In most analyses, differences were considered 
statistically significant when the P value was ≤ 0.05.  
2.8 Collaborations 
Several experiments described in this study were outsourced and/or done in conjunction 
with several national and international collaborators (Table 2-4).  
Table 2-4 List of Collaborators 
Collaborator Contribution 
Ayad Eddaoudi 
Flow Cytometry Core Facility 
University College London, UK 
Fluorescence activated cell sorting of ZFN 
Prkdc fibroblast clones 
Pramila Gurung  
Third-year undergraduate student 
RHUL, UK 
Primer design and execution of PCRs to 
screen for loss of neomycin selection cassette 
in genomic DNA from ZFN Prkdc fibroblast 
clones 
Lisa Woodbine 
Genome Stability and Damage Centre 
University of Sussex, UK 
H2AX phosphorylation immunofluorescence 
analysis and clonongenic cell survival assays 
following gamma-radiation ZFN Prkdc 
fibroblast clones 
Eric Paul Bennett and Camilla 
Andersen 
Copenhagen Centre for Glycomics 
University of Copenhagen, Denmark 
Indel detection amplicon analysis (IDAA) in 
ZFN Prkdc fibroblast clones  
Daniyal Asghar 
Third-year undergraduate student 
RHUL, UK 
Design of gRNAs and primers for ATM gene 
editing. Execution of PCRs and TIDE for indel 
detection in genomic DNA from CRISPR-Cas9 
edited HEK293T cells. 
Taeyoung Koo 
Centre for Genome Engineering 
Institute of Basic Science, South Korea 
Next-generation sequencing of ATM targets in 
genomic DNA from CRISPR-Cas9 edited 
HEK293T cells. 
83 
 
3 Gene Editing in Prkdc-SCID Using 
Zinc Finger Nucleases 
 
 
3.1 Introduction  
Mice homozygous for the Prkdc SCID mutation are severely deficient in functional T and 
B lymphocytes. The mutation leads to a block in V(D)J recombination, preventing 
rearrangement of immunoglobulin and antigen receptor genes and thus causing an 
arrest in the early development of B and T lineage-committed cells, while other 
haematopoietic cells appear to develop and function properly. SCID mice readily support 
lymphocyte development and can be reconstituted with normal lymphocytes from other 
mice (Bosma, Custer et al. 1983, Bosma and Carroll 1991, Vladutiu 1993). Thus, these 
mice are of interest for studies of both normal and abnormal lymphocyte development 
and function. In addition, SCID mice also present as a good model for an ex vivo genome 
editing approach, where transplantation of gene corrected haematopoietic progenitors 
with selective growth advantage could reconstitute and restore the immune system.  
A previous study undertaken in this lab demonstrated proof-of-principle editing of Prkdc 
gene in fibroblasts and haematopoietic stem/progenitor cells (HSC/HSPCs) obtained 
from Prkdc-SCID mouse. Using zinc finger nucleases and a corrective repair matrix, the 
study showed correction of the SCID mutation as well as partial rescue of the T-cell 
phenotype in mice transplanted with gene-edited HSCs (Abdul-Razak 2013).  
In fibroblasts, gene editing led to the generation of a polyclonal population, which was 
originally analysed as a single sample. This chapter describes work undertaken to 
investigate gene editing events in single-cell clones derived from the ZFN-targeted cell 
pool. The main aims of this section were to verify repair of Prkdc DNA sequence and 
whether the repair correlated with functional rescue of the DNA PK enzymatic activity in 
vitro. 
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3.1.1 Homology-directed repair strategy 
A homology-directed repair strategy was employed to target the Prkdc gene and modify 
the mutated nucleotide (a T-to-A transversion) in cultured, mTert-immortalised SCID 
mouse fibroblasts (Abdul-Razak, 2013). HDR relies on the engineered introduction of a 
DSB break in the DNA close to the region to be modified; and on the intrinsic ability of 
cells to repair breaks in their DNA using homologous recombination. Two obligatory 
heterodimeric zinc-finger nucleases (Sangamo BioSciences, California USA) were 
designed to target Prkdc and introduce a double-stranded break 86-bp downstream of 
the SCID mutation site located in exon 85. The homologous sequence containing the 
wild-type nucleotide (T) at the mutation site was ~7.5 kb-long, and a selection marker 
was supplied on a plasmid as a donor template (referred to as the ‘Prkdc-neo’). The 
homology region was derived from a BAC clone containing Prkdc sequence, and 
conceptually was divided into homology arms left (HAL) and right (HAR), joined at the 
SCID mutation site. The 5.1 kb HAL encompassed sequences from intron 79 until SCID 
mutation site in exon 85; HAR included 2.4 kb of homologous DNA sequence 
downstream of SCID site covering sequences from exon and intron 85, as well as an 
additional neomycin-resistance gene (neo) selection cassette (Neo-R). The 1.6 kb Neo-
R consisted of neo floxed between two unidirectional LoxP sites and was inserted in 
intron 85 (Fig. 3-1).  
Recombination of the donor template with the cellular genome could lead to correction 
of the mutated nucleotide and incorporation of floxed neo cassette in the intron. 
Alternatively, the donor template can also recombine through NHEJ with the genomic 
DNA, generating random integrants (Fig. 3-2). In both circumstances, neo would be 
introduced in the modified cells, conferring resistance to antibiotic G418. Antibiotic 
selection after gene targeting allows for positive selection and confers growth advantage 
to cells that have undergone genetic modification.  
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Figure 3-1 Schematic Representation of Prkdc-neo Donor Template 
Prkdc-neo repair template was cloned as a double stranded circular plasmid DNA. Wild-type 
Prkdc sequences spanning homology arms left (HAL; 5.1 Kb) and right (HAR; 2.4 Kb) were 
obtained from a BAC clone. A selection marker cassette (1.6 Kb) containing a neomycin gene 
(neo) floxed between two loxP sites was incorporated in the HAR, as close as possible to the 
SCID mutation. Plasmid map created with SnapGene®.  
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Figure 3-2 Strategy for HDR of Prkdc SCID Mutation Using ZFNs 
Prkdc SCID is caused by a truncating mutation (T>A) in Prkdc exon 85. A homology-directed repair strategy using zinc finger nucleases was designed to repair 
the mutated nucleotide. ZFNs were designed to mediate a double stranded break downstream the mutation within exon 85. Wild-type Prkdc sequence containing 
correct nucleotide sequence was supplied on a plasmid donor template with left and right homologous arms (HAL, HAR). As a selection marker, neomycin gene 
floxed between two unidirectional loxP sites (NeoR) was included in the right arm of homology. Homologous recombination of the donor template with the 
cellular genome would lead to correction of mutated nucleotide and incorporation of floxed neo cassette conferring selective advantage to gene edited cells.   
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To validate the gene editing strategy, fibroblasts isolated from a Prkdc-SCID mouse and 
immortalised using mouse Tert (mTert) gene were utilised. First, ZFN genes were 
delivered on integration-proficient lentivectors followed by transfection of a repair 
template (10 µg) using calcium phosphate co-precipitation. Subsequently, G418 
selection was applied, leading to selective growth of a G418-resistant (G418-R) cell 
population, arising from either HDR- or NHEJ-mediated recombination. In order to 
determine the efficiency of gene targeting, single-cell clones were derived from the 
diversified G418-R polyclonal population (Fig. 3-3) (Abdul-Razak 2013). The clones 
were genotyped for successful recombination events using PCR and Sanger 
sequencing. Phenotype analyses was carried out by assessing DNA-PK activity.  
Subsequently, Cre-LoxP recombination was used to remove neo and generate selection 
marker free G418-sensitive (G418-S) cell populations. The Cre-lox system is a 
technology that can be used to induce site-specific recombination events in the 
genome. The system consists of two components derived from the P1 bacteriophage 
namely, the Cre recombinase and a LoxP recognition site (Sauer and Henderson 1988, 
Sauer 1998). Cre (or cyclization) recombinase is a 38 kDa protein responsible for intra- 
and inter-molecular recombination at the loxP recognition sites.  Cre acts independently 
of any other accessory proteins or co-factors. LoxP (locus of X (cross)-over in P1) sites 
are 34 bp-long recognition sequences consisting of two 13 bp long palindromic repeats 
separated by an 8 bp-long asymmetric core spacer sequence. The LoxP sequence does 
not occur naturally in any known genome other than P1 phage, and is long enough that 
there is virtually no chance of it occurring randomly. Therefore, inserting LoxP sites at 
deliberate locations in a DNA sequence allows for very specific manipulations. The Cre 
recombinase catalyses the site-specific recombination event between two LoxP sites, 
which can be located either on the same or on separate pieces of DNA (Sauer and 
Henderson 1988, Sauer 1998).  
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Figure 3-3  Workflow for Clonal Analysis of Genetically Modified SCID Fibroblasts 
Gene editing reagents zinc finger nucleases and donor repair template were introduced into cultured SCID fibroblasts using lentiviral transduction and 
calcium phosphate transfection, respectively. Drug (G418) selection was used to isolate recombinant fibroblasts and generate a G418-resistant (G418-
R) cell pool. PCR and Sanger sequencing were used to characterise polyclonal population. Subsequently, monoclonal populations were derived using 
dilution cloning. Gene editing events were analysed in individual cell clones using PCR and Sanger sequencing. For phenotype analysis, the activity of 
DNA-dependent protein kinase was assessed using H2AX phosphorylation and cell survival assays in response to DNA damage. Lastly, Cre-LoxP 
recombination was utilised to remove neo from the genome of edited cells and G418-sensitive (G418-S) clones were derived. These clones were then 
again subjected to genotype and phenotype analyses.  
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3.1.2 Validation of genome edits in monoclonal populations  
Introducing a nuclease in cells (with or without a donor template) results in a mixed 
population of cells. Following the introduction of a double strand break in mammalian 
cells, cellular machinery repairs the DSB by non-homologous end joining or homology 
directed repair. Repair via the NHEJ pathway predominates in mammalian cells resulting 
in the creation of indel errors, short heterogeneous insertions and deletions of nucleic 
acid sequences, at the site of the DSB. The HDR pathway requires the presence of a 
repair template, which is used to fix the DSB in a more specific manner. HDR faithfully 
copies the sequence of the repair template to the cut target sequence. Some cells will 
not be edited, some will have one allele edited, and some will have both alleles edited.  
In order to validate genome editing in ZFN targeted SCID fibroblasts, monoclonal 
populations derived from the targeted polyclonal cell pool were analysed individually. 
This involved amplification and sequencing of a region around the SCID mutation and 
ZFN cleavage sites.  
3.1.3 Rescue of DNA-PK enzymatic activity  
Loss of DNA PKcs enzymatic activity is associated with the impaired ability of cells to 
repair their DNA in response to DNA damage. The truncating mutation in Prkdc SCID 
fibroblasts abolishes most of the catalytic activity of DNA PKcs. Hence, correction of the 
mutated nucleotide should lead to restoration of DNA PKcs activity. In order to 
demonstrate that correction of SCID mutation leads to phenotypic rescue, DNA PKcs 
activity was assayed in ZFN-targeted clones. This was assessed using cell survival 
assays or analysis of H2AX phosphorylation in response to DNA damage in gene-edited 
clones. DNA damage assays were conducted using the cytotoxic drug Melphalan or by 
subjecting the cells to γ-radiation.  
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3.2 Results 
3.2.1 Genotyping ZFN targeted clones 
An ‘inside-out’ PCR strategy amplifying the 3’ donor-genome junction was utilised to 
screen for HR in ZFN targeted clones. A successful HR event can be verified by PCR 
amplification of a region from inside the repair construct extending to the genome outside 
of the region of homology; cells resistant to G418 as a result of a non-homologous 
random integration event will not undergo PCR amplification with such primers (Abdul-
Razak 2013). 14 out of 36 (38%) G418-R clones screened demonstrated gene targeting 
(Fig. 3-4). 
 
Figure 3-4 Verification of Gene Targeting in ZFN Prkdc Fibroblast Clones 
Schematic at top represents the PCRs used to validate targeting in G418-resistant (G418-R) cells 
generated using gene editing with zinc finger nucleases. The PCR product obtained using primers 
‘a’ and ‘b’, generating a 304 bp amplicon (represented by arrows), was used to determine 
genotype of the genomic region spanning the SCID mutation site and ZFN cut site. Primers ‘c’ 
and ‘d’ were used to amplify the donor-genome 3’ junction. Forward primer ‘c’ binds neo inside 
the repair template while the reverse primer ‘d’ lies outside the region of homology. Band ‘c-d’ will 
only be present in targeted cells and absent from cells where the repair template randomly 
integrated. Gel image at the bottom shows 1,335 bp PCR band in gene targeted clones. Gel, 1% 
agarose, 1x TAE buffer; M, Hyperladder 1 kb; ZFN, zinc finger nuclease; Neo-R, neomycin 
selection cassette. 
 
The recombination event at the targeted locus should restore the correct nucleotide 
sequence at the mutation site. To precisely determine the genotype and whether one or 
both alleles had been edited, standard sequencing was performed on PCR products 
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amplified from genomic DNA spanning the ZFN cleavage site (Fig. 3-4) from the 14 
targeted clones. A successful targeting event would lead to correction of at least one 
allele showing a double-peak, indicating mutant (A) and wild-type (T) nucleotides, at the 
mutation site. Majority of clones (9 out of 14) obtained from the ZFN targeted population 
showed presence of a double peak indicating mono-allelic correction of Prkdc gene at 
the SCID site. However, this was also followed by the presence of indels at the ZFN 
cleavage site. This region located in exon 85 of Prkdc downstream of mutation locus 
contained highly variable heterozygous indels. Only one clone (c.11) showed mono-
allelic correction at the SCID site along with a 3-bp (TAT) insertion at the ZFN cut site, 
as confirmed by Sanger sequencing (Fig. 3-5). The data produced by capillary 
electrophoresis allowed identification of sequence changes as well as detection of mixed 
sequences at the SCID mutation and ZFN cleavage sites. Genome modification at the 
mutation site is reported as SCID, heterozygous (ht) when both wild-type (wt) and SCID 
nucleotides are present, or wt. At ZFN cleavage site heterozygous genotype is indicated 
when there are indels on at least one allele (Fig. 3-6).  
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Figure 3-5 Genotyping ZFN Prkdc Fibroblast Clones 
Chromatographs obtained from sequencing PCR products amplifying the region spanning the SCID mutation site from gene targeted clones 2, 9, 11 and 16. 
All four clones display mono-allelic correction at SCID locus, indicated by presence of double peaks corresponding to SCID (A) and wild-type (T) nucleotides. 
ZFN cut site shows heterozygous mixed sequences in all clones. Clone 11 showed a 3-bp insertion (TAT) at the ZFN site. ZFN, zinc finger nuclease.  
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Figure 3-6 Characterization of Genome Modifications in ZFN Prkdc Fibroblast Clones 
Top shows a schematic depicting possible outcomes of HR between Prkdc allele targeted with ZFNs and donor template. Event 1+3 would correct the SCID 
mutation and incorporate the selection cassette (NeoR) giving rise to G418-resistant populations. Event 2+3 would also incorporate Neo-R but without repair 
of mutation. Event 1+2 would repair the mutation but these cells would be sensitive to G418 sensitive (G418-S). Bottom panel shows gene editing events in 
ZFN targeted clones (n=14). Majority of clones (64%; green) showed mono-allelic correction of Prkdc mutation indicated by the presence of a heterozygous (ht) 
sequence at the SCID site. However, these also have ht indels at the ZFN site. These clones were generated because of recombination event 1+3. Only one 
clone (#1), shown in yellow, showed no correction of the SCID mutation followed by wild-type (wt) sequence at ZFN site. Approximately 20% (purple) clones 
showed no correction of SCID site while ZFN site contained indels (event 2+3). HR, homologous recombination; ZFN, zinc finger nucleases.  
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3.2.2 DNA-PK activity in gene edited G418-R fibroblasts 
3.2.2.1 Clonogenic cell survival in response to Melphalan  
Clonogenic assays examine the potential of single cells to grow and reproduce into large 
colonies in the presence of cytotoxic factors (Munshi, Hobbs et al. 2005, Franken, 
Rodermond et al. 2006) . SCID fibroblasts are sensitive to the radiomimetic drug 
Melphalan. To verify that successful gene editing could abrogate radiosensitivity, colony 
survival assays with Melphalan were conducted. Cells tested included 4 gene edited 
G418-R clones (c.3, c.5, c.10 and c.11) and SCID fibroblasts. The fibroblast cell line 
Balb/c NIH-3T3 served as positive control. All cells were plated in varying seeding 
densities, treated with Melphalan and allowed to grow until colonies appeared. Under 
standard conditions, which is in the absence of Melphalan, all clones yielded low rates 
of colony formation with an average of 10% of total cells inoculated generating colonies, 
indicating the inability of these cells to form colonies. Cells treated with Melphalan yielded 
further reduced plating efficiency values, with <1% cells forming colonies (not shown).   
3.2.2.2 Cell survival in response to Melphalan using MTT assay   
Since the fibroblasts failed to grow as colonies, results from clonogenic assays were 
inconclusive. As an alternative, the colorimetric MTT assay was used for studying 
proliferation and determination of survival of cells after cytotoxic damage. MTT assay is 
based on the formation of a dark-coloured formazan dye by reduction of the tetrazolium 
salt MTT by metabolically active cells. After some incubation, the water-insoluble 
formazan dye forms crystals, which are dissolved in an organic solvent and their amount 
is determined semi-automatically using a microplate reader (Price and McMillan 1990, 
Hansen and Bross 2010). Absorbance readings are related to the number of cells 
therefore providing the possibility to use the MTT assay as a proliferation assay to assess 
cell growth (Price and McMillan 1990). Relative cell proliferation or viability was 
determined in cells treated with or without Melphalan.  
Cell viability of ZFN targeted clones was determined 4 days after treatment with 10µM 
Melphalan. As expected, the control wild-type fibroblasts recovered from DNA damage 
showing 95% viability post-treatment while SCID fibroblasts showed up to 2-fold 
decrease (p≤0.05, two-tailed T-test, n=9). However, the gene edited targeted clones 
(clone 5 and 11) remained sensitive to DNA damage despite the repair of mutated 
nucleotide (Fig. 3-7).  
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Figure 3-7 Cell Viability of G418-Resistant Clones  
Cell viability of G418-resistant gene targeted (clones 5 and 11) or random integrants (clones 3 
and 10) in response to 10 µM Melphalan using MTT assay. Data are represented as mean ± SD. 
There is a 2-fold difference between wild-type and SCID fibroblasts (*** = p≤0.05, n=9), but no 
significant difference between SCID fibroblasts and gene edited clones (p≤0.05, n=9). SCID 
mTert, immortalised SCID fibroblasts; Balb/c mTert, immortalised wild-type fibroblast from Balb/c 
mice. 
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3.2.3 Cre-LoxP recombination for excision of neo  
Intronic presence of the neomycin selection marker can have unwanted effects on the 
expression of the gene-edited locus. To remove the neo selection marker from Prkdc 
locus, Cre-LoxP recombination was employed. The Prkdc-neo repair template was 
designed to contain neo floxed between two unidirectional LoxP sites. Expression of Cre 
recombinase would therefore lead to recombination between the two LoxP sites, excising 
neo, leaving a single 34 bp LoxP ‘scar’ sequence in Prkdc intron 85 (Fig 3-8).  
 
Figure 3-8 Cre-LoxP Recombination at Prkdc Locus 
Expression of cre recombinase in gene-edited fibroblasts would mediate the removal of neo from 
the target locus by site-specific recombination, leaving a single loxP site left in intron 85 of Prkdc.  
 
3.2.3.1 Inefficient removal of neo  
Cre was transiently introduced in ZFN targeted clones (c.5, c.11 and c.12) by transfection 
of pMC-Cre plasmid using calcium phosphate co-precipitation method. A plasmid 
encoding eGFP used in parallel indicated poor transfection efficiency in SCID fibroblasts. 
Analysis of genomic DNA from Cre-treated polyclonal as well as monoclonal populations 
showed inefficient removal of neo (Fig. 3-9).  
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Figure 3-9 pMC-Cre Transfections to Remove Neo Selection Marker 
(a) Schematic plasmid map of pMC-Cre plasmid created with SnapGene® (b) Bright field and fluorescence microscopy images of ZFN Prkdc fibroblast clones 
(c. 5 and 11) 48 hours post- transfection with plasmid encoding eGFP. (c) Shows neo positive bands in gene targeted SCID fibroblast clones (c. 5, 11 and 12) 
before and after transfection with pMC-Cre plasmid. Products were run on a 1% agarose gel. M, Hyperladder 1 kb, negative control (-ve), SCID fibroblasts.  
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3.2.3.2 Enrichment of Cre-treated cells  
To address the low efficiency of neo removal by transfection of cre recombinase gene, 
flow cytometry sorting was used. Cre was transiently introduced in cells from ZFN Prkdc 
fibroblast gene targeted clones (c.5 and c.10) and random integrants (c.3 and c.11) by 
transfecting a plasmid encoding eGFP-Cre fusion gene (pCAG-GFP:Cre) (Fig. 3-10). 
Post-transfection cells expressing GFP were enriched using flow cytometry, expanded 
in culture and screened for the loss of neo. 
Three different PCRs were designed to screen for the removal of the neo cassette from 
the three possible Prkdc alleles present in the ZFN Prkdc fibroblast clones. These are 
illustrated in (Fig. 3-11a). Treatment with Cre led to removal of neo in all four clones, 
leaving an intronic 34 bp LoxP ‘scar’ site (Fig. 3-11b). To isolate cells where neo was 
removed and the SCID mutation was corrected, the Cre-treated clones 5 and 11 were 
subjected to flow cytometry sorting for eGFP expression, followed by limiting dilution, 
and 20 further clones were generated. PCR screening in these cells showed efficient 
removal of neo and presence of a single intronic LoxP site at the Prkdc locus (Fig. 3-
11c). As expected, following the removal of neomycin these clones became sensitive to 
G418 (G418-S) showing cell death when grown in presence of G418 (Fig. 3-12).  
Downstream sequence analysis of genomic DNA using Sanger sequencing and Indel 
Detection by Amplicon Analysis (IDAA) from G418-S clones displayed the same pattern 
as the parent clones – mono-allelic correction of the mutated nucleotide along with Indels 
(3-bp insertion) at the ZFN cut site (Fig. 3-13). An exception to this was clone 11.2, where 
the ZFN target sequence remained unaffected while SCID mutation was corrected on 
one allele (Fig. 3-14)  
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Figure 3-10 pCAG-eGFP:Cre Transfections to Remove Neo Selection Marker 
(a) Schematic plasmid map of pCAG-eGFP:Cre created with SnapGene® (b) Bright field and fluorescence microscopy images of ZFN Prkdc fibroblast clones 
(c. 5, c.11 and 12) 48 hours post-transfection with pCAG-eGFP:Cre plasmid. 
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Figure 3-11 Cre-LoxP Mediated Removal of Neomycin Selection Marker 
(a) Schematic of PCRs used to screen for the presence of neomycin selection marker cassette indicating primer sites and amplicon sizes. Arrows represent 
PCR primers and their direction. (b) PCR products ran on 3% agarose gel from ZFN Prkdc fibroblasts clones (gene targeted clones 5 and 11; random integrant 
clones 3 and 10) before and after Cre-LoxP recombination indicating loss of neomycin cassette. (c) PCR products ran on 1% agarose gel from clones derived 
from Cre-treated ZFN Prkdc clone 5 (clones 5.1, 5.11 and 5.12). M, Hyperladder 1 kb, Neo-R, neomycin-resistance selection marker cassette. 
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Figure 3-12 G418 Treatment in Cre-Treated Prkdc Fibroblasts  
Microscopy images from control and Cre-treated ZFN Prkdc fibroblast clones (c.5.1, 11.1 and 11.2) cultured in presence of antibiotic G418 (800 µg/ml). Cre-
treated clones showed increased sensitivity to G418 showing total cell death by day 6. 
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Figure 3-13 Indel Detection Amplicon Analysis (IDAA) in ZFN Prkdc Fibroblasts 
Fragment analysis showing fluorescently labelled amplicons containing the indels. Peaks 
represent amplicon size in base pairs (denoted in red) based on fluorescent intensity. SCID and 
wild-type Balb/c fibroblast show one peak representing a single amplicon while gene targeted 
fibroblast clones show multiple peaks indicating presence of a mixture of alleles. Cells derived 
from gene targeted clone 11 show a second allele with a 3-bp insertion before (G418-R11, middle 
panel) and after Cre recombination (G418-S clones). Indels, insertions or deletions. 
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Figure 3-14  Genotype Analyses of G418-S Clones by Sanger Sequencing  
Chromatographs obtained from Sanger sequencing the region around Prkdc ZFN target site in Cre-treated ZFN Prkdc fibroblast clones. Both clones show 
mono-allelic correction of SCID mutation indicated by presence of double peaks at SCID site. Additionally, clone 11.1 show a 3-bp insertion at the ZFN target 
site while in clone 11.2, ZFN site is not affected.  
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3.2.4 DNA-PK activity in gene edited G418-S fibroblasts 
3.2.4.1 Cell survival in response to Melphalan  
G418-S clones (c.5.1, c.11.1 and c.11.2), SCID mTert fibroblasts, and wild-type Balb/c 
mTert fibroblasts were subjected to 10 µM Melphalan and cell viability was determined 
using MTT assay. As expected, treatment with Melphalan drastically reduced cell viability 
in DNA-PKcs deficient SCID fibroblasts by up to 30% (p<=0.05 two-tailed T-test; n=9) 
(Fig. 3-15). In comparison, the gene edited clones showed no significant difference in 
cell viability upon cytotoxic treatment. This suggests that the cells remained sensitive to 
DNA damage despite the repair of mutated nucleotide as well as removal of neo. 
 
Figure 3-15 Cell Viability of G418-S Clones  
Cell viability of G418-sensitive (Cre-treated) ZFN Prkdc fibroblast clones 5.1, 11.1 and 11.2 in 
response to 10 µM Melphalan using MTT assay. Data are represented as mean ± SD. 4-fold 
difference between wild-type and SCID fibroblasts. No significant difference between SCID 
fibroblasts and gene edited clones (p≤0.05, n=9). SCID mTert, immortalised SCID fibroblasts; 
Balb/c mTert, immortalised wild-type fibroblast from Balb/c mice. 
 
3.2.4.2 Clonogenic cell survival in response to γ-radiation 
SCID fibroblasts are sensitive to γ-radiation showing a dose-dependent decrease in cell 
survival as compared to wild-type fibroblasts with 3 Gγ gamma irradiation being the 
optimal dose to kill SCID cells. Gene editing should rescue this phenotype however this 
was not observed, with both G418-R c.11 and G418-S c.11.2 displaying decreased cell 
survival in response γ-radiation (n=2) (Fig. 3-16). 
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Figure 3-16 Clonogenic Cell Survival in Response to γ-Radiation Following neo Removal 
Fibroblasts were subjected to increasing dosage of γ-radiation (3 Gγ being the maximal dose to 
kill Prkdc fibroblasts). Cell survival was quantified by counting colonies relative to untreated 
samples. Data are represented as mean (n=2). SCID mTert, immortalised SCID fibroblasts; 
Balb/cmTert, wild-type immortalised fibroblasts; G418-S c.11.2, targeted SCID fibroblast clone 
with neo removed; G418R c.11, targeted SCID fibroblast clone with neo. 
 
3.2.4.3 H2AX phosphorylation   
When DNA DSBs are induced by ionizing radiation in cells, histone H2AX is quickly 
phosphorylated into gamma-H2AX around the DSB site. DNA-PKcs regulates the 
phosphorylation of H2AX and cell cycle progression in response to DNA damage. To 
confirm that repair of mutated SCID nucleotide restored DNA-PKcs activity, cells from 
G418-S clones (c.5.1, c.11.1, c.11.2, c.11.16, and c.11.18), SCID mTert fibroblasts, and 
wild-type Balb/c mTert fibroblasts were treated with γ-radiation. Under these 
experimental conditions, H2AX was phosphorylated. The level of gamma H2AX foci in 
all cells increased rapidly with a peak level at 0.25 - 1.0 h after 3 Gγ gamma irradiation 
(n=3) (Fig. 3-17). With ongoing DNA repair, the number of H2AX foci rapidly decreased 
in wild-type fibroblasts within 24 hours. SCID fibroblasts, deficient in DNA PKcs, showed 
slower decline in the number of H2AX foci. Compared to SCID fibroblasts, gene edited 
clones showed decrease in H2AX foci, however this was not significant.  
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Figure 3-17 H2AX Phosphorylation in Response to γ-Radiation 
Number of H2AX foci formed at 0, 0.25, 2, 6, and 24 hour intervals post γ-radiation (3 Gγ) in ZFN Prkdc fibroblasts. Data are represented as mean ± SD (n=3). 
SCID mTert, immortalised SCID fibroblasts; Balb/c mTert, wild-type immortalised fibroblasts; G418-R c.11, targeted Prkdc fibroblast clone with neo; G418-S 
c.11.1, 11.2,11.16 and 11.18, targeted SCID fibroblast clones with neo removed. 
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3.3 DISCUSSION  
This chapter described experiments that were undertaken to obtain formal proof of gene 
editing and repair of the Prkdc SCID mutation in murine SCID fibroblasts. Use of zinc 
finger nucleases and a homologous repair template previously reported successful gene 
targeting and phenotypic rescue of DNA PKcs activity in a polyclonal population of SCID 
fibroblasts (Abdul-Razak 2013). However, the clonal lines generated from this polyclonal 
repertoire were not studied, which is an important step of the genome editing workflow.  
The fibroblast clones were previously generated using positive drug (G418) selection. 
Any cell with a copy of the repair template would therefore show resistance to the drug. 
To rule out clones that contained randomly integrated copies of the repair template, I 
used a PCR specific for determining gene targeting at the Prkdc locus. This showed that 
up to 40% of the clones were targeted at the Prkdc locus using homologous 
recombination. These levels were line in with a similar study in SCID mouse fibroblasts 
where ZFNs were used to target the Prkdc-SCID mutation (Rahman, Kuehle et al. 2015) 
It is worthwhile to note here that SCID fibroblasts may have a bias towards HDR. As 
seen in Fanconi anaemia, which is also a DNA repair disorder, in the absence of NHEJ, 
cells preferentially employ the HDR arm of DNA repair, especially when a homologous 
donor template is present (Rio, Banos et al. 2014). 
 The gene targeting however did not correlate with functional rescue of DNA-PKcs as 
determined by a preliminary in vitro enzymatic assay that was previously carried out in 
the parent polyclonal populations (not shown) and the poor cell survival of fibroblasts 
observed upon cytotoxic DNA damage. It is noteworthy to mention primary fibroblasts do 
not form colonies in the absence of a feeder layer, especially upon cytotoxic treatment 
(Dr Lisa Woodbine, personal communication). 
These setbacks led to further genotyping of the targeted clones using Sanger 
sequencing and IDAA. Sequence analysis showed that while gene targeting led to the 
repair of mutated SCID nucleotide in the majority of clonal lines tested, additional 
heterozygous sequence alterations were introduced at the ZFN target site. There was 
only one cell clone (c.11) that showed an in-frame 3-bp insertion in the coding sequence, 
which would lead to addition of an isoleucine residue in the protein sequence. These 
sequence alterations could explain the loss in DNA PKcs activity observed. Since no 
targeted clone without an unaffected sequence at the ZFN cut site was identified, further 
experiments were carried out using select few cell lines. Clone 11 that showed an in-
frame change in its genomic sequence was analysed as the primary candidate.  
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Before carrying out further phenotypic experiments, I sought to remove the selection 
marker present in the repaired locus. This was done because the intronic presence of a 
neo selection marker cassette has been reported to perturb gene function previously 
(Pham, MacIvor et al. 1996). The HDR strategy was designed with this in consideration 
and hence neo was introduced floxed between two unidirectional LoxP sites. To remove 
neo, Cre recombinase was transiently expressed in a select few targeted clonal cell lines 
using plasmid transfection. Unfortunately, primary SCID fibroblasts were found 
extremely challenging to transfect using a variety of lipid-based transfection reagents 
(data not shown) To bypass this, a new strategy based on selective enrichment of 
transfected cells was developed. Cells were transfected with a new plasmid which 
encoded Cre fused to GFP under the regulation of a stronger, CAG, promoter. 
Fluorescence was used as a measure of transfection. Since GFP/Cre was not a true 
fusion protein, being separated by a T2A polypeptide, low transfection rates observed 
were unlikely due to GFP quenching The small population of transfected cells were then 
enriched using flow cytometry sorting based on expression of eGFP. Use of the new 
plasmid and cell sorting was effective at isolating transfected cells and led to the 
generation of neo free, G418-sensitive cells containing a single loxP scar sequence in 
the downstream intron. Removal of neo was confirmed by genotyping the cell sorted 
clones as well as by subjecting them to G418 drug treatment for 8 to 10 days, 
demonstrating the removal of the marker at the genomic and phenotypic levels.  
Subsequently, these clonal populations were genotyped to characterize the sequence 
around the ZFN target site. G418-sensitive cells derived from clones 5, 11 and 12 
retained the same signature deletion of the coding region. All cells derived from clone 11 
showed the 3-bp insertion except clone 11.2, which interestingly showed wild-type 
sequence at the ZFN site along with repair of the SCID mutation. This suggested that 
perhaps clone 11 was not a completely homogenous cell population to begin with. 
However, identification of a cell clone with the desired edit – correction of SCID 
nucleotide and unaffected ZFN target site – was encouraging.  
Following genotype analysis, G418-sensitive cells were assayed for the rescue of DNA 
PKcs activity using two different techniques – cell survival assays and H2AX 
phosphorylation. The first method looked at cell survival in response to damage by 
cytotoxic drug Melphalan and by γ-radiation. Cell survival assays not only demonstrate 
DNA damage repair but also indicate the potential of cells to recover from the damage 
and grow as per normal (Munshi, Hobbs et al. 2005, Franken, Rodermond et al. 2006). 
Initial colony forming assays demonstrated the poor colony forming abilities of scid 
fibroblasts. To facilitate the formation of colonies, the cells were plated on a feeder layer 
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of primary embryonic fibroblasts, upon DNA damage. This led to formation of intact 
colonies which were easier to score than in the previous attempt.  
The second technique used was based on direct detection of DSB damage. The 
formation of DSBs triggers activation of many factors, including phosphorylation of the 
histone variant H2AX, producing gamma-H2AX. Phosphorylation of H2AX plays a key 
role in DNA damage response and is required for the assembly of DNA repair proteins 
at the sites containing damaged chromatin as well as for activation of checkpoints 
proteins which arrest the cell cycle progression (An, Huang et al. 2010, Podhorecka, 
Skladanowski et al. 2010). Unfortunately, neither of the assays used showed significant 
rescue of DNA PKcs enzymatic activity in G418-sensitive clonal cell lines in comparison 
to wild-type control cells. This was consistent even in clone 11.2, which had shown the 
genomic profile of a corrected clone. 
It is not clear why clone 11.2 failed to show rescue of DNA-PK activity when it has the 
expected genomic structure from a repair event: mono-allelic correction of SCID 
mutation, and wild-type sequence at the ZFN target site. As we have not sequenced the 
full Prkdc gene or analysed epigenetic marks in this clone, it is possible that de novo 
mutations or epigenetic changes introduced during genetic manipulation or the extended 
period in culture are responsible for the inability to display evidence of normal DNA-PK 
activity.  
In any case, given that only one clonal population carried the desired edit highlights the 
potential problems in genome editing procedures caused by intrinsic DNA repair defects 
in Prkdc SCID fibroblasts. NHEJ is the primary DNA damage repair pathway in 
vertebrates. Although it is known to be error-prone introducing insertions and deletions 
at the repair site, NHEJ can perfectly join the two broken ends of DNA in some cases. 
Studies have shown that NHEJ is not as error-prone as perceived; in fact, in the absence 
of NHEJ, cells utilise an alternative and highly mutagenic repair pathway, to process the 
damaged DNA ends (Betermier, Bertrand et al. 2014). This pathway is known as 
alternative (alt-NHEJ) or microhomology-mediated end-joining (MMEJ) (Wang, Perrault 
et al. 2003, Wang and Xu 2017). Since SCID fibroblasts are defective in NHEJ, the DSB 
introduced by ZFNs could have been inaccurately repaired by alt-NHEJ causing the 
sequence alterations observed. This however is only speculative and would require 
definitive and quantitative assessment. A possible method to overcome this limitation 
would be to carry out a larger screen of edited cells. Out of the 30 clones initially tested 
in this study, only one sub-clone with the desired edit was identified. Furthermore, since 
the ZFN target site was present in the repair template, the template could have been re-
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cut by the nuclease even after a correct homologous recombination effect. To avoid this, 
a repair template lacking the nuclease cut site should be utilised. A simple method of 
doing that is introducing a silent mutation at the cut site in the homologous template 
(Hollywood, Lee et al. 2016).  
Given the nature of the DNA repair defect in SCID cell lines, the results obtained here 
were disappointing but not completely unexpected. Nonetheless this study highlighted 
that genome editing can be carried out in cells defective in DNA damage repair. In fact, 
a high proportion of cells targeted showed mono-allelic repair of the genetic mutation. 
Lastly this study demonstrated the necessity of laborious and exhaustive genome editing 
technology workflow. It is crucial to thoroughly analyse genomic modification at a clonal 
level as a single unidentified genetic change can lead to deleterious effects on protein 
expression and function, and potential artefacts in downstream experiments. 
Building up on the conclusions from this Chapter, we decided to progress this work using 
the CRISPR-Cas9 technology. CRISPR-Cas9 system is a robust genome editing 
platform that is increasingly being used across various disease models. However, it has 
still not been used in the context of Prkdc-SCID. We decided to switch to this system in 
order to generate new clonal populations and interrogate the questions that remain 
unanswered here. CRISR-Cas9 based gene editing of Prkdc-SCID is described in the 
next Chapter.  
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4 Gene Editing in Prkdc-SCID Using 
CRISPR-Cas9  
 
 
4.1 Introduction  
The CRISPR-Cas9 genome editing platform is a versatile and efficient technology that 
enables a variety of gene targeting strategies (Cox, Platt et al. 2015). Building upon the 
work using engineered ZFNs described in the previous Chapter, this section will 
investigate the use of CRISPR-Cas9 technology to target and correct the murine Prkdc 
SCID mutation in cultured Prkdc SCID fibroblasts. CRISPR-Cas9 technology has shown 
progress in efficient genome editing of many genetic diseases with ever growing 
applications. However, the system has not been employed in the context of Prkdc-SCID 
so far. This study would thus provide novel proof-of-concept information on the targeting 
and recombination at the Prkdc locus. Moreover, since Cas9 nuclease and ZFNs create 
different double-strand breaks cuts in the DNA – Cas9 generates a blunt end cut while 
ZFNs induce a staggered cut – the recombination output could vary. The previous 
Chapter aimed to rescue DNA PKcs enzymatic activity due to the repair of underlying 
mutation; however, this was met with challenges pertaining to mutations being 
introduced at the nuclease target site in all clones tested. Therefore, the main aims of 
this section were to develop CRISPR-Cas9 gene editing reagents to target Prkdc, correct 
the SCID point mutation using a homologous recombination strategy, and generate 
single-cell clones for downstream analysis.   
The CRISPR-Cas9 system comprises of two components - a nuclease (Cas9) and a 
short RNA sequence (guide RNA or gRNA), which directs Cas9, through its 
complementary bases, to a specific DNA sequence which then mediates a double-
stranded break (Jinek, Chylinski et al. 2012). Three independent gRNAs were designed 
to target the Prkdc SCID mutation – two in exon 85 close to the previously investigated 
ZFN site described in Chapter 3 and one in the downstream intron 85. These guides 
were then separately used in conjunction with the Cas9 nuclease and the previously 
described Prkdc-neo donor template for homology-directed repair of the SCID point 
mutation (Fig. 4-1). 
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Figure 4-1 Homology-Directed Repair of Prkdc SCID Mutation Using CRISPR-Cas9  
Prkdc SCID is caused by a truncating mutation (T to A transversion) in exon 85 of Prkdc gene. A homology-directed repair strategy using CRISPR-Cas9 was 
designed to repair the mutated nucleotide. Three different gRNAs were designed to introduce a double stranded break close to the SCID mutation. Wild-type 
Prkdc sequence containing correct nucleotide was supplied on a plasmid donor template flanked between homology arms left (HAL) and right (HAR). As a 
selection marker, neomycin gene floxed between two unidirectional loxP sites (NeoR) was included in the right arm of homology. Homologous recombination 
of the donor template would lead to correction of mutated nucleotide and incorporation of floxed Neo-R conferring selective advantage to gene targeted cells. 
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Separately, a modified Prkdc-neo donor DNA template was also investigated, where 
Cas9-recognition sites (known as protospacer adjacent motifs or PAM regions) were 
altered using site-directed mutagenesis. Having intact CRISPR PAM targets in the 
homologous donor template can cause degradation of donor plasmids by Cas9 activity 
in cells or modification of genomic sequence upon recombinant of the template 
(Hollywood, Lee et al. 2016). This can be detrimental especially if the change affects the 
coding region of a gene. A possible way to avoid this is to mutate the PAM regions into 
silent mutations within the donor template (Hollywood, Lee et al. 2016). 
To carry out gene targeting, Prkdc gRNAs were cloned in spCas9 expression plasmids. 
These were then transfected into immortalized SCID fibroblasts along with donor DNA 
plasmids containing neo selection marker. G418 antibiotic selection was used to pool 
targeted cells, leading to the generation of a polyclonal G418-resistant (G418-R) cell 
population. To determine the efficiency of gene editing, single-cell clones were derived 
from the diversified G418-R population. The clones were genotyped for successful 
recombination events using standard PCRs and sequencing. The overall gene targeting 
approach is illustrated in (Fig. 4-2).  
The previous chapter showed a high rate of sequence alterations at the nuclease cut site 
in ZFN targeted cells suggesting a lack of DNA damage repair in SCID fibroblasts. To 
test this, editing events at Prkdc locus will be compared in SCID and Balb/c wild-type 
fibroblasts. For this, a Prkdc guide RNA will be developed into a third-generation lentiviral 
vector and transduced into cells. Downstream editing events will be validated via 
standard PCRs and bioinformatics tools.
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Figure 4-2 Experimental Design of CRISPR-Cas9 Prkdc Gene Editing 
Gene editing reagents Cas9 and gRNA, and a donor repair template were introduced into cultured SCID fibroblasts on plasmid backbones using calcium 
phosphate transfection. Drug G418 selection was used to select targeted fibroblasts and generate a G418-resistant (G418-R) cell pool. PCR and Sanger 
sequencing were used to characterise polyclonal population. Off-target profiling to be carried out using next-generation sequencing of predicted off-target 
genomic sites. Consecutively, monoclonal populations were derived using dilution cloning and genotyped  
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4.2 Results  
4.2.1 In-silico design of Prkdc guide RNAs  
Single spCas9 guide RNAs (gRNA-1 and -2; 20 nucleotides each) targeting Prkdc exon 
85 were designed using the web tool CHOPCHOP v1. The guides were designed to 
match a 20-nucleotide target in the input DNA sequence from Prkdc exon 85 adjacent to 
a ‘NGG’ PAM specific for spCas9 nuclease. For target selection, guides were designed 
with cut sites within 100 bp of the junction of the homology within exon 85. 
gRNA sequence targeting Prkdc intron 85 (gRNA-3; 20-nt) was designed using Cas-
Designer. It is a web-based bioinformatics tool which scores Cas9 targets in each input 
sequence with potential off-target numbers with 2 nucleotide mismatches and out-of-
frame scores via microhomology-predictor. gRNA sequences, PAM and distance from 
SCID mutation site are mentioned in Table 4-1 and (Fig. 4-3). 
Table 4-1 Prkdc-SCID gRNAs 
gRNA gRNA Sequence (5’ - 3’) SpCas9 PAM Location of Cut Site 
gRNA-1 AGCTAAGAGAAAGTTAGCAG GGG 19 bp downstream 
gRNA-2 GCTTAGCGTATTTTATGTTG TGG (- strand) 17 bp upstream 
gRNA-3 AGCTAAGAGAAAGTTAGCAG GGG 117 bp downstream 
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Figure 4-3 Schematic of Prkdc CRISPR-Cas9 gRNAs 
Three different spCas9 (‘NGG’ PAM) gRNAs were designed adjacent to SCID mutation on Prkdc. gRNA 1 and 2 target regions close to SCID mutation site 
(T>A) on exon 85. gRNA-1 target site overlaps with the previously used zinc finger nucleases. gRNA-3 targets a region in the downstream intron. 
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4.2.2 Cloning of guide RNAs in Cas9 expression plasmid  
For expression in culture, gRNAs 1, 2 and 3 and their complementary sequences with 
overhangs for the BbsI (or BpiI) enzyme were obtained as single-stranded 
oligonucleotides, annealed and cloned into a plasmid backbone encoding spCas9-GFP. 
The plasmid PX458 contains a short filler region flanked by two BbsI restriction sites 
downstream of human U6 promoter, which drives the expression of gRNA (plasmid map 
in (Fig. 4-4). The filler region was removed and replaced by double-stranded gRNA 
nucleotides containing appropriate overhangs. Plasmid cloning was carried out using a 
single-step digestion-ligation protocol where the plasmid backbone was digested with 
BbsI restriction enzyme and ligated with annealed oligo-duplex at the same time. Correct 
cloning of gRNA nucleotides was verified by sequencing the recombinant plasmid with a 
primer binding within the human U6 promoter. The cloning strategy and resulting 
sequence of gRNAs cloned in the Cas9 backbone is illustrated in (Fig. 4-4).  
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Figure 4-4 Cloning of Prkdc gRNAs in Cas9 Expression Plasmid 
Prkdc-SCID gRNAs were cloned on a Cas9 plasmid co-expressing GFP using a single-step cloning protocol. (Left) First, single-stranded gRNAs were annealed 
to form a duplex. Next, the donor Cas9 plasmid was digested with BbsI restriction enzyme and ligated with the oligo duplex at the same time. (Right) Cloning 
was verified by sequencing of the recombinant plasmid. Chromatographs obtained after Sanger sequencing show gRNA sequences inserted in the Cas9 
backbone. 
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4.2.3 Prkdc gRNA cleavage efficiency  
Guide RNA cleavage efficiency is determined by the detection of indels at the Cas9 cut 
site. Plasmids encoding spCas9-GFP and sgRNAs 1, 2 or 3 were introduced in cultured 
SCID fibroblasts using lipid-based transfection and green fluorescence was used to 
monitor plasmid expression. In all cases, SCID fibroblasts showed poor transfection 
efficiencies. (Fig. 4-5) shows the low transfection efficiency observed in SCID fibroblasts 
24- and 48-hours post- transfection. Indels were detected at 48 hours post-transfection 
time point using the Tracking Indels by Decomposition (TIDE) method. To carry out TIDE, 
regions around the Cas9 cleavage sites for all three guides were amplified by PCR from 
control (unedited) and edited cells. These were then subjected to standard capillary 
Sanger sequencing. Subsequently, the obtained sequences were analysed using the 
TIDE software to quantitate the indel spectrum. TIDE analysis showed cleavage 
efficiency of 8.4%, 3% and 3.8% for gRNAs 1, 2 and 3 respectively with R2=0.99. The 
indel profiles for all three gRNAs are illustrated in (Fig 4-6).  
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Figure 4-5 Transfection of Prkdc gRNAs in SCID Fibroblasts  
Microscopy images showing transfection of Cas-GFP encoding Prkdc gRNA 1, 2 and 3, 48 hours post-transfection. Bright field and fluorescence images were 
captured in the same field. 
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Figure 4-6 Indel Detection using TIDE  
Charts showing spectrum of indels generated by Prkdc gRNAs 1, 2 and 3 in immortalised SCID 
fibroblasts. Results are shown as total efficiency of gRNA indicated by % of sequences containing 
insertions or deletions (indels) around the Cas9 cut site (represented by 0), and probability of 
nucleotide inserted at +1 bp location. R2 represents the goodness of fit. The P-value is associated 
with the estimated abundance of each indel calculated by a two-tailed t-test.
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4.2.4 Gene targeting of Prkdc exon 85 
A homology-mediated repair strategy was used to target and repair the SCID mutation 
on Prkdc exon 85. For HDR, Cas9-GFP expression plasmids encoding gRNA 1 or 2 were 
transfected into immortalised SCID fibroblasts in the presence or absence of the Prkdc-
neo donor template. Plasmid expression was monitored using the fluorescence of GFP 
from the marker gene. In all cases, SCID fibroblasts showed poor transfection 
efficiencies (Fig. 4-7). Following the introduction of gene editing reagents, cells were 
subjected to G418 drug selection for 5 days to generate a G418-resistant targeted cell 
population. To validate gene targeting using HR, an inside-out PCR strategy amplifying 
the 3’ HR junction was used as an initial screen (Fig. 4-8). All samples transfected with 
Cas9 in the presence of gRNAs and the donor template showed gene targeting despite 
low transfection levels and led to the generation of G418-resistant colonies. No gene 
targeting was observed in cells transfected only with a donor template or with a Cas9 in 
absence of a gRNA (Fig. 4-8). 
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Figure 4-7 Transfection of Genome Targeting Reagents 
Gene targeting was carried out by introduction of Cas9 and Prkdc gRNAs (1 and 2) along with a donor template in immortalised SCID fibroblasts. Bright field 
and fluorescence microscopy images were captured in the same field 48-hours post-transfection. 
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Figure 4-8 Gene Targeting of Prkdc Exon 85  
On the left is shown a schematic representing PCRs that were used for genotyping gene edited cells. Arrows indicate PCR primers and their orientation. In 
order to verify gene targeting, an inside out PCR amplifying the genome–donor 3´-junction was used. Top right panel shows G418-resistant colonies stained 
with crystal violet, that were generated because of gene targeting using Cas9 and Prkdc gRNAs 1 and 2. Gel image shows the diagnostic gene targeting band 
in polyclonal SCID fibroblasts obtained by an inside-out PCR amplification of the genome–donor 3´-junction. No band was seen in cells targeted with donor in 
the absence of CRISPR-Cas9 reagents. M, Hyperladder 1 Kb; G1, gRNA-1; G2, gRNA-2, Gel, 1% agarose, 1x TAE buffer.  
125 
 
 
To determine the efficiency of the gene targeting approach and to analyse the types of 
gene edits, 30 single-celled clones from each gRNA targeted polyclonal cell pool were 
isolated. These monoclonal populations were expanded in culture and genomic DNA 
was extracted for genotype analysis. Firstly, an inside-out PCR amplifying the 3’ HR 
junction was used to determine gene targeting in independent clones. 36% (i.e. 11 out 
of 30) of cells clones obtained from gRNA-1 cell pool and 33% (10 out of 30) clones 
obtained from gRNA-2 population showed the diagnostic band indicative of gene 
targeting (Fig. 4-9). In comparison, no gene targeting was observed in cell clones derived 
from G418-R population obtained using donor template and Cas9 without a gRNA. 
 
Figure 4-9 Gene Targeting in Prkdc CRISPR-Cas9 Clones 
Gel images showing diagnostic gene targeting band (3’ donor-genome junction) in clones isolated 
from gene edited polyclonal cell pools using Prkdc gRNA 1 and 2. Gene targeting was verified 
using an inside-out amplification of genome-donor 3’ junction. (Top) Gel image showing PCR 
amplicons from 30 targeted clones derived from gRNA-1 and donor template treated cell pool. 
(Bottom) PCR amplicons from gRNA-2 clones. Overall approximately 30% of clones analysed 
showed targeted recombination of donor template in the presence of CRISPR-Cas9. M, 
Hyperladder 1 kb; Gel, 1% agarose, 1x TAE buffer.  
 
To validate genome editing, a short region spanning the mutation and sgRNA target site 
(304 bp) was amplified and sequenced from clones positive for HR. Possible outcomes 
of HR between the Prkdc allele and the donor template are illustrated in (Fig. 4-10). The 
data produced by capillary electrophoresis led to identification of sequence changes as 
well as detection of mixed sequences at the SCID mutation and Cas9 cleavage sites. 
Genome modification at the mutation site is reported as heterozygous (ht) for mono-
allelic correction indicating both wild-type and SCID sequences, corrected for bi-allelic 
correction, or as SCID if there was no repair. At the Cas9 cleavage site, the genotype is 
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indicated as heterozygous when there were indels on at least one allele, or as wild-type 
in case no indels were observed (Table 4-2). Targeting using gRNA-1 indicated mono- 
or bi-allelic correction of the SCID nucleotide in 60% of clones (n=10). However, this was 
also followed by the presence of heterogeneous indels at the Cas9 cleavage site, as 
observed previously in experiments using ZFNs. 30% of the clones showed no HDR at 
the SCID mutation, however they had indels at the Cas9 cut site. Only one clone (clone 
#7) did not show evidence of indels at the Cas9 cut site. As for gene targeting using 
gRNA-2, only 25% clones (n=8) indicated HDR (mono- or bi-allelic) at the SCID site along 
with indels at the Cas9 cut site. HDR at the mutation locus could not be determined in 
the remaining 75% clones while indels were identified at the Cas9 cut site (Fig. 4-10).  
Table 4-2 Mutational Profile of CRISPR-Cas9 Prkdc Fibroblast Clones 
Genotype at the mutation site and Cas9 cut site were assessed using Sanger sequencing. At the 
mutation site, the genotype is reported as SCID for presence of SCID nucleotide, corrected for 
wild-type nucleotide, or heterozygous (ht) for presence of both SCID and wild-type nucleotides. 
At Cas9 cut site, ht indicates presence of insertions or deletions while wt represents unaffected 
sequence. y: yes, n: no, ht: heterozygous, wt: wild-type, nd: not determined. 
Clonal line # 
HDR at mutation site Genotype at Cas9 cut 
site Yes/No Genotype 
Prkdc-gRNA1 
    c-2 y ht ht 
c-7 n SCID wt  
c-9 n SCID  ht – deletion  
c-10 y ht  ht 
c-14 y ht ht 
c-18 y ht ht 
c-19 y corrected ht – 3 bp GCA deletion 
c-23 y corrected ht 
c-24 n SCID ht – deletion 
c-25 n SCID ht – deletion 
Prkdc-gRNA2 
    c-2 y ht ht 
c-8 n nd ht 
c-9 n nd ht 
c-10 y corrected ht 
c-15 n nd ht 
c-25 n nd ht 
c-29 n nd  ht 
c-30 n nd  ht 
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Figure 4-10 Genome Modification in CRISPR-Cas9 Prkdc Clones 
(Left) Schematic depicting possible outcomes of homologous recombination between Prkdc targeted with Cas9 and Prkdc gRNAs and a donor template. Event 
1+3 would lead to correction of SCID mutation and incorporate the selection cassette (NeoR) giving rise to G418-resistant population. Event 2+3 would also 
create a G418-R population but without the repair of mutated nucleotide. Recombination 1+2 would also repair the mutation however these cells would be 
sensitive to G418 (G418-S). (Right) Gene editing in Prkdc gRNA 1 or 2 targeted clones (n = 10 or 8, respectively) was by Sanger sequencing. Approximately 
60% and 25% (green) clones from gRNA-1 and 2 showed mono-allelic correction by HDR of Prkdc mutation indicated by the presence of a heterozygous 
sequence at the SCID site. However, this was followed by the presence of indels at the Cas9 cleavage site. These clones were generated because of 
recombination event 1+3. Only one gRNA-1 clone, depicted in yellow, showed mono-allelic correction of the SCID mutation followed by wild-type sequence at 
Cas9 cut site. No such clone was obtained for gRNA-2. Approximately 20% (purple) clones obtained from RGEN-1 showed no correction of SCID site while 
Cas9 site contained indels (recombination event 2+3). For RGEN-2, majority of clones showed this profile.  
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4.2.5 Gene targeting of Prkdc intron 85 
Previous gene targeting experiments employed nucleases with target sites close to the 
SCID mutation, lying within Prkdc exon 85. Downstream analysis showed that while 
effective at repair of SCID mutation, targeting exonic regions introduced indels in SCID 
fibroblasts. To overcome this problem, a third gRNA (gRNA-3) was designed that while 
being near (117 base pairs downstream) to the SCID mutation targeted the downstream 
intron. gRNA-3 was used, along with the Prkdc-neo repair template, to target the SCID 
mutation using the previously described gene targeting approach (Fig. 4-2).  
Genome editing reagents were transfected into SCID fibroblasts using calcium 
phosphate coprecipitation (Fig. 4-11). The gene targeted Gene targeted cells were 
selected with G418 and analysed for gene targeting using the inside-out PCR approach. 
Cells transfected with Cas9 in presence of gRNA-3 and donor template showed gene 
targeting (despite a low transfection efficiency) and led to the generation of G418-
resistant cells. No gene targeting was evident in cells transfected with donor template 
and Cas9 in absence of the gRNA (Fig. 4-12). 
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Figure 4-11 Transfection of Prkdc gRNA-3 Cas9 Plasmid  
Microscopy images showing expression of Prkdc gRNA-3 Cas9-GFP plasmid 48-hours post-
transfection. Bright field and fluorescence images were captured in the same field of cells.  
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Figure 4-12 Demonstration of Gene Targeting Using Prkdc gRNA-3 
Gel image showing diagnostic gene targeting band in polyclonal cells targeted with Prkdc gRNA-
3 and Prkdc-neo donor template. No band was seen in cells targeted with donor in absence of 
CRISPR-Cas9 reagents. gRNA-1 cell population was used as a positive control. M, Hyperladder 
1 Kb, G1: gRNA-1, G3: gRNA-3 
 
4.2.6 Modification of donor DNA template 
The initial gene editing experiments targeted Prkdc exon 85 with the HR donor template 
carrying intact PAM sequences for both guides tested. Genotyping of clonal populations 
showed that while HR led to mono- or even bi-allelic correction of the mutation, the HR 
template was modified at PAM sites and incorporated in the Prkdc locus with variable 
indels, thereby modifying the coding sequence of Prkdc. This would be unfavourable for 
gene expression or on the activity of the protein produced. To avoid re-cutting of the 
donor template, PAM regions for gRNA-1 and gRNA-3 were altered by creating single 
nucleotide substitutions. The mutations were designed using the web-tool Benchling. 
Since the PAM for gRNA-1 was present in the coding region of Prkdc (exon 85), a silent 
mutation was designed. The PAM for gRNA-3, which was in intron 85, was designed to 
be converted into a stop codon. PAM regions in the existing HR template Prkdc-neo were 
modified using site-directed mutagenesis. Site-directed mutagenesis is an in vitro 
procedure that uses custom designed oligonucleotide primers to confer a desired 
mutation in a double-stranded plasmid. The primer design results in a product that will 
re-circularize to form a doubly-nicked plasmid, which can then be transformed into E.coli. 
For site-directed mutagenesis of Prkdc-neo, it was amplified using primers containing 
the intended mutation. The modified plasmid was then verified by sequencing the 
plasmid DNA (Fig. 4-13). 
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Figure 4-13 Site-Directed Mutagenesis of Prkdc-Neo Donor Template 
Left panels show designs of Prkdc gRNA 1 and 3 PAM modification. gRNA-1 PAM GGG was modified to GTG (silent glycine mutation). gRNA-3 PAM TGG was 
modified to TGA (stop codon). Right panels show chromatographs obtained from Sanger sequencing of the mutated plasmid. Modified codons are highlighted 
in pale orange. 
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4.2.7 Gene targeting using modified donor DNA 
The modified donor DNA templates with PAM regions mutated for gRNA-1 and 3 were 
used in conjunction with Prkdc guides gRNA-1 or gRNA-3 respectively for HDR of SCID 
point mutation. The gene targeting approach used was the same as described 
previously. Analysis of polyclonal G418 selected population showed successful targeting 
in SCID fibroblasts in both cases (Fig. 4-14). 
 
Figure 4-14 Gene Targeting Using Modified Prkdc-neo Donor 
Gel image showing diagnostic gene targeting band (amplifying 3’ donor-genome junction) in 
polyclonal SCID fibroblasts obtained after gene editing using Prkdc gRNA 1 or 3 along with normal 
or modified donor DNA.  M, hyperladder 1 Kb; G1, gRNA-1; G3, gRNA-3 
 
4.2.8 Generation of CRISPR lentiviral vectors 
For the generation of lentiviral vectors, the designed gRNAs 1 was obtained as single-
stranded oligos and cloned into lentiCRISPRv2 plasmid backbone. The LentiCRISPRv2 
plasmid contains two expression cassettes, hSpCas9 and the chimeric guide RNA. 
Prkdc-SCID gRNA-1 was cloned into the chimeric gRNA scaffold with appropriate 
overhangs using a single-step restriction digestion-ligation method. This involved 
digestion of the vector with the BsmBI restriction enzyme and ligation with the annealed 
oligo-duplex simultaneously. Correct cloning of gRNA nucleotides was verified by 
sequencing the recombinant plasmid with a primer binding within the human U6 promoter 
region. The cloning strategy and resulting sequence of gRNA cloned in the 
lentiCRISPRv2 plasmid backbone is illustrated in (Fig.15). 
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Figure 4-15 Cloning of Prkdc gRNA-1 on LentiCRISPR Backbone 
Prkdc-SCID gRNA-1 targeting exon 85 was cloned in lentiCRISPRv2, a dual-expression lentiviral transfer plasmid encoding human spCas9, gRNA scaffold and 
lentiviral vector components. Left panel shows the cloning strategy. Single-stranded gRNA oligos with overhangs were annealed to form a duplex and 
subsequently ligated in the LentiCRISPRv2 plasmid backbone digested with BsmBI restriction enzyme. Right panel shows chromatograph from Sanger 
sequencing of the recombinant plasmid showing correct insertion of the gRNA. cPPT, central poly purine tract; WPRE, woodchuck hepatitis post-transcriptional 
regulatory element; RRE, Rev-responsive element; Puro, puromycin gene; psi, packaging signal. 
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Third-generation integration-proficient lentiCRISPR viral vector encoding Prkdc -SCID 
gRNA-1 and gRNA-2 was generated in HEK293T cells. Viral particle titrations were 
carried out in HeLa cells and quantified as transducing units per ml (TU/ml) using real-
time PCR. Day 1 and day 2 titres of generated lentiCRISPR viral vector are shown in 
Table 4-4.  
Table 4-3 LentiCRISPR Viral Vector Titres 
Lentiviral Vector 
Transfer 
Plasmid 
Viral Titre (TU/ml) 
Day 1 Day 2 
lentiCRISPRv2-Prkdc-gRNA-1 pRY562 3.4E+07 1.5E+07 
lentiCRISPRv2-Prkdc-gRNA-2 pRY563 3.4E+07 7.1E+06 
 
4.2.9 Comparison of gene editing in wild-type and SCID fibroblasts  
The alternative-NHEJ (Alt-NHEJ) DNA damage repair pathway is suggested to take 
place in absence of NHEJ (Betermier, Bertrand et al. 2014). To test this, DNA damage 
response was tested in SCID and wild-type fibroblasts using Cas9 nuclease targeting 
Prkdc gene. An integrating lentiCRISPR viral vector encoding Cas9 and Prkdc gRNA-1 
was transduced into wild-type and SCID fibroblasts. To compare the effect of gene 
editing, the region around the Cas9 cleavage site was amplified and subjected to 
sequencing. (Fig. 4-16a) shows cutting by Cas9 in wild-type fibroblasts led to fewer 
indels with low editing efficiency (3.8%), while a wide spectrum of indels were noted in 
SCID fibroblasts (editing efficiency 30.8%) suggesting the inability of SCID cells to carry 
out DNA repair using NHEJ.  
To quantitate the efficiency of guides in both cell types and identify the resulting indels, 
sequences from PCR products were analysed using TIDE software. Gene editing in 
SCID cells led to creation of a wide spectrum of indels with editing in 30% of cells. In 
comparison, only a very small proportion of wild-type cells were edited thus generating 
fewer indels (Fig. 4-16b). This suggests that after cutting, the DNA was repaired in wild-
type cells, while the same repair mechanism is absent in SCID cells. However, it has to 
be noted that gRNA-1 target site in wild type cells differed by 1-bp at the 5’ terminal.  
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Figure 4-16 Comparison of Gene Editing in Wild-Type and Prkdc Fibroblasts 
Prkdc-SCID guide RNA (gRNA 1) and Cas9 encoding lentiviral vectors (MOI 40) were transduced in wild-type (wt) and SCID mouse fibroblasts. (a) On the left 
is shown a gel image indicating band obtained from amplifying region around Cas9 cleavage site in wt and SCID fibroblasts. Chromatographs on the right were 
obtained from sequencing the PCR band and show the location of SCID mutation (T>A), sequence of Prkdc gRNA-1 followed by NGG PAM, and location of 
Cas9 cut site. (b) Chart showing spectrum of indels generated upon gene editing by Prkdc gRNA-1 in wt and SCID fibroblasts. Spectrum is shown as % of 
modified sequences around Cas9 cut site (represented by 0). M, Hyperladder 50 bp; Gel, 1.5% agarose, 1x TAE buffer. 
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4.3 Discussion  
This chapter described targeting of the Prkdc gene and repair of the SCID point mutation 
using CRISPR-Cas9 technology. Gene targeting was carried out in murine immortalised 
fibroblasts. Three independent guides targeting the SCID mutation on the Prkdc gene 
were designed and validated. Two guides were identified within exon 85 near to the SCID 
mutation site. gRNA-1 indeed overlapped with the previously described ZFN target site. 
A third guide was identified in the downstream intron. All three guides were obtained as 
DNA oligonucleotides and their efficiency to edit Prkdc locus was tested in SCID 
fibroblasts. Unfortunately, mouse fibroblasts were found to be very difficult to transfect 
using lipid-based transfection reagents. A standard method to detect indels, formed by 
repair following editing, is to use enzyme-mismatch assays, namely, T7E1 or Surveyor 
assay (Ran, Hsu et al. 2013). The sensitivity of these assays however is around 5% 
(Abdul-Razak 2013, Ran, Hsu et al. 2013) and did not yield conclusive results in 
preliminary experiments (data not shown). This was not surprising given the poor 
efficiency of transfection of gene editing reagents in murine SCID fibroblasts. Thus, a 
different technique, TIDE, was used to assess gene editing. TIDE is a bioinformatic tool 
that aligns genomic sequences from edited and unedited cells along with a gRNA 
sequence to identify indels. TIDE analysis led to robust and rapid detection of cutting. 
Moreover, it also provided information about the cut site, giving a spectrum of indels 
generated. Use of TIDE analysis showed editing in SCID fibroblasts using all three 
gRNAs albeit with low efficiencies. This could largely be due to the poor transfection to 
begin with. Only three guides were tested in this section, however, usually several 
different gRNAs must be screened to identify the best candidate. In such scenarios, 
gRNA screening can be done using in vitro cell reporter assays, where the target region 
is synthetically introduced in an easy to transfect cell line (Kim, Koo et al. 2017). 
Moreover, such kits also overcome the limitation of poor transfection in primary cells as 
seen in this case. Alternatively, the genome editing reagents could be delivered into cells 
as mRNA or protein. Delivery of gRNA as purified RNA complexed with Cas9 protein is 
being increasingly used with high efficiencies for manipulation in mammalian cells (Kim, 
Kim et al. 2014). Having established gene editing at Prkdc with an all-plasmid system, 
future work related should employ the use of mRNA/protein delivery systems.  
Despite the low editing efficiency, the guides were separately used for homology-
mediated repair of SCID mutation. Gene targeting was carried out using an all-plasmid 
approach, where gRNA and Cas9 and the repair template were expressed on plasmid 
constructs. Calcium phosphate co-precipitation was used to transiently introduce the 
gene editing reagents in to the cells. This method was used as it showed comparable 
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efficiency of transfection in SCID fibroblasts as obtained using lipid-based reagents in 
preliminary experiments. It also has the added advantage of low costs, with reagents 
produced in-house, and can be easily up-scaled for larger number of cells.  Both gene 
targeting experiments - targeting exon 85 using gRNA 1 and 2 or targeting intron 85 
using gRNA 3 - led to generation of G418-resistant cell populations. These cell 
populations can also be generated due to random integration of the donor template 
conferring drug resistance. A method of validating gene editing is to obtain and screen 
several clones from the primary transformed pool of cells. This necessitates two rounds 
of screening. First, a primary screen to determine the relative fraction of cells containing 
the edit. This is important because the nuclease cleavage and repair process is not 
completely efficient or accurate (Ran, Hsu et al. 2013, Hollywood, Lee et al. 2016). 
Hence, resistant populations were genotyped for targeted integration using a PCR that 
amplified the donor-genome junction. Successful gene targeting was obtained in all three 
cases only when gRNA, Cas9 and donor template were present in combination. Knowing 
the efficiency of the edit determined the number of single-cell clones that were isolated 
for expansion. The secondary screen was performed on the 30 single-cell derived 
monoclonal populations from gRNA 1 and 2 targeted cell pools. Around 30% of clones 
from both cell pools showed gene targeting, comparable to gene targeting with ZFNs. 
Furthermore, mutational analysis of the clones showed a similar profile as observed in 
ZFN-targeted clones – repair at mutation site followed by heterogenous indels at the 
nuclease target site. Three different genotype profiles were observed in gene targeted 
clones. These were identified to be because of HR between the Prkdc allele and Prkdc-
neo donor DNA. Possible outcomes of recombination along with a comparison of 
genotypes in ZFN and CRISPR-Cas9 clones is shown in (Fig. 4-17).  
A major difference between the ZFN and CRISPR-Cas9 targeted cells were that while 
all clones from ZFN population only showed mono-allelic correction, cells targeted with 
Cas9 displayed both mono- and bi-allelic correction of the mutated nucleotide. The 
presence of indels at the nuclease cut site was consistent in both ZFN and Cas9 
experiments. Only one clone (Cas9-gRNA-1 targeted clone #7) showed targeting of 
Prkdc followed by an intact nuclease site. This suggests an intrinsic defect in DNA repair 
in DNA-PK deficient SCID fibroblasts and that a wider screen with greater number of 
clones would be required to identify cells with the desired edit – that is corrected SCID 
nucleotide followed by an intact nuclease target site. Nevertheless, these experiments 
demonstrate that CRISPR-Cas9 system can be used to carry out genome editing and 
HDR in cell models that show defects in DNA repair processes.  
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Figure 4-17 Comparison of Genome Editing in Prkdc ZFN And Cas9 Clones 
(Left) Schematic representation of possible recombination outcomes between Prkdc allele and Prkdc-neo donor template. Event 1+3 would lead to correction 
of SCID mutation and incorporate the selection cassette (NeoR) giving rise to G418-resistant population. Event 2+3 would also create a G418-R population 
albeit repair of mutated nucleotide. Recombination 1+2 would also repair the mutation however these cells would be sensitive to G418 (G418-S). (Right) 
Comparison of gene editing in ZFN (n=14) and CRISPR-Cas9 (gRNA 1, n=10; gRNA 2, n=8) gene edited clones determined by Sanger sequencing. 
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Furthermore, these experiments highlighted two major limitations of the gene 
targeting approach used. Firstly, the location of Cas9 nuclease target site. 
Cutting in the coding region can introduce unwanted mutations. In case of 
the Prkdc-SCID fibroblasts, where the NHEJ pathway is defective, the 
inaccurate alt-NHEJ prominently takes place for DNA damage repair 
(Betermier, Bertrand et al. 2014). Because of this, mutations were detected 
in the coding region of Prkdc at the Cas9 cut site in all cells analysed. This 
can have a detrimental effect on gene expression and protein activity even 
though the original mutation was repaired. To overcome this limitation, the 
gene targeting approach was modified by using a gRNA that targeted the 
SCID mutation by introducing the DSB in the downstream intron. For 
effective HDR to occur, the DSB should lie within 100-150 bp of the mutation 
site (Ran, Hsu et al. 2013). gRNA-3 was identified within this range and 
shown to mediate genome editing in SCID fibroblasts. When used in 
conjunction with the existing donor DNA template, it showed gene targeting 
in polyclonal cells. However, further validation of gene editing using this 
guide RNA is required by demonstrating gene editing events in monoclonal 
populations.  
The second limitation of the gene targeting approach was the presence of 
nuclease target sites in the donor DNA. Presence of intact target sites in the 
donor DNA can cause it to be degraded by the target-specific nuclease 
present in the cells, in this case Cas9; thus, modifying the donor DNA as well 
as the genomic locus upon recombination. The initial gene editing 
experiment targeted Prkdc exon 85 with a HR template carrying intact PAM 
sequences for both guides. Genotyping of clonal populations showed that 
while HR led to correction of the mutation, the Cas9 site included 
modifications. One method to overcome this limitation is to modify PAM 
regions in the donor DNA by creating silent mutations (Hollywood, Lee et al. 
2016). Since, guides 1 and 3 showed higher editing efficiencies, PAM regions 
for these were modified in the donor DNA using site-directed mutagenesis, 
and the modified donor DNA plasmids were used for a repeated gene 
targeting experiment. Introduction of these modified donor DNA plasmids in 
SCID fibroblasts led to significant cell death. However, the cells were 
recovered with continued culture and showed successful gene targeting by 
PCR. This however requires further validation by genotyping of monoclonal 
populations followed by next-generation sequencing. 
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Nuclease specific gene editing in SCID fibroblasts continually showed 
inaccurate repair of DNA. Since SCID cells carry a defect in NHEJ, it was 
hypothesised that in the absence of NHEJ, alt-NHEJ was the dominant DNA 
damage repair process (Betermier, Bertrand et al. 2014, Shibata and Jeggo 
2014). To test this, CRISPR-Cas9 system was used to introduce DSBs, a 
form of DNA damage, in SCID and wild-type Balb/c fibroblasts. Prkdc gRNA-
1 sequence lies in both wild-type and SCID cells, with 1-bp difference at the 
5’ end, and it has been shown to mediate cutting in SCID cells. Hence this 
guide was chosen to introduce DSBs. Since these cells were found to be 
difficult to transfect, gRNA-1 was developed into a third-generation 
lentiCRISR viral vector. It is noteworthy to mention that the CRISPR-Cas9 
reagents were developed in both integrating and non-integrating lentiviral 
vectors. In fact, the non-integrating lentiviral vector was better suited to allow 
for transient expression of Cas9 nuclease, long-term expression of which 
could be disadvantageous in cultured systems. However, the viral vector 
titres obtained for the non-integrating lentiCRISPR vectors were very low for 
experimental use (data not shown). I therefore performed the preliminary 
experiments with the integrating lentiviral vector.  
Transduction of a lentiCRISPR vector, encoding Cas9 and gRNA-1, led to 
cutting at the SCID locus in both wild-type and SCID cells, albeit at a very 
low frequency in the wild-type cells. This could mean that in wild-type cells 
the locus was cut but efficiently repaired or that there was no editing to begin 
with. In SCID cells, cutting by Cas9 however led to a spectrum of indels. We 
hypothesise that this could be due to the presence of an inefficient DNA 
repair mechanism, alternative NHEJ (alt-NHEJ), that takes place in the 
absence of NHEJ. Unlike it’s classical counterpart, the alt-NHEJ is more 
prone to causing mutations at the DSB site. Although this experiment gave 
an insight in DNA damage repair in both cell types, further work investigating 
and assessing DNA repair damage pathways is required.   
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5 CRISPR-Cas9 Gene Editing as 
a Therapeutic Approach for 
Ataxia Telangiectasia 
 
 
5.1 Introduction  
Previous chapters described genome editing in Prkdc SCID, a DNA repair 
disorder characterised by severe defects of the immune system and radio-
sensitivity. Although the SCID mouse is an archetype for proof-of-principle 
gene repair, clinical translation of genome editing as a therapy for DNA-PK 
radiosensitive SCID is limited. This is primarily because of the rarity of the 
condition in humans. PRKDC-SCID is an ultra-rare disease, with only two 
patients identified so far. Ataxia telangiectasia (shortened as A-T) is a 
related, rare, genetic DNA repair disorder. Inherited as an autosomal 
recessive trait, A-T has an estimated prevalence of 1 in 40,000-400,000 
people (Lavin 2008). People affected with A-T carry mutations on the gene 
known as ataxia telangiectasia mutated (ATM; OMIM 607585), which 
encodes the ATM protein, an apical kinase with critical roles in cellular 
response to DNA damage, apoptosis and cell cycle checkpoint control. 
Characterised largely as a neurological disorder, A-T is a complex condition 
that affects multiple systems within the body, including nervous, immune and 
respiratory systems. The hallmark feature of A-T is progressive 
neurodegeneration in cerebellum accompanied with immunodeficiency and 
predisposition to cancers. People with A-T are also hypersensitive to the 
effects of radiation and incur chromosomal instabilities (Lavin 2008). 
Currently, the disease has no cure. Gene and cell therapies however hold 
promise for treating aspects of the disease. This chapter describes the work 
undertaken to utilise the CRISPR-Cas9 system to target human ATM locus 
with the fundamental aim to identify and develop gene editing approaches 
that could potentially be therapeutic for A-T models. Firstly, bioinformatics 
tools were used to investigate human and mouse ATM gene structures and 
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all A-T causing mutations known-to-date were systematically catalogued. 
Based on this analysis, various genome editing strategies were designed. 
These included NHEJ- and HR-mediated gene repair strategies applicable 
to select few ATM mutations with either a higher incidence rate in A-T 
patients or for which primary cell models already exists; and, universal 
approaches that could theoretically be applicable to A-T models irrespective 
of underlying ATM mutations. Furthermore, a strategy to generate a 
humanised A-T mouse model was examined in silico. Lastly, to establish 
proof-of-principle, CRISPR-Cas9 gRNAs targeting various regions across 
ATM were designed and genome editing was validated in human cells.  
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5.2 Results  
5.2.1 Analyses of human and mouse ATM genes 
Human and mouse ATM genes were analysed using Ensembl genome 
browser to construct gene maps indicating intron-exon boundaries and 
protein domains. Fig. 5-1 and 5-2 illustrate human ATM and mouse Atm 
maps, respectively.  
Similarity between human and mouse ATM cDNA was analysed using local 
alignment tool EMBOSS Matcher. The alignment revealed 72.2% sequence 
similarity between the two loci. Furthermore, the exon-intron structures were 
also highly conserved. An exception was the in-frame deletion of a very short 
exon (exon 45) in mouse Atm. Exons before and after exon number 45 
however were alike to the human ATM counterparts. Major differences were 
noted in untranslated regions of both genes. The 5’UTR of human ATM is 
very complicated with two leading exons, the same is not true for mouse Atm. 
Mouse Atm further had a shorter 3’UTR as opposed to the human 
counterpart. Details of human and mouse ATM genomic loci are summarised 
in Table 5-1.  
Table 5-1 Description of Human and Mouse Atm Locus 
Features ATM Atm 
Genomic Location 
(GRCh38) 
Chromosome 11: 
108,222,484-108,369,102 
Forward strand 
Chromosome 9: 
53,439,149-53,536,70 
Reverse strand 
Exons 63 exons (62 coding) 64 exons (63 coding) 
ORF 9,171 bp 9, 201 bp 
Transcripts 25 5 
Primary Transcript 
ATM-201 (13,147 bp) 
NM_000051 
Atm-001 (10,006 bp) 
NM_007499 
Protein 3,056 aa 3,066 aa 
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Figure 5-1 
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Figure 5-1 Schematic of Human ATM Exonic Structure and ATM Protein Domains 
ATM consists of 66 exons (exon 1 is an alternative exon 1a or 1b), spanning an open reading frame of 9,171 bp, with the translation initiation codon (ATG) lying 
in exon 4. Indicated for each exon are number and length in base pairs. Also shown are the sequences of codons adjacent to or overlapping exon boundaries, 
with graphical depiction of the codon location: vertical lines between exons indicate that the codons are fully contained within the adjacent exons, while left or 
right pointing exon boundaries reflect the split of the codon at the junction (right: one nucleotide at the 5’ exon; left, two nucleotides at the 5’ exon). ATM protein 
domains include the N-terminal substrate binding domain (encoded within exon 6), leucine zipper (exons 27-28), a proline rich region (exon 30), FAT domain 
(exons 41-54), PI3-K domain (exons 57-64), C-terminal substrate binding domain (exons 60-61), and FATC domain (exon 65). 
Source: Ensembl http://www.ensembl.org  
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Figure 5-2 
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Figure 5-2 Schematic of Atm (Mouse) Exonic Structure  
Atm gene consists of 64 exons (exon 1 comprised of the 5’UTR) with the transcription initiation codon (ATG) lying in exon 2. Atm cDNA depicted here contains 
62 coding exons spanning an open reading frame of 9, 201 bp. Indicated for each exon are number and length in base pars. Also shown are the sequences of 
codons adjacent to or overlapping exon boundaries, with graphical depiction of the codon location: vertical lines between exons indicate that the codons are 
fully contained within the adjacent exons, while left or right pointing exons boundaries reflect the split of the codon at the junction (right: one nucleotide at the 
5; exon; left, two nucleotides at the 5; exon). 
Source: Ensembl http://www.ensembl.org  
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5.2.2 Characterisation of A-T causing mutations  
Mutations known to cause Ataxia Telangiectasia were obtained from the 
Human Gene Mutation Database (HGMD®) to construct a mutation map (Fig. 
5-3). As of March 2016, over 600 different A-T causing mutations had been 
identified and published. As indicated in the map, these mutations span 
across entire genomic region of ATM without specific mutational ‘hotspots’. 
Details of mutations depicted on the map including their type and location on 
the ATM are listed in Appendix I. 
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Figure 5-3 
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Figure 5-3 ATM Mutation Map 
Over 600 mutations across the ATM gene locus have been identified as disease-causing leading to ataxia telangiectasia (A-T) or A-T variant phenotype, which 
is clinically milder. Depicted is the ATM locus indicating the exonic structure. Different A-T mutation types are colour coded, including nonsense/missense and 
splicing mutations, small deletions, small insertions, and insertions/deletions. Regulatory mutations, gross insertions or deletions and complex rearrangements 
have not been included. Disease-causing mutations are spread across ATM with no evident hot-spots. The majority are missense/nonsense mutations that 
either lead to truncation of ATM protein, or production of an unstable protein that is rapidly degraded or a mutant protein with abolished or residual protein 
kinase activity. Splicing mutations lead to loss of exons or intron retention. Mutations described in chapter to be targeted using CRISPR/Cas have been 
highlighted bold and italic, and include: (i) missense ATM2T>C located in exon 4, (ii) missense ATM103C>T located in exon 5, (iii) splicing ATM5762ins137 
c.5763-1050A>G located in intron 40, and (iv) small deletion ATM7638del9 c.7638_7646del located in exon 54.  
Source: The Human Gene Mutation Database (HGMD) http://www.hgmd.cf.ac.uk/ac/index.php (updated 26 March 2016) 
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5.2.3 In silico design of genome editing strategies  
5.2.3.1 A NHEJ-mediated strategy to target the ATM 5762ins137 
mutation 
ATM 5762ins137 is a disease-causing mutation that lies in the intron 40 of 
ATM. The A to G substitution mutation at the intronic position -1050 activates 
an intronic cryptic splice donor site resulting in aberrant splicing of a 137-bp 
intronic sequence into the mature ATM transcript. The aberrant transcript is 
thought to produce an unstable protein, which then rapidly gets degraded. 
The 5762ins137 mutation however is “leaky”, which causes low level 
production of the correct transcript. This causes residual kinase activity in 
patients with this mutation. 5762ins137 mutation thus confers the variant A-
T phenotype and is prevalent in 10-15% of all UK patients (Stankovic, Kidd 
et al. 1998). To target the ATM 5762ins137 A>G point mutation, CRISPR-
Cas technology can be used to induce NHEJ indels at or near the ectopic 
intronic splice site. Presence of NHEJ-mediated indels would disrupt the 
cryptic splice site allowing for the formation of normal transcript without 
intervening sequence (Fig. 5-4).  
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 Figure 5-4 NHEJ-Based Disruption of ATM5762ins137A>G Mutation 
(Left) ATM5762ins137A>G is a commonly occurring mutation that affects 10-15% of all A-T patients in the UK. Located in intron 40 of ATM, A>G transversion 
at c.5763-1050 point mutation leads to the activation of a cryptic splice site, which causes aberrant splicing and insertion of a 137-bp intronic sequence in the 
transcript. This transcript produces an unstable ATM protein which is rapidly degraded.  
(Right) Genome editing can be used to disrupt this mutation and restore wild-type protein production. gRNAs designed in close proximity to this mutation are 
denoted by the protospacer adjacent motif (PAM), which is where CRISPR/Cas nuclease is directed to cleave the DNA and create a double-stranded break 
(DSB). Creation of a DSB activates the error-prone NHEJ DNA repair pathway which re-joins the DNA ends by creating small insertions/deletions (indels) at 
the break site. Presence of indels causes frameshift mutation which can lead to disruption of the cryptic site allowing restoration of normal splicing between 
exons 40 and 41, and production of normal ATM transcript and protein. 
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5.2.3.2 HDR strategies for repair small ATM mutations: applicable to 
2T>C, 103C>T and 7638del9 
Small mutations can be corrected using homology-directed repair with 
single-stranded oligonucleotide donor DNA templates. Such a strategy could 
therefore be applicable to correction of a variety of nonsense, missense, and 
small insertions as well as deletions. Commonly reported nonsense 
mutations ATM 2T>C, 103C>T and the deletion mutation 7638del9 were 
identified for HDR. ATM 2T>C mutation, which lies on exon 4, is observed 
several times in the UK population. The ATM 103C>T mutation in exon 5 is 
a founder mutation commonly reported in Jewish families. Both mutations 
lead to absence of protein (Gilad, Bar-Shira et al. 1996). The ATM 7638del9 
mutation, is an in-frame deletion of 9 nucleotides in exon 54 (codons 2546-
2548), which is known to destabilize the protein and abolish its kinase activity 
(Laake, Telatar et al. 1998). HDR of these mutations would require induction 
of a double-stranded break near the mutation site and the correct or deleted 
sequence to be supplied on a short single-stranded DNA template. (Fig. 5-
5) illustrates HDR approaches for all three mutations.  
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Figure 5-5 HDR Mediated Correction of Small ATM Mutations 
ATM7368del9 and ATM2T>C are two commonly reported A-T causing mutations. ATM7368del9 is a 9-bp (TAG AAT TTC) deletion in exon 54 which leads to 
the formation of a non-functional ATM protein. ATM2T>C is a missense mutation that disrupts the translation initiation codon (ATG-to-ACG) in exon 4, as a 
result of which no ATM protein is produced. Homology-dependent genome editing can be used to permanently correct these mutations. In order to do so, 
gRNAs are designed in close proximity to each mutation (denoted by PAM), which direct CRISPR/Cas nuclease to introduce a DSB. The correct endogenous 
sequence can be supplied on a synthetic single-stranded oligonucleotide (ssODN) repair template. Creation of a DSB and presence of the repair template 
would allow homologous recombination to take place, thus correcting the mutation leading to normal protein production. Such a strategy could also be applied 
across a variety of similar patient-specific mutations like ATM103T>C. 
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5.2.3.3 Universal ATM genome editing strategies  
Two different knock-in approaches were designed for universal gene editing 
of ATM. (1) knock-in of 5’ or 3’ halves of an ATM cDNA into the endogenous 
ATM locus, and (2) knock-in of a full-length ATM expression cassette into the 
AAVS1 safe harbour locus. Both strategies would require the use of large 
ATM cDNA fragments, providing either half or the whole ATM open reading 
frame.  
The 5’ knock-in would be applicable to repair mutations in the 5’ end of the 
endogenous ATM locus. This can be achieved by inducing a double cut at 
introns 3 (i.e. just before the start codon) and 32, which lies mid-way of the 
gene, using two separate gRNAs and Cas9 nuclease. Use of dual gRNAs 
would enable the excision of the 5’ end of the gene. A repair cassette 
including arms of homology, ATM exons 4-32, a synthetic splice donor, and 
a downstream intronic splicing enhancer could then be used to knock-in the 
5’ cDNA block (Fig. 5-6). Likewise, mutations in the 3’ half of the endogenous 
ATM locus could be repaired by 3’ knock-in. This can be achieved by 
inducing a single cut in intron 32 using single gRNA. The synthetic repair 
template would include arms of homology, a synthetic splice acceptor, ATM 
exons 33-65, and a transcription terminator (a standard sequence 
incorporating three stop codons and the bovine growth hormone polyA 
element) (Fig. 5-6). With either approach, the repaired ATM locus will include 
a superexon providing the 5’ or 3’ half of the synthetic cDNA generating a 
chimeric transcript.  
Another universal approach would be utilising the targeting of human AAVS1 
(or adeno-associated virus integration site 1) “safe harbour” locus for the 
knock-in of full synthetic ATM cDNA cassette by HDR. AAVS1 is a human 
locus which encodes the constitutively expressed PPP1R12C gene, in which 
transgenes can be knocked-in resulting in stable transgenic expression and 
no obvious detrimental effect. This can be achieved by inducing a CRISPR-
Cas cut in AAVS1 in addition to introduction of a synthetic template including 
arms of homology, a promoter, ATM exons 4-65, a mutated WPRE and a 
transcription terminator. HDR with the synthetic donor would result in 
transgenic expression of a full-length ATM from the AAVS1 locus (Fig. 5-7). 
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Figure 5-6 Partial Knock-In of ATM cDNA Cassettes  
ATM cDNA will be divided into two blocks – exons 4 to 32 and exons 33-65 - containing sequences encoding for the N- and C- terminal domains of ATM protein, 
respectively. Targeted insertion of these cDNA cassettes would allow for correction of any A-T causing mutation lying within these regions; a strategy that could 
be applied across multitude of patients harbouring different A-T mutations. Exogenous N- or C-terminal terminal synthetic cDNA cassettes supplied on an 
integration-deficient lentiviral vector (IDLV) will be inserted into the 5’ or 3’ end of the ATM locus by a homology-dependent genome editing strategy. (Left) For 
5’ knock-in to take place, firstly, the intervening genomic sequence between introns 3 and 32 will be excised. This will be done by designing gRNAs in these 
introns (denoted by PAM) which will direct the CRISPR/Cas nuclease to create two DSBs. Simultaneously, an exogenous N-terminal gene editing template 
consisting of cDNA encoding exons 4-32 (~4.6 kb) flanked by homology arms left (HAL) and right (HAR), a splice donor (SD) and DISE element will be supplied. 
This would allow homologous recombination between the genome-editing template and endogenous ATM locus, and targeted insertion of exons 4-32 at the 5’ 
end of the locus. Presence of downstream splicing elements would ensure formation of a functional transcript and normal ATM protein. (Right) For targeted 
insertion of C-terminal cassette, a single DSB will be introduced in intron 32. A C-terminal template consisting of HAL, a splice acceptor (SA), exons 33-65 
cDNA (~4.6 kb), a transcription terminator (TT), and HAR will be supplied exogenously on an IDLV. Successful homologous recombination would lead to 
insertion of this genome-editing template in intron 32. The resulting transcript will encode sequences from the endogenous 5’ end and supplied 3’ cDNA block 
resulting in normal protein production. 
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Figure 5-7 Targeted knock-in of full-length ATM cDNA into the AAVS1 ‘safe harbour’ locus 
AAVS1, located in chromosome 19 in the human genome, encodes for the constitutively expressed PPP1R12C gene. This region is known as a ‘safe harbour’ 
because it is amenable to the integration of a transgene and allows for its stable expression. Targeted integration of a full-length ATM cDNA cassette into the 
AAVS1 can be used as a universal therapeutic strategy of benefit to A-T patients with recessive mutations. HDR-mediated knock-in will be achieved by 
introducing a DSB in the human AAVS1 locus using the CRISPR/Cas system (denoted by PAM) and by simultaneously supplying ATM cDNA and regulatory 
sequences on an exogenous synthetic template. The genome-editing template will include arms of homology corresponding to the AAVS1 locus, a short 
promoter (ATM-specific or hPGK), ATM cDNA encoding exons 4-65 (9.2 kb), Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and a 
transcription terminator (TT). Owing to its large size, the genome-editing template can be supplied on an adenoviral vector. Successful insertion of the template 
into the AAVS1 locus would lead to the generation of a functional ATM transcript restoring ATM protein levels. 
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5.2.4 In silico design of humanised A-T mouse model 
Animal models are essential for the future validation of the genome editing 
strategies described thus far. However, the current A-T animal models are 
not suitable to answer how many cells need to be corrected to achieve 
clinical benefit. There are at least two further problems with the existing A-T 
mouse models: they are not humanised hence they do not carry a relevant 
section of the human gene as the target for therapeutic correction, and their 
phenotype does not adequately reflect the neurodegeneration observed in 
patients. To begin to address these issues, we decided to pursue generation 
of a humanised mouse model of A-T, as a stepping stone towards the future 
generation of a set of humanised A-T models. We have explored in silico the 
creation of such model for the human ATM5762ins137 mutation. This 
mutation has been chosen as it can be corrected both by NHEJ as well as 
HDR. 
A transgenic A-T mouse model can be created by partial knock-in of a portion 
of ATM human sequence into the mouse Atm locus using HR. In order to 
develop a humanised A-T mouse model, the intronic splicing mutation ATM 
5762ins137 A>G was chosen. The mutation lies in intron 40 of human ATM 
gene. Sequence analysis of human and mouse ATM gene sequences 
around the mutation site revealed high levels of similarity in the structure of 
these introns and exons (Table 5-2). Local alignment of ATM exons 40 and 
41 with Atm exons 37 and 38 showed 90.9% and 82.3% sequence similarity, 
respectively (Fig. 5-8). 
161 
 
 
Figure 5-8 Pairwise Sequence Alignment of Human and Mouse ATM Locus 
(a) ATM exon 41 (top) and Atm exon 39 (bottom) showed 82.3% similarity. (b) ATM 
exon 40 (top) and Atm exon 38 (bottom) showed 90.9% similarity. Matches are 
indicated by straight line. Dots denote mismatch between the sequences aligned. 
Source: EMBOSS Matcher 
 
Table 5-2 Comparison of Human and Mouse ATM Around 5762insA>G   
Human ATM Mouse Atm 
Intron 39 3,044 bp Intron 37 5,877 bp 
Exon 40 88 bp Exon 37 88 bp 
Intron 40 2,175 bp Intron 38 2,108 bp 
Exon 41 156 bp Exon 38 156 bp 
Intron 41 2,095 bp Intron 38 3,299 bp 
 
 
In order to carry out HDR, human ATM sequence can be supplied on an 
exogenous template containing a portion of human ATM harbouring the 
5762ins137 point mutation (intron 39 to intron 41), flanked by homologous 
arms derived from Atm. The knock-in strategy including design of the 
exogenous knock-in DNA template is depicted in (Fig. 5-9). 
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Figure 5-9 
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Figure 5-9 Proposed Knock-In Strategy for Humanised A-T Mouse Model 
A humanised A-T mouse model can be created by using homology-directed repair (HDR) strategy to knock-in a portion of human ATM gene into the mouse 
Atm locus. The exogenous ATM donor template would contain a 3 kb human ATM sequence carrying the A-T causing ATM5762ins137 mutation flanked 
between 1 kb homology arms left (HAL) and right (HAR) each derived from mouse Atm locus. The ATM5762ins137 mutation is a commonly occurring mutation 
that affects 10-15% of all A-T patients in the UK. 
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5.2.5 In silico design of gRNAs  
Single spCas9 gRNAS targeting regions across ATM locus were designed 
using web-based bioinformatics tools CHOPCHOP v2, Cas-Designer or 
Benchling. The guides were designed to match a 20-nt target in the input 
DNA sequence from the target genomic region adjacent to the ‘NGG’ PAM 
specific for spCas9 nuclease. All guides were designed with cut sites within 
100 bp of the region to be edited. A single gRNA targeting the human AAVS1 
locus was designed using Benchling.   
Details of ATM and hAAVS1 guides are mentioned in Table 5-3 and Table 
5-4 respectively. 
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Table 5-3 Human ATM CRISPR-Cas gRNAs 
 ATM Target gRNA Name gRNA Sequence (5’ - 3’) PAM (spCas9) Location of Cut Site  Design Tool 
 2T>C (Exon 4) G.2T>C ATGCATATATAGAGAGAAAG AGG (-strand) 66 bp upstream (intron 3)  Cas-Designer 
 103C>T (Exon 5) G.103C>T TACTAATCACACTTATTTCA AGG (-strand) 68 bp upstream (intron 4)  Cas-Designer 
 5762ins137 (Intron 40) G.5762insA>G TGAATGGGATATAGAAAAAC GGG 9 bp upstream (intron 40)  CHOPCHOP v2 
 7368del9 (Exon 53) G.del9 TACTGTCTAGATACTGCAGT GGG (-strand) 
112 upstream bp (intron 
52) 
 Cas-Designer 
 Intron 3 G.int3 GCCTTGCTTGCAGTAGTAGC AGG (-strand) NA  Cas-Designer 
 Intron 32 G.int32 GTAGAGAGGTAGTCAAAACT AGG NA  CHOPCHOP v2 
 
Table 5-4 Human AAVS1 gRNA 
 Target Region gRNA Name gRNA Sequence (5’ - 3’) PAM (spCas9) Location of Cut Site  Design Tool 
 Human AAVS1 G.AAVS1 GTCACCAATCCTGTCCCTAG TGG NA  Benchling 
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5.2.6 ATM gene editing in human cells  
ATM gene editing was carried out in HEK293T cells stably expressing Cas9 
from the AAVS1 locus. gRNAs targeting ATM regions – 2T>C, 103C>T, 
5762ins137, intron 3 and intron 30 - were transfected as synthetic RNA 
molecules and genomic DNA was harvested post-transfection. In order to 
detect indels generated as a result of gene editing, genomic regions 
spanning the Cas9 cut site were amplified and sequenced before and after 
transfection. (Fig. 5-10) shows PCR amplicons from all five ATM target 
regions.  
 
Figure 5-10 Cas9 cleavage site amplifications from ATM mutations 
Genomic regions spanning Cas9 cut sites at different ATM target sites were 
amplified using PCR from HEK293T DNA. Gel image shows the resulting amplicons 
from ATM targets: 2T>C (289 bp), 103C>T (225 bp), intron 32 (223 bp), intron 3 (768 
bp) and 5762ins137 (211 bp). M, Hyperladder 50 bp; Gel, 1% agarose, 1X TAE 
buffer. 
 
Sequence read from control cells showed a clean sequence; except for 
103C>T mutation due to a naturally occurring polymorphism in the cell line 
used, and hence was excluded from the analysis. Gene editing was carried 
out as normal at the other targets. Upon gene editing, the traces consisted 
of a mixture of sequences indicating a heterozygous cell population 
consisting of edited and unedited cells. In case of ATM5762ins mutation 
locus, cutting by Cas9 led to creation of NHEJ-mediated indels disrupting the 
mutation site (Fig. 5-11).  
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Figure 5-11 Gene editing of ATM5762ins137 mutation  
ATM5762ins137 splicing mutation was targeted by introducing a specific gRNA in Cas9 expressing HEK-293T cells. Genomic region around the Cas9 cleavage 
site was amplified from edited and unedited cells and subjected to Sanger sequencing. Sequence obtained from unedited or control cells showed a uniform 
sequence (top left) while sequence obtained from edited cell pool consisted of a mixture of signals (bottom left). Red rectangle reflects the Cas9 target and cut 
sites and location of ATM mutation. Cutting by Cas9 led to introduction of insertions and deletions causing frameshift mutations at the ATM5762ins137 mutation 
locus. 
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In order to quantify the indels generated, sequence traces from edited and 
control samples were analysed using the bioinformatics tool TIDE. Table 5-
5 summarises the overall gene editing frequency of various ATM target 
regions obtained using TIDE. Apart from overall efficiency of a gRNA, TIDE 
further gives a profile of types of indels generated (Fig. 5-12). 
Table 5-5 Editing Efficiency of ATM gRNAs Using TIDE  
ATM Target Indels (%) 
2T>C 79.8 
5762ins137A>G 51.6 
Intron 3 22.9 
Intron 32 21.9 
170 
 
 
Figure 5-12 
171 
 
Figure 5-12 Indel Profiles for ATM Targets Using TIDE  
Various ATM regions (2T>C, 5762ins137A>G; intron 40, intron 3 and intron 32) were targeted using CRISPR-Cas9 in HEK293T-Cas9 cells. Efficiency of gene 
editing was assessed using bioinformatics tool TIDE. Results are obtained as total efficiency of guide RNA, profile of insertions or deletions (indels) generated 
around the cut site (0 represents the Cas9 cleavage site), and probability of nucleotide inserted as +1bp location. 0 represents the Cas9 cleavage site. 
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5.3 Discussion  
This chapter established the foundation for genome editing of the ATM gene for the first 
time. ATM is one of the largest human genes with a plethora of disease-causing 
mutations. Computational analysis of its genomic sequence and mapping of mutations 
showed hundreds of different kinds of mutations spanning the entire genomic structure 
of ATM. No mutation rich areas (hotspots) or commonly occurring large deletions, 
insertions or gene re-arrangements could be identified. While many founder mutations 
within families have been reported (Gilad, Bar-Shira et al. 1996, McConville, Stankovic 
et al. 1996, Laake, Telatar et al. 1998, Stankovic, Kidd et al. 1998, Chun and Gatti 2004, 
Coutinho, Mitui et al. 2004, Fares, Axelord Ran et al. 2004, Stray-Pedersen, Jonsson et 
al. 2004, Birrell, Kneebone et al. 2005, Mitui, Bernatowska et al. 2005, Chessa, Piane et 
al. 2009, Carranza, Vega et al. 2017), there are no frequently occurring mutations that 
affect a large proportion of the population. A bulk of (~50%) of A-T mutations are 
nonsense/missense mutations that lead to production of either an unstable or non-
functional ATM protein. About 30% of mutations are due to splicing defects. Current 
genetic treatments primarily target these two categories of mutations using compounds 
that skip pre-termination codons that occur because of nonsense/missense mutations or 
antisense-oligonucleotides to restore splicing errors. Both forms of treatment show 
promise as therapies but are limited by the need of repeated dosage, and are mutation-
specific (Lavin, Gueven et al. 2007). Targeted genome editing can be used to 
permanently modify the ATM sequence. Given the widespread profile of ATM mutations, 
this section explored a variety of gene editing strategies applicable to different kinds of 
mutations, which could ultimately be further developed as therapies for Ataxia 
Telangiectasia. 
For proof-of-principle, both NHEJ and HDR targeting specific ATM mutations were 
designed. Nonsense mutations – 2T>C and 103C>T – were chosen based on the 
availability of primary cell models from patients. The 9-bp deletion mutation (del7638) is 
a commonly known mutation reported in the UK population. The ATM5762ins137A>G 
splicing defect was identified as one of the major targets, it is a relatively common 
mutation that affects 10-15% of all A-T patients in the UK (Stankovic, Kidd et al. 1998). 
This mutation is known to create a cryptic splice site which then leads to insertion of an 
aberrant intronic splicing in the ATM transcript. However, due to the leaky nature of the 
mutation, cells from patients heterozygous for 5762ins137 mutation are estimated to 
produce 4% of the normal amount of protein. Patients homozygous with this mutation 
have also been described with ~10% ATM kinase activity, which is sufficient to moderate 
the phenotype although not prevent it (Taylor, Lam et al. 2015). Thus, targeted disruption 
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of this splice site using either NHEJ or HDR could be advantageous. A NHEJ-disruption 
strategy would be particularly useful as the process is effective in both dividing and 
quiescent cells. This is particularly critical in the context for A-T as the non-dividing 
Purkinje neurons located in the cerebellum are the primary therapeutic targets (Taylor 
and Byrd 2005). 
Separately two different potentially global strategies were also developed which could 
be used interchangeably to target and correct any ATM mutation. Currently, knock-in of 
the whole ATM gene or its cDNA is a challenging prospect given the large genomic size. 
The open reading frame of ~9.2 kb, exceeds the packaging capacity of many commonly 
used delivery vectors even in the absence of regulatory sequences and homology arms. 
Attempts at production and delivery of shorter gene, known as mini-ATM, are in progress 
however there is no published data available. This chapter explored partial and full ATM 
cDNA knock-ins. Partial knock-in of N- or C-terminal of the gene would require delivery 
of either half of the ATM cDNA as exon blocks or “superexons” at the endogenous ATM 
loci. An N-terminal knock-in would be applicable for any mutation in the first half of the 
gene and vice-versa. The advantages here are a reduced genomic load in delivery 
vectors and that a single approach could be used across different patients without 
designing mutation specific treatments. As for full-length knock-in, the human AAVS1 
locus was investigated. Consistent delivery, robust transgene expression, the AAVS1 
safe harbour site is a preferred target for gene knock-ins. Insertion at this site has been 
shown to be safe with no phenotypic effects reported, and the surrounding DNA appears 
to be kept in an open confirmation, enabling stable expression of a variety of transgenes 
(Sadelain, Papapetrou et al. 2011). Successful targeting of the human AAVS1 locus with 
site-specific nucleases and homologous recombination of donor DNA bearing selection 
markers has been previously demonstrated in cells, including human embryonic stem 
and induced pluripotent stem cells, derived from different disease models (Sadelain, 
Papapetrou et al. 2011). Similar approaches have been previously reported for Fanconi 
anemia (Rio, Banos et al. 2014) and RS-SCID (Rahman, Kuehle et al. 2015), both of 
which are DNA repair disorders showing a developmental block in the generation of 
immune cells.  
Lastly, this chapter explored generation of a humanised mouse model for A-T. Several 
murine models of A-T harbouring mutations on Atm gene have been successfully 
generated showing some of the clinical manifestation of the disease, however they do 
not fully recapitulate the hallmark phenotype of neurodegeneration (Barlow, Hirotsune et 
al. 1996, Lavin 2013). A porcine model of A-T to better phenocopy the disease and bridge 
the gap between human and current animal models has been recently developed 
174 
 
(Beraldi, Chan et al. 2015). Initial characterisation of A-T pigs revealed early cerebellar 
lesions including loss of Purkinje cells suggesting a developmental aetiology for A-T. In 
addition, like patients, A-T these pigs show growth retardation and develop motor skill 
deficiencies, characteristic to A-T (Beraldi, Chan et al. 2015). Humanised mouse models 
are powerful tools for studying and treating a variety of human diseases and can provide 
an alternative to the current models for the study of the mechanism underlying A-T 
disorder and for development of new therapies (Lavin 2013). The ATM splicing mutation 
5762ins137A>G was selected to be introduced in Atm. This mutation, as discussed 
previously, is a good candidate for genome editing because i) it can be corrected through 
both NHEJ-disruption and HDR; ii) it has a leaky phenotype which means there is some 
residual ATM protein kinase activity; and iii) the mutation has been frequently reported 
in 10-15% of the UK A-T patients. To introduce ATM5762ins137 in mouse Atm, first, the 
genomic region around the mutation site were analysed in both human and mouse. In 
humans, this mutation lies in intron 40, sequence comparisons showed that this region 
corresponded to mouse Atm intron 38. The structure (indicated by exon-intron 
boundaries) and sequences of human exon 40 and 41 were identified to be identical to 
mouse Atm exons 37 and 38, respectively. Therefore, a knock-in construct containing 
relevant human sequences along with the mutation and mouse Atm sequence homology 
arms was envisioned.  
CRISPR-Cas gene editing platform was chosen to target ATM due to its robustness and 
efficiency. Several different bioinformatics tools were used to identify ATM gRNAs. Top 
ranked gRNAs were tested for gene editing in HEK293T cells stably expressing Cas9. 
These cells were chosen as they are easy to transfect with high efficiencies. Second, 
since Cas9 is endogenously expressed, only a small RNA molecule needs to be 
introduced in the cells. This makes the screening process quicker and more effective. 
gRNAs were introduced as commercially produced synthetic RNA oligonucleotides for a 
faster turnaround.  
Gene editing was tested using the software TIDE, which is a simple, rapid and cost-
effective R-based tool that accurately quantifies the efficacy and simultaneously 
identifies the predominant types of indels in a gene edited pool of cells using a 
decomposition algorithm. Commonly available indel detection methods include enzyme 
mismatch cleavage assays based on Surveyor and T7E1 endonucleases. These can 
detect small sequence changes however; they are semi-quantitative and suffer from high 
background signals in presence of sequence polymorphisms. More importantly, these 
enzymatic assays do not provide insight into the nature, diversity and frequency of the 
mutations introduced in a pool of gene edited cells (Brinkman, Chen et al. 2014). TIDE 
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like high-throughput sequencing can be used to analyse sequence around the induced 
break site at highly reduced costs and in less time.  
Introduction of ATM gRNAs in HEK-Cas9 cells showed high levels of gene editing at 
various ATM targets providing promising preliminary data for developing the outlines 
strategies. A particularly interesting result was the mono-allelic disruption of 
ATM5762ins137 splicing mutation as a result of NHEJ due to cutting by Cas9 near the 
mutation locus. Further validation of these edited genomic loci using next-generation 
sequencing was under progress at the time this Thesis was being written.   
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6 Conclusions and Further Work 
 
 
6.1 Summary 
This work described genome editing in two rare disease models – Prkdc severe 
combined immunodeficiency or SCID and Ataxia Telangiectasia – that arise due to 
genetic defects affecting core proteins involved in DNA damage response. The point 
mutation in Prkdc, causative of a radiosensitive form of SCID in mice, was edited using 
zinc-finger nucleases as well as CRISPR-Cas9 platform in a proof-of-concept in vitro 
model. Various genomic targets on ATM, defects on which cause Ataxia Telangiectasia, 
were targeted using CRISPR-Cas9 technology in human cell lines. This was the first ever 
demonstration of CRISPR-Cas9 based gene editing for both disorders.   
Primary skin fibroblasts from SCID mice were used as the in vitro model for Prkdc SCID. 
Molecular analyses of clonal cell lines were carried out by techniques such as PCR, 
Sanger sequencing and indel detection using amplicon analysis. Clonal analysis of ZFN 
gene-edited cells demonstrated repair of the underlying SCID mutation. To demonstrate 
correlation between genomic correction of the mutation and restoration of the encoded 
DNA-PKcs protein and its activity this study established two different assays. The first 
assay involved the use of the drug melphalan, a nitrogen mustard commonly used in the 
treatment of a wide variety of cancers (Ross et al., 1978). Mutant cells deficient in DNA-
PKcs activity have previously been reported to exhibit significant hypersensitivity to 
Melphalan (Caldecott and Jeggo 1991, Muller, Christodoulopoulos et al. 1998). Cells 
edited using ZFNs were subjected to DNA damage using Melphalan and their potential 
to survive and grow was investigated in cell survival and clonogenic assays. Separately, 
phosphorylation of histone H2AX after exposure to ionising radiation (IR) was utilised as 
an indicator of DNA PKcs activity. H2AX phosphorylation is an early step in response to 
DNA damage. Under normal growth conditions, IR-induced H2AX phosphorylation is 
carried out by DNA PK and ATM in a redundant, overlapping manner (Stiff, O'Driscoll et 
al. 2004). However, perhaps due to the intrinsic deficiency in DNA repair in SCID Prkdc 
fibroblasts, genome editing led to unwanted genomic alterations at nuclease cut sites 
which prevented the rescue of DNA PKcs activity in gene edited cells.  
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Separate to ZFNs, the Prkdc SCID mutation was also edited using the CRISPR-Cas9 
system, leading to mono- and bi-allelic correction of the mutation as demonstrated by 
clonal analysis. Upon comparison between gene editing using the two nucleases, Cas9 
showed higher efficiency in bi-allelic repair of SCID mutation. However, like in the ZFN 
study, the initially designed nuclease target sites mediated a double stranded break 
(DSB) within a Prkdc exon. This again led to unwanted sequence changes in the coding 
region of Prkdc in all cell clones tested. Given the defects in non-homologous end-
joining, the occurrence of the mutagenic alternative-NHEJ pathways was speculated 
since out of all the clones tested. Perhaps a wider screen of edited cells would allow for 
identification of a cell containing the desired edit.  
Building up from these results, the genome editing reagents were redesigned. First, a 
new Cas9 nuclease target site located downstream of Prkdc intron 85 was identified 
using bioinformatic tools and successful genome editing at this site was demonstrated in 
SCID fibroblasts. Introduction of unexpected genome-editing indels at an intronic site is 
much less likely to have detrimental effects on the mRNA product of the targeted gene. 
Second, the donor DNA used for homologous recombination was modified by site-
directed mutagenesis to no longer include the nuclease target site. A common problem 
in gene editing can arise if the HR template contains the intact nuclease site. In this case, 
the nuclease may bind and cut the HR template. Additionally, even after successfully 
introducing the mutation with the HR template, the nuclease may continue to cut the 
genomic site if the target site was left intact. To avoid any unintended consequences, 
the template target site can be modified in advance. In case of CRISPR-Cas9, on-target 
specificity of Cas9 nuclease is determined by a short 3-bp PAM region adjacent to the 
guide RNA recognition sequence. Based on scores from codon usage index, PAM 
regions for the Cas9 PAM sites were modified on the HR donor templates using site-
directed mutagenesis. Use of these improved gene editing reagents led to successful 
gene targeting in Prkdc SCID fibroblasts. However, clonal analysis to confirm the 
genotype of cells could not be completed due to time restrictions. Further work involving 
isolation, expansion and characterisation of clones from the edited cell pool would be 
required to substantiate the positive impact of the modifications made to the gene editing 
reagents.  
Given that Prkdc SCID is a model of an ultra-rare DNA PKcs deficiency in humans, this 
study was transitioned towards development of gene editing as a potentially therapeutic 
strategy for another related DNA repair disorder, Ataxia Telangiectasia. A-T is due to 
defects on ATM. There are several parallels between DNA PKcs and ATM. Both proteins 
are members of the PIKK family and involved in DNA damage repair. ATM is further 
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involved in cell cycle checkpoint control, survival and apoptosis. Furthermore, deficiency 
in either of the proteins leads to sensitivity to IR and immunodeficiency.  
Genome editing has not been previously described for A-T to the best of my knowledge. 
To look for suitable target sites on ATM, all the known A-T mutations were mapped to 
genomic regions on ATM. The mutation map produced highlighted over 600 different 
kinds of mutation span across ATM without any mutational hotspots. To demonstrate 
ATM gene editing, a sub-set of mutations that are prevalent in the UK and could be easily 
targeted through genome editing strategies in patient cell lines were identified. Given the 
plethora of mutations, three different gene knock-in strategies were designed in this 
study. Separately, generation of a mouse model was also envisioned. Proof-of-concept 
genome editing by CRISPR-Cas9 was shown at all chosen ATM targets in HEK-293T 
polyclonal cells through the introduction of NHEJ-mediated indels after DNA cutting, 
confirmed both by TIDE and NGS. These data combined with the in vitro assays 
developed to assess DNA damage set a foundation for further work on genome editing 
in A-T models.  
6.2 Study Limitations 
Like with any scientific experiment there were certain limitations in this study. First was 
the issue of delivery. Throughout the study, we were limited to using plasmids as the 
delivery platform in immortalised SCID mouse fibroblasts. These cells were however 
found challenging to transfect using conventional reagents which resulted in low 
transfection efficiencies. This affected Cre-LoxP recombination which then had to be 
coupled with FACS to enrich the small proportion of transfected cells. Likewise, poor 
transfection of Cas9-gRNA plasmids led to low levels of cutting in scid fibroblasts. These 
limitations could be overcome by using electroporation of existing plasmids or via viral 
vector transductions. To enhance gene editing, CRISPR-Cas9 reagents could be 
introduced in cells as protein-mRNA complexes delivered using nucleofection. 
Alternatively, an easy-to-transfect mouse cell line, such as Neuro2A, could be employed 
for initial testing of gene editing reagents.  
It is worthwhile to note that despite the low levels of indels seen initially, relatively high 
levels of gene editing by HDR were achieved. This could be due to the inherent defect 
in NHEJ DNA repair in Prkdc fibroblasts. In the absence of high-level NHEJ, HR is 
favoured. A possible implication of this is that the ratio of NHEJ:HDR is likely to be 
different in cells that are not defective in DNA repair, and hence a bias towards more 
effective HDR may have been of benefit in the current experiments. 
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The other major limitation of the system was the absence of NHEJ in SCID fibroblasts. 
NHEJ is the prominent DNA repair mechanism and is most of the time more active than 
HDR. This difference in activity makes treating diseases that require gene correction or 
insertion of a gene more challenging than those requiring gene inactivation. However, in 
case of SCID fibroblasts, the ration of NHEJ:HDR is likely to be different than in cells that 
are not defective in DNA repair. Thus, it is worthwhile not to discount the bias towards 
effective HDR as seen in current experiments.  
The absence of NHEJ also points to another issue. It has been proposed that in case of 
lack/block in proteins mediating NHEJ, cells employ the alternative or alt-NHEJ pathway. 
Under normal conditions, NHEJ pathway is prominently employed to repair broken ends. 
Although it is not error-free and does include insertions and deletions, DNA in some cells 
can be re-joined without mutations. However, alt-NHEJ is highly mutagenic and is prone 
to causing mutations at the DSB site. Gene editing relies on the creation of a DSB and 
exploiting the repair pathways that respond to it. In our experiments, gene editing in SCID 
cells, led to several mutations at the nuclease target locus (at the genomic site as well 
as in the repair template) suggesting that caution must be taken when attempting editing 
in models of DNA repair defects. One way to overcome this problem is to target a non-
coding region of the gene, although some degree of impact of genomic alterations in 
intronic regions should not be completely discounted. Use of repair template devoid of 
nuclease target site is another strategy. However, this may not be possible for all 
nuclease target sites selected. Alternatively, HDR could be carried out using a single 
stranded oligonucleotide to avoid cutting and hence ineffective recombination. 
Like in any other gene editing study, the last issue pertains to the understanding and 
improving specificity of the nucleases. The specificity of genome editing tools is one of 
the main safety concerns for clinical translation. Genetic modifications are permanent, 
and deleterious off-target mutations have the potential to create cells with oncogenic 
potential, reduced fitness, or complete functional impairment. Even low levels of off-
target mutagenesis may lead to expansion of edited cells carrying unwanted mutations. 
Several methods have been developed for genome-wide analysis of off-target analyses 
of nucleases. Off-target profile of the ZFNs described in this study have previously been 
studied, indicating no major targets (Abdul-Razak 2013). However, off-target profiling of 
the Cas9 targets described for Prkdc and ATM have yet to be undertaken.  
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6.3 Further Work 
Following the work and described in this thesis, work in the immediate future would be 
molecular analyses of Prkdc SCID fibroblasts clones that were generated using the 
optimised gene editing reagents, followed by assays of phenotypic rescue of DNA PKcs 
activity. This would be the most accurate model possible to correlate genotype-
phenotype correction of Prkdc SCID mutation following HDR. This thesis demonstrated 
the on-target specificity of Cas9 nuclease at Prkdc, however, further work assessing off-
target implications of the selected genomic targets is required.  
Conclusions from zinc finger nuclease study showed that none of the clones generated 
carried the signature of a true correction and that a larger screen might be required. In 
this respect, future work can entail use of the nucleases described along with a single-
stranded oligonucleotide donor DNA followed by a larger screen of clones. 
Beyond validating the repair templates and nucleases described for Prkdc in this thesis, 
an interesting avenue for exploration would be interrogation of DNA repair mechanisms 
in response to nuclease specific DSB generation in SCID cells. So far, the results from 
this thesis speculate whether it is possible to carry out genome editing in models of DNA 
repair defects without a definitive answer and thus requires further evaluation. 
For ATM gene editing, we used TIDE and NGS to demonstrate targeted modification in 
a human cell line. Phenotypic analyses of the gene-edited cells are required to validate 
these events, and off-target analyses to study specificity. Based on our encouraging 
preliminary results, the genome editing strategies conceptualised in this study will need 
to be translated into appropriate in vitro and in vivo models for rescue of haematopoietic 
as well as CNS A-T defects.  
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APPENDIX I - List of ATM Mutations 
Exon and 
intervening 
sequence 
(IVS) 
Length 
(bp) 
CDS 
position        
(1 is A in 
ATG; 9,171 
is A in TGA) 
Mutations from Human Gene Mutation Database® (updated 26 March 2016) 
Missense and 
nonsense (370) 
Splicing (112) Small deletions (160) 
Small insertions 
(51) 
Indels (22) 
3 355       
IVS 3 4408             
4 102 1-72 c.1A>G  c.27delT   
   c.2T>C  c.97delC   
   c.3G>A     
   c.37C>T     
   c.67C>T     
IVS 4       c.72+2T>C       
        c.73-2A>G       
5 113 73-185 c.103C>T  c.138_141delTTCA   
   c.128T>C  c.193delC   
   c.146C>G     
   c.170G>A     
IVS 5               
6 146 186-331 c.271C>T  c.217_218delGA   
   c.295A>G     
   c.299T>A     
   c.299T>A     
IVS 6       c.331+2T>G       
        c.331+5G>A       
        c.332-1G>A       
7 165 332-496 c.309C>G c.487C>T c.364_368delAATTA c.397_398insT  
   c.320G>A  c.368delA c.432dupA  
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   c.331A>T  c.370_374delATCAT   
   c.362T>A  c.381delA   
   c.378T>A  c.450_453delTTCT   
   c.434T>G  c.480_484delTCAGC   
   c.452C>T     
   c.458G>T     
   c.484C>T     
IVS 7       c.496+5G>A       
8 166 497-662 c.513C>G c.513C>T c.510_511delGT   
   c.538C>T c.662G>T c.640delT   
   c.544G>C     
   c.572T>A     
   c.590G>A     
   c.597T>A     
   c.609C>A     
   c.610G>T     
IVS 8               
9 239 663-901 c.664C>T c.748C>T c.689delA  
c.738_739delC
TinsA 
   c.667G>T c.802C>T c.717_720delCCTC   
   c.670A>G  c.741delT   
   c.692A>G  c.756_757delTG   
   c.691C>T  c.782delC   
   c.743G>T  c.790delT   
   c.742C>T  c.824delT   
   c.749G>A     
   c.748C>T     
   c.802C>T     
   c.875C>T     
IVS 9       c.901+1G>A       
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        c.901+2T>A       
        c.901+3A>T       
        c.902-1G>T       
10 164 902-1065 c.902G>A  c.1027_1030delGAAA c.1055dupT  
   c.967A>G  c.1028_1031delAAAA   
   c.995A>G  c.1037_1040delTTGA   
   c.998C>T     
   c.1009C>T     
IVS 10       c.1066-6T>G       
11 170 1066-1235 c.1110C>G c.1235G>C c.1110delC 
c.1139_1142dupACA
G  
   c.1120C>T  c.1158delG   
   c.1132A>G  c.1179_1180delGG   
   c.1153A>G  c.1215delT   
   c.1156A>G     
   c.1229T>C     
IVS 11       c.1236-404C>T       
        c.1236-2A>G       
        c.1236-2A>T       
12 372 1236-1607 c.1240C>T c.1236G>T c.1290_1291delTG c.1332_1333dupCC  
   c.1316T>C  c.1348delG   
   c.1339C>T  c.1355delC   
   c.1346G>C  c.1358delC   
   c.1369C>T  c.1402_1403delAA   
   c.1396C>T  c.1514_1515delTT   
   c.1440A>C  c.1524delT   
   c.1464G>T  c.1564_1565delGA   
   c.1463G>A     
   c.1464G>A     
   c.1514T>C     
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   c.1520T>A     
   c.1541G>A     
   c.1547T>C     
IVS 12       c.1607+1G>T       
13 195 1608-1802 c.1636C>G c.1802G>T c.1753_1756delTTAG   
   c.1648A>G  c.1782delA   
   c.1709T>C     
   c.1744T>C     
   c.1784T>C     
IVS 13               
14 96 1803-1898 c.1810C>T  c.1847_1849delCTA c.1863dupA  
   c.1837G>T     
   c.1880T>G     
IVS 14       c.1898+1G>T 
c.1898+3_1898+4delA
T     
        c.1898+2T>G       
15 226 1899-2124 c.1924G>T  c.2062delG c.1930_1931ins16 
c.2114_2119de
lACTCATinsTC
ATAC 
   c.1931C>A     
   c.1931C>G     
   c.1960C>A     
   c.2066C>G     
   c.2104C>G     
   c.2119T>C     
IVS 15               
16 126 2125-2250 c.2135C>A   c.2192dupA 
c.2152_2154de
lTGTinsAAAC 
   c.2158C>T     
IVS 16       c.2250+2T>C       
        c.2251-10T>G       
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        c.2251-1G>A       
17 126 2251-2376 c.2276G>A c.2376G>A c.2284_2285delCT   
   c.2302A>G     
   c.2336T>C     
   c.2353C>T     
   c.2362A>C     
IVS 17       c.2376+1G>A       
18 90 2377-2466 c.2383C>A     
   c.2414G>A  c.2466+1delG   
   c.2413C>T     
   c.2465T>G     
   c.2512A>G     
   c.2548G>T     
   c.2554C>T     
   c.2572T>C     
   c.2614C>T     
IVS 18       c.2466+1G>A 
c.2464_2466+2delTTA
GT     
          c.2466+1delG     
19 172 2467-2638   c.2483delA c.2502dupA 
c.2547_2548de
lGGinsTT 
IVS 19       c.2638+2T>G c.2521delG     
        c.2838+1G>A       
        c.2639-384A>G       
20 200 2639-2838 c.2650C>T  c.2680delG 
c.2806_2809dupCTA
G  
   c.2662G>T  
c.2689_2693delTTCT
T   
   c.2734C>T  c.2720_2723delGTGT   
   c.2771G>A     
   c.2789T>G     
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   c.2804C>G     
IVS 20               
21 83 2839-2921 c.2849T>G  c.2880delC  
c.2839-
3_2839delTAG
TinsGATACTA 
   c.2877C>G     
   c.2909T>G     
IVS 21       c.2921+1G>A   c.2921+2dupT   
        c.2921+3A>T       
        c.2921+5G>A       
        c.2922-2A>G       
        c.2922-1G>A       
22 156 2922-3077 c.2924A>G   c.3058dupA  
   c.2932T>C     
   c.2941C>T     
   c.3002T>A     
IVS 22       c.3078-1G>A       
23 76 3078-3153 c.3102T>A  c.3085delA   
   c.3102T>G  c.3111delT   
   c.3115A>T  c.3110delC   
   c.3136C>T     
IVS 23       c.3154-2A>C       
        c.3154-2A>G       
24 131 3154-3284 c.3161C>G c.3284G>C c.3219delA  
c.3245_3247de
lATCinsTGAT 
   c.3174G>A  c.3273_3284+4del16   
   c.3214G>T     
   c.3245A>T     
   c.3248A>G     
   c.3273G>T     
   c.3275C>A     
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IVS 24       c.3285-2A>G       
25 118 3285-3402 c.3295G>A  c.3381_3384delTCAG  
c.3754_3756de
lTATinsGA 
   c.3334C>G  c.3388_3391delGGAA   
   c.3335C>T     
   c.3349C>T     
   c.3372C>G     
   c.3383A>G     
   c.3382C>T     
IVS 25       c.3403-12T>A       
26 174 3403-3576 c.3467C>T c.3576G>A    
   c.3485T>G     
   c.3511C>T     
   c.3541A>T     
IVS 26       c.3576+687C>T       
27 170 3577-3746 c.3630G>A  c.3602_3603delTT   
   c.3663G>A  c.3626_3627delTT   
   c.3668A>G  c.3668delA   
   c.3673C>T  
c.3693_3697delATCT
T   
   c.3763T>G  c.3695_3713del19   
IVS 27       c.3746+1G>A       
        c.3747-1G>C       
28 247 3747-3993 c.3836G>A  c.3802delG c.3880dupA  
   c.3848T>C  c.3850delA c.3894dupT  
   c.3886C>T  c.3856delT   
   c.3931C>T  
c.3905_3911delGTAC
CAG   
     
c.3910_3916delAGAG
ACA   
IVS 28 3,026     c.3993+1G>A       
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        c.3993+5G>T       
        c.3994-159A>G       
        c.3994-2A>G       
29 116 3994-4109 c.4066A>G  c.4002_4005delCTTA c.4007_4008insA  
     c.4052delT   
     c.4105delT   
IVS 29       c.4110-9C>G       
        c.4110-1G>A       
30 127 4110-4236 c.4138C>T  c.4111delG c.4143dupT  
   c.4148C>T     
   c.4198A>T     
IVS 30       c.4237-2A>G       
31 200 4237-4436 c.4258C>T  c.4358_4359delTA c.4344dupA  
   c.4279G>A  c.4373delG c.4415dupT  
   c.4303A>T  c.4389delT   
   c.4310G>A     
   c.4318A>T     
   c.4324T>C     
   c.4362A>C     
   c.4370T>G     
   c.4388T>G     
   c.4394T>C     
   c.4396C>T     
   c.4400A>G     
IVS 31       c.4437-1G>C       
32 175 4437-4611 c.4477C>G     
   c.4507C>T     
   c.4565G>A     
   c.4574T>C     
   c.4587T>G     
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   c.4597G>T     
IVS 32       c.4612-12A>G c.4611_4611+9del10     
33 165 4612-4776 c.4664T>A  c.4632_4635delCTTA c.4661dupA  
   c.4697C>G  c.4642_4645delGATA   
   c.4709T>C  c.4649delA   
   c.4722G>T  
c.4683_4689delTTTA
GAT   
   c.4724G>A     
   c.4732C>T     
IVS 33       c.4776+2T>A       
        c.4776+2T>C       
        c.4777-2A>C       
34 133 4777-4909 c.4852C>T c.4777G>T c.4844delA c.4840_4841dupCT  
   c.4858C>T     
IVS 34       c.4909+1G>A       
35 96 4910-5005   c.4989_4990delTG  
c.4956_4957de
lGCinsTT 
IVS 35               
36 172 5006-5177 c.5044G>T     
   c.5071A>C     
IVS 36       c.5177+1G>A       
        c.5177+5G>A       
37 142 5178-5319 c.5089A>G c.5319G>A c.5290delC   
   c.5186T>C  c.5309delC   
   c.5189G>T     
   c.5188C>T     
   c.5197G>C     
   c.5228C>T     
   c.5262G>T     
   c.5293C>T     
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IVS 37       c.5319+2T>C 
c.5320-5_5320-
2delTCTA     
        c.5319+9A>G       
38 177 5320-5496 c.5326G>T  c.5324delT c.5405dupA  
   c.5354C>A  c.5366delT c.5441dupT  
   c.5410A>T  c.5435_5437delCTT   
   c.5414G>A     
   c.5415G>A     
   c.5419A>G     
   c.5441T>A     
   c.5471T>G     
IVS 38       c.5496+2T>C       
        c.5497-2A>C       
39 178 5497-5674 c.5515C>T  c.5539_5549del11 c.5554dupC 
c.5631_5639de
lCTCGCAAACi
nsAAACA 
   c.5554C>T  c.5549delT c.5664dupC  
   c.5557G>A  c.5559_5560delTA   
   c.5558A>T  
c.5650_5657delACAA
CCCC   
   c.5566G>T  c.5653delA   
   c.5574G>A     
   c.5623C>T     
   c.5644C>T     
IVS 39       c.5675-2A>C       
40 88 5675-5762 c.5692C>T   c.5712dupA  
   c.5738T>G     
   c.5741A>G     
   c.5749A>T     
IVS 40 2,175     c.5763-1050A>G       
        c.5763-2A>T       
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41 156 5763-5918 c.5771C>A  
c.5809_5813delAATT
A  
c.5791delGins
CCT 
   c.5821G>C  c.5878delA   
   c.5825C>T  c.5910delA   
   c.5858C>T     
   c.5882A>G     
   c.5890A>G     
   c.5890A>T     
   c.5908C>T     
IVS 41               
42 88 5919-6006 c.5908C>T c.5932G>T 
c.5979_5983delTAAA
G c.5977dupA  
   c.5932G>T c.5971G>T    
   c.5971G>T     
   c.6004C>T     
   c.6040G>T     
   c.6047A>G     
   c.6056A>G     
   c.6067G>A     
   c.6082C>T     
   c.6088A>G     
   c.6095G>A     
IVS 42               
43 89 6007-6095  c.6095G>A c.6056delA c.6015dupC  
IVS 43       c.6095+1G>A 
c.6096-9_6096-
5delTTCTT     
44 103 6096-6198 c.6100C>T     
   c.6108T>G     
   c.6115G>A     
   c.6145T>G     
   c.6188G>A     
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IVS 44       c.6198+1G>A       
        c.6199-1G>T       
45 149 6199-6347 c.6200C>A c.6154G>A c.6215delG   
   c.6203T>C  c.6228delT   
   c.6315G>C     
   c.6314G>C     
   c.6325T>G     
IVS 45       c.6347+1G>A       
46 105 6348-6452 c.6326G>A  c.6444delA c.6371_6372insG  
   c.6332A>G   c.6404_6405insTT  
   c.6374A>G     
IVS 46       c.6452+1G>A 
c.6453-
1_6457delGAGTAA     
47 120 6453-6572 c.6482G>C     
   c.6491A>C     
IVS 47       c.6572+1G>A       
        c.6572+1G>T       
        c.6573-9G>A       
48 235 6573-6807 c.6575C>G  
c.6573_6577delATCA
G c.6776_6777dupCT 
c.6672_6680de
lGGCTCTACGi
nsCTC 
   c.6679C>T  c.6629delA  
c.6736_6755de
lins20 
   c.6685G>T  c.6710delA   
   c.6761A>C  c.6754delA   
     c.6779_6780delTA   
IVS 48               
49 168 6808-6975 c.6814G>A  c.6812delC c.6867dupT 
c.6910_6911de
lGAinsTG 
   c.6820G>A  c.6916_6917delAG c.6908dupA  
   c.6829C>G     
   c.6838C>T     
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   c.6860G>C     
   c.6873G>A     
   c.6890A>C     
   c.6913C>T     
   c.6919C>T     
IVS 49       c.6976-3C>G       
50 114 6976-7089 c.6988C>G  c.7010_7011delGT c.6987_6988insT  
   c.6995T>C   c.6997dupA  
   c.7013T>C   c.7037dupC  
   c.7028A>G     
IVS 50       c.7090-2A>C       
51 218 7090-7307 c.7096G>T  c.7150delA 
c.7159_7160insAGC
C  
   c.7166C>G  c.7241_7244delAAGC   
   c.7181C>T  
c.7278_7283delCCTT
AG   
   c.7187C>G  
c.7279_7284delCTTA
GG   
   c.7202T>C     
   c.7271T>G     
   c.7291A>G     
   c.7305C>G     
IVS 51       c.7307+1G>A       
52 208 7308-7515 c.7311C>A c.7449G>A c.7519_7520delGA c.7481dupA  
   c.7316T>C  c.7517_7520delGAGA   
   c.7327C>T     
   c.7355T>C     
   c.7375C>G     
   c.7390T>C     
   c.7397C>T     
   c.7408T>G     
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   c.7446G>A     
   c.7449G>A     
   c.7456C>T     
   c.7462T>C     
   c.7463G>T     
   c.7463G>A     
   c.7471T>C     
IVS 52               
53 114 7516-7629 c.7542T>A    
c.7793_7798de
lGAACAGinsC
C 
   c.7542T>G     
   c.7570G>C     
   c.7592T>C     
   c.7606G>T     
   c.7622T>G     
IVS 53       c.7630-2A>C 
c.7629_7629+4delTGT
AA     
        c.7630-2A>T       
54 159 7630-7788 c.7660C>G c.7653T>C 
c.7638_7646delTAGA
ATTTC   
   c.7709A>G  c.7671_7674delGTTT   
   c.7775C>G  c.7705_7718del14   
   c.7777C>T     
IVS 54       c.7788+8G>T       
        c.7789-3T>G       
55 139 7789-7927 c.7792C>T c.7789G>T c.7829_7830delGA c.7876_7877dupGC 
c.7875_7876de
lTGinsGC 
   c.7840C>T c.7865C>T 
c.7886_7890delTATT
A   
   c.7865C>T c.7788G>A c.7925_7926delGA   
   c.7874A>G c.7926A>C    
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   c.7879T>C     
   c.7913G>A     
   c.7926A>C     
IVS 55       c.7928-1G>A c.7927+5delG     
56 83 7928-8010 c.7967T>C  c.7989_7991delTGT   
   c.7985T>A     
   c.8000T>C     
   c.8003A>G     
IVS 56       c.8010+186C>T       
        c.8011-2A>C       
57 141 8011-8151 c.8030A>G c.8150A>G c.8030delA   
   c.8045C>G  c.8070delT   
IVS 57               
58 117 8152-8268 c.8071C>T c.8156G>A c.8206_8207delAA  
c.8201_8211de
lins11 
   c.8089A>G  c.8251_8254delACTA  
c.8236_8239de
lAGGAinsTCC
CT 
   c.8096C>T  
c.8264_8268delATAA
G   
   c.8100A>T     
   c.8098A>T     
   c.8105T>G     
   c.8110T>C     
   c.8110T>G     
   c.8122G>A     
   c.8124T>A     
   c.8140C>T     
   c.8147T>C     
   c.8155C>T     
   c.8156G>A     
210 
 
   c.8161G>A     
   c.8177C>T     
   c.8187A>C     
   c.8185C>T     
   c.8189A>C     
   c.8264A>G     
   c.8265T>G     
   c.8266A>T     
IVS 58       c.8269-1G>A       
59 150 8269-8418 c.8287C>T  c.8283_8284delTC   
   c.8293G>A  c.8368delA   
   c.8307G>A  c.8395_8404del10   
   c.8314G>A  c.8408delA   
   c.8373C>A     
IVS 59         
c.8418+5_8418+8delG
TGA     
60 166 8419-8584 c.8471G>A  c.8422delG c.8476_8477dupAA 
c.8565_8566de
lTGinsAA 
   c.8473C>T  c.8432delA   
   c.8480T>G  c.8440delG   
   c.8479T>A  c.8484delA   
   c.8486C>T  c.8504_8518del15   
   c.8489T>G  c.8578_8580delTCT   
   c.8494C>T     
   c.8535G>A     
   c.8546G>C     
   c.8545C>T     
   c.8558C>G     
   c.8560C>T     
   c.8565T>A     
   c.8565T>G     
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IVS 60       c.8585-2A>C       
        c.8585-1G>C       
61 87 8585-8671 c.8599G>C  c.8624delA   
   c.8620C>T     
   c.8624A>G     
   c.8633T>G     
   c.8659C>G     
IVS 61               
62 115 8672-8786 c.8672G>A  
c.8711_8716delAGAC
AG c.8714_8715dupCA 
c.8720delCinsT
T 
   c.8711A>G   c.8766dupT  
   c.8725A>G   c.8769dupT  
   c.8726G>C     
   c.8734A>G     
   c.8737G>T     
   c.8741T>C     
   c.8756G>A     
   c.8774G>T     
IVS 62       c.8786+1G>A       
        c.8787-1G>T       
63 64 8787-8850 c.8793T>A c.8850G>T c.8802delC 
c.8818_8821dupAAC
T  
   c.8824C>T  c.8814_8824del11   
   c.8850G>T  c.8833_8834delCT   
IVS 63       c.8851-973A>C       
        c.8851-1G>T       
64 137 8851-8987 c.8879G>A  c.8876_8879delACTG c.8947dupA 
c.8978_8981de
lGAAAinsAT 
   c.8968G>T     
   c.8977C>T     
IVS 64       c.8987+1G>T       
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        c.8988-1G>C       
65 3,775 
8988-9171 
(+UTR) c.9008A>G  c.9001_9002delAG c.9021dupA 
c.9003_9004de
lTTinsC 
   c.9019G>T  c.9145_9146delTT c.9064dupG  
   c.9022C>T  c.9170_9171delGA c.9079dupA  
   c.9023G>A     
   c.9029T>G     
   c.9031A>G     
   c.9068G>T     
   c.9103C>T     
   c.9139C>T     
   c.9169T>G     
   c.9170G>C     
 
 
